A O O
literature O O
search O O
carried O O
using O O
keywords O O
human B-virus B-virus
papillomavirus E-virus E-virus
, O O
head O O
neck O O
cancer O O
, O O
smoking O O
, O O
tobacco O O
, O O
cervical O O
cancer O O
. O O

The O O
English-language O O
articles O O
, O O
references O O
, O O
relevant O O
studies O O
evaluating O O
association O O
smoking O O
, O O
HPV B-virus B-virus
, O O
risk O O
head O O
neck O O
cancer O O
collected O O
analyzed O O
. O O

P16 O O
overexpression O O
analyzed O O
immunohistochemistry O O
. O O

Tissue O O
samples O O
leukoplakia O O
( O O
n O O
= O O
121 O O
) O O
HNSCC O O
( O O
n O O
= O O
427 O O
) O O
saliva O O
patients O O
HNSCC O O
( O O
n O O
= O O
215 O O
) O O
tested O O
HPV B-virus B-virus
using O O
nested O O
polymerase O O
chain O O
reaction O O
. O O

Positive O O
samples O O
sequenced O O
subtyping O O
. O O

The O O
presence O O
HPV B-virus B-virus
E6/E7 O O
mRNA O O
confirmed O O
RNA O O
situ O O
hybridization O O
. O O

High B-virus B-virus
risk I-virus I-virus
human I-virus I-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
detected O O
25 O O
per O O
cent O O
patients O O
( O O
three O O
12 O O
) O O
laryngeal O O
cancer O O
. O O

Low B-virus B-virus
risk I-virus I-virus
human I-virus I-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
detected O O
three O O
laryngeal O O
papilloma O O
patients O O
. O O

The O O
mean O O
laryngeal O O
secretion O O
concentrations O O
immunoglobulins O O
M O O
, O O
G O O
A O O
secretory O O
immunoglobulin O O
A O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
positive O O
patients O O
twice O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
negative O O
patients O O
. O O

A O O
statistically O O
significant O O
difference O O
observed O O
secretory O O
immunoglobulin O O
A O O
concentrations O O
two O O
groups O O
. O O

Patients O O
laryngeal O O
cancer O O
higher O O
laryngeal O O
secretion O O
concentrations O O
immunoglobulin O O
type O O
, O O
compared O O
patients O O
benign O O
laryngeal O O
disease O O
. O O

The O O
study O O
assessed O O
mean O O
laryngeal O O
secretion O O
concentrations O O
immunoglobulin O O
type O O
12 O O
laryngeal O O
cancer O O
patients O O
, O O
comparing O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
positive O O
patients O O
( O O
n O O
= O O
3 O O
) O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
negative O O
patients O O
( O O
n O O
= O O
9 O O
) O O
; O O
mean O O
concentrations O O
immunoglobulins O O
M O O
, O O
G O O
A O O
secretory O O
immunoglobulin O O
A O O
tended O O
greater O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
positive O O
cancer O O
patients O O
, O O
compared O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
negative O O
cancer O O
patients O O
. O O

Negative O O
HPV B-virus B-virus
status O O
perineural O O
invasion O O
( O O
PNI O O
) O O
independent O O
, O O
additive O O
factors O O
associated O O
increased O O
PDX O O
formation O O
. O O

Epstein-Barr B-virus B-virus
virus-positive E-virus E-virus
( O O
EBV+ B-virus B-virus
) O O
human O O
large O O
B-cell O O
lymphomas O O
grew O O
32 O O
% O O
HPV B-virus B-virus
+ O O
HNSCC O O
cases O O
failed O O
engraft O O
. O O

Successfully O O
established O O
HPV B-virus B-virus
+ E-virus E-virus
PDXs O O
retained O O
basaloid O O
histology O O
often O O
developed O O
cystic O O
growth O O
patterns O O
typical O O
HPV B-virus B-virus
+ E-virus E-virus
nodal O O
metastases O O
. O O

They O O
also O O
maintained O O
elevated O O
p16 O O

The O O
majority O O
civil O O
research O O
studies O O
HPV-associated B-virus B-virus
head O O
neck O O
cancers O O
concentrated O O
clinical O O
studies O O
. O O

Thus O O
, O O
molecular O O
neuropathology O O
signaling O O
pathway O O
HPV B-virus B-virus
explored O O
future O O
advance O O
prognostic O O
methods O O
. O O

Moreover O O
, O O
perspective O O
view O O
therapeutic O O
vaccines O O
molecular-targeting O O
treatments O O
receive O O
close O O
attention O O
. O O

HPV-associated B-virus B-virus
second O O
primary O O
tumors O O
may O O
present O O
synchronous O O
and/or O O
metachronous O O
lesions O O
arise O O
outside O O
oropharynx O O
prolonged O O
intervals O O
. O O

Further O O
work O O
necessary O O
identify O O
patients O O
risk O O
elucidate O O
mechanisms O O
HPV-associated B-virus B-virus
head O O
neck O O
second O O
primary O O
tumors O O
. O O

CRAds O O
targeted O O
HPV-positive B-virus B-virus
HNSCCs O O
demonstrated O O
excellent O O
vitro O O
vivo O O
therapeutic O O
effects O O
, O O
potential O O
clinically O O
translated O O
novel O O
treatment O O
modality O O
emerging O O
disease O O
. O O

data O O
provides O O
evidence O O
presence O O
DNA B-virus B-virus
viruses E-virus E-virus
SGTs O O
. O O

Mechanistic O O
studies O O
needed O O
attribute O O
tumor O O
formation O O
viruses B-virus B-virus
. O O

Human B-virus B-virus
papilloma I-virus I-virus
viruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
group O O
double-stranded O O
DNA O O
viruses B-virus B-virus
known O O
primary O O
cause O O
cervical O O
cancer O O
. O O

In O O
addition O O
, O O
evidence O O
established O O
role O O
non-melanoma O O
skin O O
cancers O O
, O O
head O O
neck O O
cancer O O
( O O
HNC O O
) O O
, O O
development O O
anogenital O O
malignancies O O
. O O

The O O
prevalence O O
HPV-related B-virus B-virus
HNC O O
, O O
particular O O
oropharyngeal O O
cancers O O
, O O
rapidly O O
increasing O O
, O O
foreseeing O O
HPV-positive B-virus B-virus
oropharyngeal O O
cancers O O
outnumber O O
uterine O O
cervical O O
cancers O O
next O O
15éˆ¦20 O O
years O O
. O O

Therefore O O
, O O
despite O O
successful O O
advent O O
vaccines O O
originally O O
licensed O O
cervical O O
cancer O O
prevention O O
, O O
HPV B-virus B-virus
burden O O
still O O
high O O
, O O
better O O
understanding O O
HPV B-virus B-virus
biology O O
urgently O O
needed O O
. O O

Autophagy O O
physiological O O
cellular O O
route O O
accounts O O
removal O O
, O O
degradation O O
, O O
recycling O O
damaged O O
organelles O O
, O O
proteins O O
, O O
lipids O O
lysosomal O O
vacuoles O O
. O O

In O O
addition O O
scavenger O O
function O O
, O O
autophagy O O
plays O O
fundamental O O
role O O
viral O O
infections O O
cancers O O
, O O
therefore O O
, O O
frequently O O
exploited O O
viruses O B-virus
benefit O O
. O O

Recently O O
, O O
link O O
HPV B-virus B-virus
autophagy O O
clearly O O
emerged O O
, O O
leading O O
conceivable O O
development O O
novel O O
anti-viral O O
strategies O O
aimed O O
restraining O O
HPV B-virus B-virus
infectivity O O
. O O

Here O O
, O O
recent O O
findings O O
oncogenic O O
HPV16 B-virus B-virus
usurp O O
autophagy O O
described O O
, O O
highlighting O O
similarities O O
differences O O
mechanisms O O
adopted O O
oncoviruses B-virus B-virus
. O O

Initially O O
discovered O O
1947 O O
, O O
Zika B-virus B-virus
virus E-virus E-virus
infection O O
received O O
little O O
notoriety O O
tropical O O
disease O O
2015 O O
outbreak O O
microcephaly O O
cases O O
reported O O
Brazil O O
. O O

Zika B-virus B-virus
single-stranded O O
RNA O O
arbovirus B-virus B-virus
Flaviviridae O O
family O O
. O O

The O O
primary O O
source O O
infection O O
humans O O
stems O O
Aedes O O
aegypti O O
mosquito O O
bites O O
also O O
occur O O
sexual O O
, O O
blood O O
, O O
perinatal O O
transmission O O
. O O

With O O
expectations O O
3 O O
4 O O
million O O
people O O
across O O
Americas O O
infected O O
next O O
year O O
, O O
World O O
Health O O
Organization O O
declared O O
event O O
Public O O
Health O O
Emergency O O
International O O
Concern O O
. O O

HPV B-virus B-virus
DNA O O
found O O
3 O O
OSCC O O
cases O O
, O O
p16 O O
IHC-positive O O
. O O

Two O O
cases O O
genotyped O O
HPV-16 B-virus B-virus
one O O
HPV-33 B-virus B-virus
. O O

Only O O
one O O
HPV-16 B-virus B-virus
cases O O
confirmed O O
harbour O O
transcriptionally O O
active O O
virus B-virus B-virus
via O O
HPV B-virus B-virus
RNA O O
ISH O O
. O O

Our O O
results O O
show O O
low O O
prevalence O O
active O O
HPV-16 B-virus B-virus
North O O
Indian O O
HNC O O
patients O O
. O O

HPV-16 B-virus B-virus
E7 O O
mRNA O O
expression O O
correlated O O
p16 O O
nuclear O O
positivity O O
increased O O
viral O O
load O O
. O O

Therefore O O
, O O
E7 O O
mRNA O O
expression O O
may O O
used O O
good O O
surrogate O O
indicator O O
active O O
form O O
HPV-16 B-virus B-virus
infection O O
. O O

In O O
Japan O O
, O O
HPV B-virus B-virus
detected O O
patients O O
NPC O O
, O O
suggest O O
HPV B-virus B-virus
influence O O
NPC O O
carcinogenesis O O
population O O
. O O

Currently O O
, O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
, O O
addition O O
tobacco O O
alcohol O O
, O O
considered O O
another O O
independent O O
risk O O
factor O O
oropharyngeal O O
squamous O O
head O O
neck O O
cancer O O
( O O
OPSCC O O
) O O
, O O
prevalence O O
HPV-16 B-virus B-virus
increases O O
50-90 O O
% O O
oropharynx O O
. O O

Also O O
, O O
incidence O O
mortality O O
head O O
neck O O
SCC O O
( O O
HNSCC O O
) O O
continue O O
higher O O
African O O
Americans O O
( O O
AA O O
) O O
Caucasian O O
Americans O O
( O O
CA O O
) O O
. O O

A O O
recent O O
study O O
found O O
poorer O O
survival O O
outcomes O O
AA O O
versus O O
CA O O
oropharyngeal O O
tumors O O
attributable O O
racial O O
differences O O
prevalence O O
HPV B-virus B-virus
positive O O
( O O
+ O O
) O O
tumors O O
; O O
HPV B-virus B-virus
negative O O
( O O
- O O
) O O
AA O O
CA O O
patients O O
similar O O
outcomes O O
( O O
Settle O O
et O O
al. O O
, O O
Cancer O O
Prev O O
Res O O
( O O
Phila O O
) O O
2:776-781 O O
, O O
2009 O O
) O O
. O O

Evidence O O
indicates O O
HPV+ B-virus B-virus
diagnosis O O
significant O O
prognostic O O
implications O O
; O O
patients O O
least O O
half O O
risk O O
death O O
compared O O
HPV- B-virus B-virus
patient O O
, O O
due O O
part O O
better O O
response O O
chemoradiotherapy O O
( O O
Fakhry O O
et O O
al. O O
, O O
J O O
Natl O O
Cancer O O
Inst O O
100:261-269 O O
, O O
2008 O O
) O O
.Epigenetic O O
events O O
promoter O O
hypermethylation O O
emerging O O
promising O O
molecular O O
strategies O O
cancer O O
detection O O
, O O
representing O O
tumor-specific O O
markers O O
occurring O O
early O O
tumor O O
progression O O
. O O

HPV B-virus B-virus
infection O O
recognized O O
play O O
role O O
pathogenesis O O
OPSCC O B-virus
, O O
HPV+ B-virus B-virus
HPV- B-virus B-virus
patients O O
appear O O
clinically O O
biologically O O
distinct O O
reported O O
genome-wide O O
hypomethylation O O
promoter O O
hypermethylation O O
HPV+ B-virus B-virus
HNSCC O O
tumors O O
. O O

A O O
recent O O
study O O
group O O
applying O O
pathway O O
analysis O O
investigate O O
biological O O
role O O
differentially O O
methylated O O
genes O O
HPV+ B-virus B-virus
HPV- B-virus B-virus
HNSCC O O
reported O O
8 O O
signal O O
transduction O O
pathways O O
germane O O
HNSCC O O
( O O
Worsham O O
et O O
al. O O
, O O
Otolaryngol O O
Head O O
Neck O O
Surg O O
149:409-416 O O
, O O
2013 O O
) O O
. O O

The O O
distribution O O
neurotropic O O
alphaherpesviruses-herpes B-virus B-virus
simplex I-virus I-virus
virus E-virus E-virus
type O O
1 O O
( O O
HSV-1 B-virus B-virus
) O O
type O O
2 O O
( O O
HSV-2 B-virus B-virus
) O O
varicella B-virus B-virus
zoster I-virus I-virus
virus E-virus E-virus
( O O
VZV B-virus B-virus
) O O
#NAME? O O
determined O O
autonomic O O
sensory O O
ganglia O O
head O O
neck O O
obtained O O
formalin-fixed O O
human O O
cadavers O O
. O O

HSV-1 B-virus B-virus
VZV B-virus B-virus
DNA O O
found O O
18 O O
58 O O
16 O O
58 O O
trigeminal O O
, O O
23 O O
58 O O
11 O O
58 O O
pterygopalatine O O
, O O
25 O O
60 O O
14 O O
60 O O
ciliary O O
, O O
25 O O
48 O O
11 O O
48 O O
geniculate O O
, O O
15 O O
50 O O
8 O O
50 O O
otic O O
, O O
14 O O
47 O O
4 O O
47 O O
submandibular O O
, O O
18 O O
58 O O
10 O O
58 O O
superior O O
cervical O O
, O O
12 O O
36 O O
1 O O
36 O O
nodose O O
ganglia O O
, O O
respectively O O
. O O

HSV-2 B-virus B-virus
detected O O
site O O
. O O

Viral O O
DNA O O
positivity O O
location O O
independently O O
distributed O O
among O O
autonomic O O
sensory O O
ganglia O O
human O O
head O O
neck O O
. O O

The O O
face O O
head O O
neck O O
cancer O O
changed O O
dramatically O O
past O O
30 O O
years O O
. O O

There O O
steady O O
decline O O
number O O
tobacco O O
alcohol O O
related O O
squamous O O
cell O O
carcinomas O O
past O O
30 O O
years O O
, O O
increasing O O
incidence O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
related O O
cancers O O
. O O

Some O O
estimates O O
suggest O O
70-90 O O
% O O
new O O
oropharyngeal O O
cancers O O
evidence O O
HPV B-virus B-virus
. O O

These O O
patients O O
different O O
demographic O O
patterns O O
, O O
likely O O
younger O O
, O O
white O O
adults O O
40s O O
50s O O
never O O
smokers O O
reduced O O
tobacco O O
exposure O O
. O O

Studies O O
shown O O
higher O O
number O O
lifetime O O
oral O O
sex O O
partners O O
( O O
> O O
5 O O
) O O
higher O O
number O O
lifetime O O
vaginal O O
sex O O
partners O O
( O O
> O O
25 O O
) O O
associated O O
increased O O
risk O O
HPV B-virus B-virus
positive O O
head O O
neck O O
cancer O O
. O O

People O O
also O O
reduce O O
risk O O
HPV B-virus B-virus
linked O O
head O O
neck O O
cancer O O
receiving O O
HPV B-virus B-virus
vaccine O O
series O O
prior O O
becoming O O
sexually O O
active O O
. O O

Recent O O
evidence O O
suggests O O
HPV B-virus B-virus
related O O
head O O
neck O O
cancers O O
present O O
different O O
symptoms O O
caused O O
tobacco O O
. O O

The O O
popular O O
test O O
HPV B-virus B-virus
status O O
p16 O O
immunohistochemical O O
stain O O
cheap O O
, O O
simple O O
, O O
studies O O
shown O O
comparable O O
sensitivity O O
specificity O O
previous O O
standards O O
. O O

It O O
widely O O
recommended O O
cancers O O
oropharynx O O
tested O O
presence O O
HPV B-virus B-virus
, O O
recommend O O
head O O
neck O O
cancers O O
. O O

Overall O O
2-year O O
5-year O O
survival O O
HPV B-virus B-virus
positive O O
head O O
neck O O
cancer O O
significantly O O
greater O O
HPV B-virus B-virus
negative O O
cancers O O
, O O
likely O O
due O O
HPV B-virus B-virus
positive O O
cancers O O
responsive O O
treatment O O
. O O

The O O
clinical O O
presentation O O
, O O
treatment O O
, O O
response O O
patient O O
EBVMCU B-virus B-virus
base O O
tongue O O
presented O O
. O O

Interim O O
follow-up O O
patient O O
revealed O O
complete O O
remission O O
discontinuation O O
immunosuppression O O
rituximab O O
therapy O O
. O O

A O O
review O O
literature O O
supports O O
conservative O O
management O O
reduction O O
immunosuppression O O
. O O

Overall O O
, O O
96.6 O O
% O O
patients O O
follow-up O O
greater O O
2 O O
months O O
achieved O O
complete O O
remission O O
conservative O O
management O O
. O O

The O O
current O O
study O O
largest O O
series O O
report O O
clinical O O
presentation O O
treatment O O
outcomes O O
EBVMCU B-virus B-virus
head O O
neck O O
. O O

Plasmablastic O O
lymphoma O O
( O O
PBL O O
) O O
aggressive O O
neoplasm O O
exclusively O O
occurring O O
AIDS O O
patients O O
. O O

Recently O O
, O O
increasing O O
cases O O
human B-virus B-virus
immunodeficiency I-virus I-virus
virus E-virus E-virus
( O O
HIV B-virus B-virus
) O O
#NAME? O O
PBL O O
reported O O
. O O

No O O
standard O O
therapy O O
protocol O O
currently O O
available O O
since O O
great O O
difference O O
PBL O O
without O O
HIV B-virus B-virus
infection O O
. O O

Here O O
, O O
present O O
rather O O
rare O O
case O O
HIV-negative B-virus B-virus
PBL O O
neck O O
dramatically O O
responded O O
radiotherapy O O
alone O O
. O O

Our O O
case O O
highlights O O
possibility O O
PBL O O
neck O O
helps O O
expand O O
understanding O O
separate O O
lymphoma O O
. O O

The O O
related O O
literature O O
review O O
summarized O O
clinicopathological O O
features O O
treatment O O
status O O
HIV-negative B-virus B-virus
PBL O O
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
family O O
small O O
double-stranded O O
DNA O O
viruses B-virus B-virus
tropism O O
epithelia O O
genital O O
upper O O
respiratory O O
tracts O O
skin O O
. O O

Approximately O O
150 O O
HPV B-virus B-virus
types O O
discovered O O
far O O
, O O
classified O O
several O O
genera O O
based O O
DNA O O
sequence O O
. O O

Approximately O O
15 O O
high-risk O O
mucosal O O
HPV B-virus B-virus
types O O
clearly O O
associated O O
cervical O O
cancer O O
; O O
HPV16 B-virus B-virus
HPV18 B-virus B-virus
carcinogenic O O
since O O
responsible O O
approximately O O
50 O O
% O O
20 O O
% O O
cervical O O
cancers O O
worldwide O O
, O O
respectively O O
. O O

It O O
also O O
clear O O
viruses B-virus B-virus
linked O O
subset O O
genital O O
cancers O O
, O O
well O O
head O O
neck O O
cancers O O
. O O

Due O O
high O O
level O O
carcinogenic O O
activity O O
, O O
HPV16 B-virus B-virus
HPV18 B-virus B-virus
studied O O
HPV B-virus B-virus
types O O
far O O
. O O

Biological O O
studies O O
highlighted O O
key O O
roles O O
cellular O O
transformation O O
products O O
two O O
viral O O
early O O
genes O O
, O O
E6 O O
E7 O O
. O O

Many O O
mechanisms O O
E6 O O
E7 O O
subverting O O
regulation O O
fundamental O O
cellular O O
events O O
fully O O
characterized O O
, O O
contributing O O
knowledge O O
oncogenic O O
viruses B-virus B-virus
promote O O
cancer O O
development O O
also O O
understanding O O
basic O O
cell O O
biology O O
. O O

Despite O O
HPV B-virus B-virus
research O O
resulting O O
extraordinary O O
achievements O O
last O O
four O O
decades O O
, O O
significantly O O
improving O O
screening O O
prophylaxis O O
HPV-induced O O
lesions O O
, O O
additional O O
research O O
necessary O O
characterize O O
biology O O
epidemiology O O
vast O O
number O O
HPV B-virus B-virus
types O O
poorly O O
investigated O O
far O O
, O O
final O O
aim O O
clarifying O O
potential O O
roles O O
human O O
diseases O O
. O O

A O O
large O O
proportion O O
HNSCCs O O
Sudan O O
associated O O
HPV B-virus B-virus
infection O O
. O O

The O O
fact O O
prevalence O O
HPV B-virus B-virus
high O O
among O O
Sudanese O O
patients O O
head O O
neck O O
cancers O O
( O O
HNC O O
) O O
obvious O O
implications O O
vaccine O O
therapy O O
. O O

Thirty-nine O O
patients O O
included O O
, O O
36 O O
( O O
90 O O
% O O
) O O
underwent O O
adjuvant O O
therapy O O
. O O

Median O O
follow-up O O
39 O O
months O O
( O O
range O O
, O O
2-147 O O
months O O
) O O
. O O

Mean O O
age O O
56 O O
years O O
, O O
87 O O
% O O
male O O
. O O

Seventeen O O
patients O O
( O O
44 O O
% O O
) O O
underwent O O
selective O O
neck O O
dissection O O
, O O
whereas O O
six O O
( O O
15 O O
% O O
) O O
underwent O O
radical O O
( O O
n O O
= O O
2 O O
) O O
extended O O
radical O O
( O O
n O O
= O O
4 O O
) O O
neck O O
dissection O O
. O O

Ninety-two O O
percent O O
extracapsular O O
extension O O
. O O

Five-year O O
Kaplan-Meier O O
estimated O O
DSS O O
, O O
OS O O
, O O
DFS O O
89 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
: O O
79 O O
% O O
-99 O O
% O O
) O O
, O O
87 O O
% O O
( O O
95 O O
% O O
CI O O
: O O
75 O O
% O O
-99 O O
% O O
) O O
, O O
84 O O
% O O
( O O
95 O O
% O O
CI O O
: O O
72 O O
% O O
-96 O O
% O O
) O O
, O O
respectively O O
. O O

The O O
disease O O
recurrence O O
rate O O
10 O O
% O O
( O O
5 O O
% O O
regional O O
, O O
5 O O
% O O
distant O O
metastasis O O
) O O
. O O

Patients O O
less O O
5 O O
pathologically O O
positive O O
lymph O O
nodes O O
( O O
P O O
= O O
0.041 O O
) O O
improved O O
DFS O O
. O O

Patients O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
cancer O O
( O O
HNC O O
) O O
better O O
prognosis O O
relative O O
types O O
HNC O O
, O O
making O O
survivorship O O
emerging O O
critical O O
issue O O
. O O

Exercise O O
core O O
component O O
survivorship O O
care O O
, O O
little O O
known O O
many O O
survivors O O
HPV-related B-virus B-virus
HNC O O
safely O O
advised O O
start O O
exercising O O
, O O
opposed O O
needing O O
evaluation O O
supervised O O
exercise O O
. O O

Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
first O O
human B-virus B-virus
tumor I-virus I-virus
virus E-virus E-virus
discovered O O
50 O O
years O O
ago O O
. O O

EBV-associated B-virus B-virus
lymphomagenesis O O
still O O
significant O O
viral-associated O O
disease O O
involves O O
diverse O O
range O O
pathologies O O
, O O
especially O O
B-cell O O
lymphomas O O
. O O

Recent O O
development O O
high-throughput O O
next-generation O O
sequencing O O
technologies O O
vivo O O
mouse O O
models O O
significantly O O
promoted O O
understanding O O
fundamental O O
molecular O O
mechanisms O O
drive O O
cancers O O
allowed O O
development O O
therapeutic O O
intervention O O
strategies O O
. O O

This O O
review O O
highlight O O
current O O
advances O O
EBV-associated B-virus B-virus
B-cell O O
lymphomas O O
, O O
focusing O O
transcriptional O O
regulation O O
, O O
chromosome O O
aberrations O O
, O O
vivo O O
studies O O
EBV-mediated B-virus B-virus
lymphomagenesis O O
, O O
well O O
treatment O O
strategies O O
target O O
viral-associated O B-virus
lymphomas O O
. O O

We O O
observed O O
high O O
prevalence O O
beta O O
human B-virus B-virus
papillomavirus E-virus E-virus
DNA O O
malignant O O
tumors O O
. O O

In O O
contrast O O
, O O
polyomavirus B-virus B-virus
DNA O O
present O O
benign O O
, O O
malignant O O
, O O
non-tumor O O
control O O
samples O O
. O O

Most O O
striking O O
significant O O
distribution O O
herpesvirus O B-virus
DNA O O
SGT O O
samples O O
, O O
particular O O
high O O
prevalence O O
Epstein-Barr B-virus B-virus
type O O
1 O O
type O O
2 O O
DNA O O
Warthin O O
's O O
tumor O O
samples O O
. O O

Molecular O O
studies O O
carcinomas O O
oral O O
cavity O O
oropharynx O O
demonstrate O O
presence O O
human B-virus B-virus
papilomavirus E-virus E-virus
genome O O
tumors O O
, O O
reinforcing O O
participation O O
human B-virus B-virus
papilomavirus E-virus E-virus
oral O O
carcinogenesis O O
. O O

Retrospective O O
cohort O O
study O O
, O O
set O O
tertiary O O
referral O O
center O O
Mexico O O
City O O
. O O

A O O
dramatic O O
increase O O
incidence O O
HPV-related B-virus B-virus
oropharyngeal O O
cancer O O
reported O O
parts O O
western O O
world O O
past O O
30 O O
years O O
. O O

They O O
constitute O O
clinically O O
distinct O O
subgroup O O
cancers O O
terms O O
molecular O O
biology O O
, O O
patient O O
characteristics O O
, O O
treatment O O
outcome O O
. O O

This O O
chapter O O
describes O O
molecular O O
characteristics O O
, O O
epidemiology O O
, O O
demographics O O
HPV-related B-virus B-virus
head O O
neck O O
cancers O O
discuss O O
available O O
methods O O
detect O O
HPV-related B-virus B-virus
tumours O O
. O O

The O O
impact O O
HPV-related B-virus B-virus
biomarkers O O
clinical O O
studies O O
radiotherapy O O
, O O
altered O O
fractionation O O
, O O
modulation O O
hypoxia O O
, O O
concurrent O O
chemo- O O
bio-radiotherapy O O
reviewed O O
well O O
perspectives O O
de-escalation O O
immune-modulation O O
discussed O O
. O O

The O O
clinical O O
data O O
149 O O
cases O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
Uighur O O
, O O
Han O O
Kazak O O
analyzed O O
. O O

The O O
HPV16/18 B-virus O
infection O O
viral O O
load O O
examined.The O O
prognosis O O
analyzed O O
cox O O
multiIvar-Iate O O
model O O
. O O

The O O
effect O O
HPV B-virus B-virus
infection O O
status O O
prognosis O O
evaluated O O
. O O

Among O O
194 O O
subjects O O
, O O
30 O O
( O O
15 O O
% O O
) O O
HPV B-virus B-virus
positive O O
25 O O
( O O
13 O O
% O O
) O O
high-risk B-virus B-virus
( O O
HR B-virus B-virus
) I-virus E-virus
#NAME? E-virus E-virus
baseline O O
brushing O O
. O O

At O O
12 O O
months O O
HPV B-virus B-virus
infection O O
cleared O O
cases O O
. O O

However O O
48 O O
months O O
HPV B-virus B-virus
newly O O
detected O O
33 O O
% O O
subjects O O
. O O

A O O
correlation O O
time O O
spent O O
community O O
increase O O
ratio O O
`` O O
low-risk B-virus B-virus
'' I-virus I-virus
( I-virus I-virus
LR B-virus B-virus
) I-virus I-virus
HPV E-virus B-virus
HR-HPV B-virus B-virus
observed O O
. O O

HPV B-virus B-virus
infection O O
associated O O
age O O
, O O
gender O O
, O O
HIV B-virus B-virus
status O O
, O O
HCV B-virus B-virus
, O O
alcohol O O
and/or O O
drug O O
exposure O O
, O O
number O O
years O O
spent O O
community O O
, O O
sex O O
drug-addicts O O
condom O O
use O O
. O O

Only O O
AIDS O O
antiretroviral O O
treatment O O
inversely O O
correlated O O
risk O O
infection O O
. O O

The O O
frequency O O
viral O O
detection O O
41 O O
% O O
( O O
31/75 O B-virus
) O O
. O O

The O O
respiratory B-virus B-virus
virus E-virus E-virus
frequently O O
detected O O
human B-virus B-virus
rhinovirus E-virus E-virus
, O O
found O O
18 O O
patients O O
( O O
24 O O
% O O
) O O
, O O
followed O O
human B-virus B-virus
metapneumovirus E-virus E-virus
, O O
human B-virus B-virus
enterovirus E-virus E-virus
, O O
human B-virus B-virus
respiratory I-virus I-virus
sincicial I-virus I-virus
virus E-virus E-virus
, O O
human B-virus B-virus
adenovirus E-virus E-virus
, O O
human B-virus B-virus
bocavirus E-virus E-virus
, O O
human B-virus B-virus
coronavirus E-virus E-virus
, O O
human B-virus B-virus
influenza I-virus I-virus
virus E-virus E-virus
, O O
detected O O
12 O O
( O O
16 O O
% O O
) O O
, O O
five O O
( O O
6.6 O O
% O O
) O O
, O O
four O O
( O O
5.3 O O
% O O
) O O
, O O
four O O
( O O
5.3 O O
% O O
) O O
, O O
two O O
( O O
2.6 O O
% O O
) O O
, O O
two O O
( O O
2.6 O O
% O O
) O O
, O O
one O O
( O O
1.3 O O
% O O
) O O
patient O O
( O O
) O O
, O O
respectively O O
. O O

Although O O
none O O
patients O O
presented O O
symptoms O O
samples O O
collected O O
, O O
peak O O
detection O O
prevalent O O
virus B-virus B-virus
autumn O O
winter O O
seasons O O
years O O
, O O
similar O O
pattern O O
occurs O O
acute O O
conditions O O
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
detected O O
70-80 O O
% O O
oropharyngeal O O
cancers O O
developed O O
world O O
, O O
incidence O O
reached O O
epidemic O O
proportions O O
. O O

The O O
current O O
paradigm O O
regarding O O
status O O
viral O O
genome O O
cancers O O
three O O
situations O O
: O O
one O O
viral O O
genome O O
remains O O
episomal O O
, O O
one O O
viral O O
genome O O
integrates O O
host O O
genome O O
third O O
mixture O O
integrated O O
episomal O O
HPV B-virus B-virus
genomes O O
. O O

Our O O
recent O O
work O O
suggests O O
third O O
category O O
mischaracterized O O
integrated O O
HPV B-virus B-virus
genomes O O
; O O
evidence O O
indicates O O
category O O
consists O O
virus-human O O
hybrid O O
episomes O O
. O O

Most O O
hybrid O O
episomes O O
consistent O O
maintained O O
replication O O
HPV B-virus B-virus
origin O O
. O O

We O O
discuss O O
evidence O O
support O O
new O O
paradigm O O
, O O
genomes O O
arise O O
, O O
importantly O O
implications O O
clinical O O
management O O
HPV B-virus B-virus
positive O O
head O O
neck O O
cancers O O
following O O
accurate O O
determination O O
viral O O
genome O O
status O O
. O O

Forty-six O O
OSCC O O
patients O O
treated O O
2007 O O
2011 O O
available O O
formalin-fixed O O
paraffin-embedded O O
( O O
FFPE O O
) O O
specimens O O
included O O
. O O

Twenty-three O O
patients O O
positive O O
p16 O O
immunohistochemistry O O
( O O
IHC O O
) O O
matched O O
23 O O
patients O O
p16-negative O O
tumours O O
. O O

Laser O O
capture O O
microdissection O O
FFPE O O
OSCC O O
tissues O O
undertaken O O
isolate O O
invasive O O
tumour O O
tissue O O
. O O

DNA O O
extracted O O
tested O O
high-risk O O
HPV B-virus B-virus
types O O
using O O
PCR-ELISA O O
method O O
based O O
L1 O O
SPF10 O O
consensus O O
primers O O
, O O
real-time O O
PCR O O
method O O
targeting O O
HPV-16 B-virus B-virus
HPV-18 B-virus B-virus
E6 O O
region O O
. O O

Genotyping O O
HPV-positive B-virus B-virus
cases O O
performed O O
using O O
reverse O O
line O O
blot O O
hybridization O O
assay O O
( O O
Inno-LiPA O O
) O O
. O O

RNAScope O O

The O O
infectious O O
nature O O
salivary O O
gland O O
neoplasms O O
revealed O O
high O O
prevalence O O
HPV B-virus B-virus
infection O O
, O O
specific O O
presence O O
EBV B-virus B-virus
Warthin O O
's O O
tumours O O
, O O
suggesting O O
potential O O
role O O
HPV B-virus B-virus
EBV B-virus B-virus
salivary O O
gland O O
diseases O O
. O O


Overall O O
, O O
review O O
points O O
smoking O O
tobacco O O
posing O O
additional O O
risk O O
development O O
head O O
neck O O
cancer O O
presence O O
HPV B-virus B-virus
infection O O
. O O

This O O
consistent O O
available O O
laboratory O O
data O O
show O O
evidence O O
biological O O
plausibility O O
interaction O O
smoking O O
progression O O
HPV B-virus B-virus
infection O O
carcinogenesis O O
. O O

It O O
therefore O O
important O O
cessation O O
smoking O O
promoted O O
smokers O O
HPV B-virus B-virus
infection O O
. O O

Chronic O O
rhinosinusitis O O
( O O
CRS O O
) O O
common O O
illness O O
, O O
yet O O
little O O
known O O
pathogenesis O O
, O O
including O O
role O O
played O O
respiratory O O
viruses B-virus B-virus
. O O

The O O
exact O O
etiopathogenesis O O
Warthin O O
's O O
tumor O O
parotid O O
gland O O
still O O
unclear O O
. O O

The O O
aim O O
present O O
study O O
evaluate O O
HPV B-virus B-virus
could O O
play O O
role O O
development O O
parotid O O
lesion O O
. O O

In O O
recent O O
years O O
, O O
incidence O O
Human B-virus B-virus
Papilloma I-virus I-virus
Virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCC O O
) O O
markedly O O
increased O O
. O O

Our O O
aim O O
design O O
novel O O
therapeutic O O
agent O O
use O O
conditionally O O
replicative O O
adenoviruses O O
( O O
CRAds O O
) O O
targeted O O
HPV B-virus B-virus
E6 O O
E7 O O
oncoproteins O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
oropharyngeal O O
carcinoma O O
recognized O O
clinically O O
distinct O O
subtype O O
head O O
neck O O
cancer O O
important O O
prognostic O O
implications O O
. O O

HPV B-virus B-virus
testing O O
recommended O O
standard O O
care O O
patients O O
diagnosed O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
. O O

Here O O
, O O
describe O O
practical O O
approach O O
HPV B-virus B-virus
testing O O
within O O
setting O O
diagnostic O O
histopathology O O
laboratory O O
. O O

We O O
shown O O
presence O O
transcriptionally O O
active O O
HPV B-virus B-virus
rarely O O
occurs O O
OSCC O O
p16 O O
appropriate O O
surrogate O O
marker O O
HPV B-virus B-virus
OSCC O O
cases O O
. O O

We O O
propose O O
non-viral O O
mechanisms O O
responsible O O
majority O O
IHC O O
p16 O O
overexpression O O
OSCC O O
. O O

Among O O
59 O O
patients O O
, O O
49 O O
( O O
83 O O
% O O
) O O
EBV-positive/HPV-negative B-virus B-virus
, O O
2 O O
( O O
3 O O
% O O
) O O
EBV-positive/HPV-positive B-virus B-virus
, O O
8 O O
( O O
16 O O
% O O
) O O
EBV-negative/HPV-negative B-virus B-virus
. O O

All O O
HPV-positive B-virus B-virus
NPCs O O
co-infected O O
EBV B-virus B-virus
. O O

There O O
significant O O
differences O O
overall O O
survival O O
three O O
groups O O
( O O
p=0.111 O O
) O O
. O O

This O O
study O O
aimed O O
determine O O
prevalence O O
human B-virus B-virus
papilomavirus E-virus E-virus
genotype O O
distribution O O
HPV16 B-virus B-virus
HPV18 O B-virus
oral O O
cavity O O
oropharynx O O
carcinomas O O
, O O
well O O
association O O
clinical O O
characteristics O O
tumors O O
. O O

One O O
six O O
cancers O O
worldwide O O
caused O O
infection O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
one O O
main O O
culprits O O
. O O

To O O
better O O
understand O O
dynamics O O
HPV B-virus B-virus
integration O O
effect O O
viral O O
host O O
methylomes O O
, O O
conducted O O
whole-genome O O
DNA O O
methylation O O
analysis O O
using O O
MeDIP-seq O O
HPV+ B-virus B-virus
HPV- B-virus B-virus
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
. O O

We O O
determined O O
viral O O
subtype O O
HPV-16 B-virus B-virus
cases O O
show O O
HPV-16 B-virus B-virus
integrates O O
host O O
genome O O
multiple O O
random O O
sites O O
process O O
predominantly O O
involves O O
transcriptional O O
repressor O O
gene O O
( O O
E2 O O
) O O
viral O O
genome O O
. O O

Comparative O O
analysis O O
identified O O
453 O O
( O O
FDR O O
â‰¤ O O
0.01 O O
) O O
differentially O O
methylated O O
regions O O
( O O
DMRs O O
) O O
HPV+ B-virus B-virus
host O O
methylome O O
. O O

Bioinformatics O O
characterization O O
DMRs O O
confirmed O O
previously O O
reported O O
cadherin O O
genes O O
affected O O
also O O
revealed O O
new O O
targets O O
HPV-mediated B-virus B-virus
methylation O O
changes O O
regions O O
covered O O
array-based O O
platforms O O
, O O
including O O
recently O O
identified O O
super-enhancers O O
. O O

M. O O
tuberculosis O O
common O O
pathogen O O
isolated O O
cervical O O
lymph O O
nodes O O
. O O

The O O
factor O O
associated O O
IRIS O O
infection O O
nontuberculous O O
mycobacteria O O
. O O

The O O
unexpectedly O O
high O O
incidence O O
mycobacterial-associated O O
IRIS O O
underlines O O
relevance O O
head O O
neck O O
examination O O
ART O O
initiation O O
. O O

Despite O O
reduction O O
smoking O O
alcohol O O
consumption O O
, O O
incidence O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OPSCC O O
) O O
rising O O
. O O

This O O
attributed O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
screening O O
HPV B-virus B-virus
recommended O O
cases O O
OPSCC O O
. O O

Despite O O
variety O O
clinically O O
available O O
tests O O
new O O
non-invasive O O
test O O
strategies O O
consensus O O
technique O O
best O O
. O O

This O O
review O O
reports O O
current O O
techniques O O
HPV B-virus B-virus
detection O O
OPSCC O O
clinical O O
applicability O O
emerging O O
techniques O O
. O O

Literature O O
searches O O
Medline O O
, O O
Embase O O
clinicaltrials.gov O O
using O O
search O O
terms O O
'head O O
neck O O
neoplasms O O
' O O
, O O
'squamous O O
cell O O
carcinoma O O
' O O
'HPV B-virus B-virus
testing O O
' O O
performed O O
. O O

45 O O
studies O O
identified O O
included O O
. O O

p16 O O
immunohistochemistry O O
( O O
IHC O O
) O O
, O O
HPV B-virus B-virus
DNA O O
situ O O
hybridization O O
( O O
ISH O O
) O O
HPV B-virus B-virus
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
commonest O O
tests O O
determine O O
HPV B-virus B-virus
status O O
. O O

p16 O O
IHC O O
HPV B-virus B-virus
DNA O O
PCR O O
highly O O
sensitive O O
whilst O O
HPV B-virus B-virus
DNA O O
ISH O O
specific O O
, O O
techniques O O
conventionally O O
utilize O O
surgical O O
biopsies O O
. O O

New O O
tests O O
using O O
PCR O O
screen O O
fine O O
needle O O
aspirates O O
, O O
saliva O O
, O O
brush O O
cytology O O
serum O O
HPV B-virus B-virus
promising O O
variable O O
sensitivity O O
specificity O O
. O O

These O O
non-invasive O O
samples O O
avoid O O
morbidity O O
surgical O O
biopsies O O
need O O
tissue O O
blocks O O
; O O
clinical O O
role O O
screening O O
surveillance O O
remains O O
largely O O
untested O O
. O O

Further O O
work O O
needed O O
validate O O
tests O O
define O O
role O O
. O O

Laryngoscope O O
, O O
126:2500-2504 O O
, O O
2016 O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
viruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
, O O
members O O
papillomaviridae O O
family O O
, O O
infects O O
squamous O O
epithelial O O
cells O O
cevix O O
, O O
lower O O
genitalia O O
, O O
oral O O
cavity O O
. O O

The O O
association O O
HPV B-virus B-virus
oropharyngeal O O
carcinogenesis O O
well O O
documented.The O O
incidence O O
oral O O
cancer O O
ranks O O
second O O
Karachi O O
South O O
genders O O
according O O
World O O
Health O O
Organization O O
( O O
WHO O O
) O O
statistics O O
. O O

This O O
attributed O O
popularity O O
chewable O O
tobacco O O
products O O
among O O
general O O
population O O
. O O

Studies O O
Gutka-eaters O O
set O O
population O O
Karachi O O
showed O O
high O O
frequency O O
HPV B-virus B-virus
( O O
17 O O
% O O
) O O
high O O
prevalence O O
HPV B-virus B-virus
squamous O O
cell O O
carcinoma O O
Pakistani O O
patients O O
( O O
68 O O
% O O
) O O
. O O

The O O
exposure O O
oral O O
mucosa O O
chewable O O
tobacco O O
causes O O
abrasions O O
making O O
susceptible O O
HPV B-virus B-virus
. O O

This O O
review O O
strives O O
summarise O O
role O O
HPV B-virus B-virus
chewable O O
tobacco-related O O
precancerous O O
cancerous O O
lesions O O
. O O

The O O
literature O O
decade O O
retrieved O O
Google O O
pubMed O O
mentioned O O
key O O
words O O
. O O

It O O
found O O
use O O
chewable O O
tobacco O O
products O O
, O O
especially O O
Gutka O O
, O O
may O O
increase O O
risk O O
oral O O
squamous O O
cell O O
carcinoma O O
( O O
OSCC O O
) O O
. O O


P16 O O
expression O O
HPV B-virus B-virus
DNA O O
detected O O
leukoplakia O O
specimens O O
. O O

Of O O
427 O O
HNSCC O O
tumors O O
, O O
9 O O
showed O O
p16 O O
overexpression O O
7/427 O O
cases O O
positive O O
HPV16 B-virus B-virus
DNA O O
, O O
saliva O O
tissue O O
. O O

E6/E7 O O
mRNA O O
positivity O O
observed O O
8 O O
HNSCC O O
samples O O
, O O
primarily O O
patients O O
habit O O
tobacco O O
consumption O O
. O O

The O O
prevalence O O
high-risk O B-virus
HPV B-virus E-virus
restricted O O
oropharynx O O
larynx O O
, O O
little O O
concordance O O
p16 O O
overexpression O O
HPV B-virus B-virus
positivity O O
. O O

All O O
patients O O
HPV-positive B-virus B-virus
saliva O O
samples O O
transcriptionally O O
active O O
HPV B-virus B-virus
present O O
tumors O O
. O O

The O O
aim O O
study O O
ascertain O O
prevalence O O
prognostic O O
value O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
status O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
. O O

Immunohistochemistry O O
GenoArray O O
HPV B-virus B-virus
genotyping O O
assays O O
used O O
evaluate O O
HPV B-virus B-virus
infection O O
status O O
256 O O
Chinese O O
patients O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
. O O

Long-term O O
survival O O
rates O O
calculated O O
using O O
Kaplan-Meier O O
method O O
. O O

Immunostaining O O
p16 O O
prevalent O O
6.6 O O
% O O
( O O
17/256 O O
) O O
patients O O
, O O
whereas O O
HPV B-virus B-virus
infection O O
detected O O
9 O O
256 O O
( O O
3.5 O O
% O O
) O O
patients O O
using O O
HPV B-virus B-virus
genotyping O O
test O O
. O O

None O O
p16-negative O O
subjects O O
found O O
HPV B-virus B-virus
infection O O
according O O
HPV B-virus B-virus
genotyping O O
test O O
. O O

P16 O O
positivity O O
common O O
among O O
nonsmokers O O
smokers O O
( O O
16.3 O O
% O O
vs. O O
4.7 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.02 O O
) O O
. O O

Among O O
nine O O
HPV-positive B-virus B-virus
cases O O
, O O
seven O O
infected O O
HPV-16 B-virus B-virus
, O O
one O O
HPV-33 B-virus B-virus
, O O
one O O
HPV-16 B-virus B-virus
HPV-11 B-virus B-virus
. O O

The O O
3-year O O
overall O O
survival O O
rate O O
87.5 O O
% O O
p16-positive/HPV-positive B-virus B-virus
patients O O
, O O
75 O O
% O O
p16-positive/HPV-negative B-virus B-virus
patients O O
, O O
76.9 O O
% O O
p16-negative/HPV-negative B-virus B-virus
patients O O
( O O
P O O
= O O
0.3 O O
) O O
. O O

A O O
low O O
rate O O
HPV B-virus B-virus
infection O O
found O O
among O O
study O O
patients O O
. O O

HPV B-virus B-virus
infection O O
status O O
may O O
useful O O
prognostic O O
marker O O
head O O
neck O O
cancer O O
patients O O
. O O

The O O
viral O O
ribonucleoprotein O O
( O O
vRNP O O
) O O
influenza B-virus B-virus
A I-virus I-virus
virus E-virus E-virus
formed O O
virion O O
RNA O O
( O O
vRNA O O
) O O
, O O
viral O O
polymerase O O
complex O O
, O O
nucleoprotein O O
( O O
NP O O
) O O
. O O

The O O
NP O O
plays O O
important O O
role O O
facilitating O O
replication O O
stabilization O O
viral O O
RNA O O
. O O

To O O
explore O O
host O O
factors O O
may O O
involved O O
regulation O O
viral O O
replication O O
interactions O O
NP O O
, O O
conducted O O
immunoprecipitation O O
experiment O O
followed O O
mass O O
spectrometry O O
identify O O
NP-associated O O
cellular O O
proteins O O
. O O

Here O O
, O O
demonstrate O O
NP O O
interact O O
colocalize O O
heterogeneous O O
nuclear O O
ribonucleoprotein O O
( O O
hnRNP O O
) O O
A2/B1 O O
mammalian O O
cells O O
interaction O O
may O O
occur O O
via O O
direct O O
binding O O
glycine-rich O O
domain O O
( O O
GRD O O
) O O
hnRNP O O
A2/B1 O O
. O O

In O O
addition O O
, O O
two O O
residues O O
tail O O
loop O O
NP O O
, O O
F412 O O
R422 O O
, O O
required O O
interaction O O
hnRNP O O
A2/B1 O O
. O O

Because O O
knockdown O O
hnRNP O O
A2/B1 O O
expression O O
reduces O O
viral O O
RNP O O
activity O O
, O O
hnRNP O O
A2/B1 O O
may O O
act O O
positive O O
regulator O O
viral O O
RNA O O
synthesis O O
influenza B-virus B-virus
A I-virus I-virus
virus E-virus E-virus
. O O

More O O
importantly O O
, O O
findings O O
research O O
demonstrate O O
host O O
proteins O O
regulate O O
replication O O
influenza B-virus B-virus
A I-virus I-virus
virus E-virus E-virus
interacting O O
NP O O
. O O

Oncolytic O O
viral O O
therapy O O
represents O O
promising O O
strategy O O
treatment O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
, O O
dl1520 O O
( O O
ONYX-015 O O
) O O
widely O O
used O O
oncolytic O O
adenovirus O O
clinical O O
trials O O
. O O

This O O
study O O
aimed O O
determine O O
effectiveness O O
Lister O O
vaccine O O
strain O O
vaccinia B-virus B-virus
virus E-virus E-virus
well O O
vaccinia B-virus B-virus
virus E-virus E-virus
armed O O
endostatin-angiostatin O O
fusion O O
gene O O
( O O
VVhEA O O
) O O
novel O O
therapy O O
HNSCC O O
compare O O
dl1520 O O
. O O

The O O
potency O O
replication O O
Lister O O
strain O O
VVhEA O O
expression O O
function O O
fusion O O
protein O O
determined O O
human O O
HNSCC O O
cells O O
vitro O O
vivo O O
. O O

Finally O O
, O O
efficacy O O
VVhEA O O
compared O O
dl1520 O O
vivo O O
human O O
HNSCC O O
model O O
. O O

The O O
Lister O O
vaccine O O
strain O O
vaccinia B-virus B-virus
virus E-virus E-virus
effective O O
adenovirus O O
HNSCC O O
cell O O
lines O O
tested O O
vitro O O
. O O

Although O O
potency O O
VVhEA O O
attenuated O O
vitro O O
, O O
expression O O
function O O
endostatin-angiostatin O O
fusion O O
protein O O
confirmed O O
HNSCC O O
models O O
vitro O O
vivo O O
. O O

This O O
novel O O
vaccinia B-virus B-virus
virus E-virus E-virus
( O O
VVhEA O O
) O O
demonstrated O O
superior O O
antitumor O O
potency O O
vivo O O
compared O O
dl1520 O O
control O O
vaccinia B-virus B-virus
virus E-virus E-virus
. O O

This O O
study O O
suggests O O
Lister O O
strain O O
vaccinia B-virus B-virus
virus E-virus E-virus
armed O O
endostatin-angiostatin O O
fusion O O
gene O O
may O O
potential O O
therapeutic O O
agent O O
HNSCC O O
. O O

The O O
roles O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
head O O
neck O O
neoplasms O O
well O O
reported O O
, O O
little O O
known O O
relationship O O
salivary O O
gland O O
tumours O O
. O O

This O O
study O O
investigated O O
presence O O
HPV B-virus B-virus
EBV B-virus B-virus
salivary O O
gland O O
diseases O O
. O O

The O O
transduction O O
analysis O O
luciferase-expressing O O
viruses B-virus B-virus
demonstrated O O
5æœˆ3æ—¥ B-virus B-virus
fiber O O
modification O O
maximized O O
virus B-virus B-virus
infectivity O O
. O O

In O O
vitro O O
, O O
viruses B-virus B-virus
( O O
5/324 B-virus B-virus
5/3CB016 B-virus B-virus
) O O
demonstrated O O
profound O O
oncolytic O O
effects O O
. O O

The O O
5/3CB016 B-virus B-virus
virus E-virus E-virus
selective O O
HPV-positive B-virus B-virus
HNSCC O O
cells O O
, O O
whereas O O
5/324 B-virus B-virus
virus E-virus E-virus
killed O O
HNSCC O O
cells O O
regardless O O
HPV B-virus B-virus
status O O
. O O

In O O
vivo O O
, O O
single O O
injections O O
viruses B-virus B-virus
demonstrated O O
anti-tumor O O
effects O O
days O O
following O O
viral O O
inoculation O O
. O O

However O O
, O O
four O O
viral O O
injections O O
, O O
statistically O O
significant O O
reductions O O
tumor O O
growth O O
compared O O
control O O
group O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

The O O
aim O O
study O O
screen O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infections O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCCs O O
) O O
using O O
P16 O O
immunostaining O O
. O O

In O O
screening O O
group O O
, O O
6.9 O O
% O O
1.2 O O
% O O
screening O O
rate O O
noted O O
cut O O
points O O
> O O
0 O O
> O O
0.001 O O
, O O
respectively O O
. O O

The O O
results O O
provide O O
data O O
inform O O
public O O
health O O
considerations O O
feasibility O O
saliva O O
screening O O
tool O O
at-risk O O
populations O O
long-term O O
goal O O
prophylactic O O
vaccination O O
oral O O
HPV B-virus B-virus
. O O

Brushings O O
tumor O O
surface O O
compared O O
HPV B-virus B-virus
DNA O O
isolation O O
formalin-fixed O O
paraffin-embedded O O
( O O
FFPE O O
) O O
tumor O O
biopsies O O
, O O
served O O
reference O O
standard O O
. O O

In O O
matrices O O
, O O
HPV B-virus B-virus
DNA O O
detected O O
using O O
commercially O O
available O O
test O O
kit O O
. O O

In O O
addition O O
, O O
p16 O O
assessed O O
tumor O O
biopsies O O
immunohistochemistry O O
( O O
IHC O O
) O O
. O O

The O O
tumors O O
considered O O
p16 O O
positive O O
70 O O
% O O
cancer O O
cells O O
expressed O O
p16 O O
. O O

TP53 O O
mutations O O
determined O O
direct O O
sequencing O O
paraffin-embedded O O
carcinoma O O
tissue O O
31 O O
young O O
patients O O
compared O O
two O O
older O O
age O O
OSCC O O
reference O O
groups O O
: O O
one O O
institute O O
( O O
N O O
= O O
87 O O
) O O
independent O O
one O O
( O O
N O O
= O O
675 O O
) O O
. O O

Biologically O O
active O O
tumour O O
HPV B-virus B-virus
detected O O
p16-immunohistochemistry O O
followed O O
HPV-DNA B-virus B-virus
GP5 O O
+ O O
/6 O O
+ O O
#NAME? O O
. O O

We O O
utilized O O
guidelines O O
identify O O
health O O
issues O O
would O O
indicate O O
value O O
evaluation O O
prior O O
safely O O
prescribed O O
unsupervised O O
exercise O O
. O O

We O O
performed O O
retrospective O O
chart O O
review O O
150 O O
patients O O
HPV-related B-virus B-virus
HNC O O
assess O O
health O O
issues O O
6 O O
months O O
completing O O
definitive O O
therapy O O
. O O

Patients O O
least O O
one O O
health O O
issue O O
deemed O O
appropriate O O
receive O O
evaluation O O
prior O O
prescription O O
unsupervised O O
exercise O O
. O O

We O O
utilized O O
logistic O O
regression O O
identify O O
clinical O O
demographic O O
factors O O
associated O O
need O O
evaluation O O
, O O
likely O O
performed O O
outpatient O O
rehabilitation O O
clinicians O O
. O O

We O O
identified O O
patients O O
human B-virus B-virus
papilloma I-virus I-virus
virus-related E-virus E-virus
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
staging O O
neck O O
CTs O O
. O O

Demographic O O
clinical O O
variables O O
recorded O O
. O O

We O O
retrospectively O O
classified O O
metastatic O O
lymph O O
node O O
burden O O
CT O O
cystic O O
solid O O
assessed O O
radiologic O O
extracapsular O O
spread O O
. O O

Biopsy O O
, O O
subsequent O O
imaging O O
, O O
clinical O O
follow-up O O
reference O O
standard O O
treatment O O
failure O O
. O O

The O O
primary O O
end O O
point O O
disease-free O O
survival O O
. O O

Cox O O
proportional O O
hazard O O
regression O O
analyses O O
clinical O O
, O O
demographic O O
, O O
anatomic O O
variables O O
treatment O O
failure O O
performed O O
. O O

This O O
study O O
shows O O
TP53 O O
mutations O O
common O O
OSCC O O
young O O
adult O O
patients O O
; O O
infection O O
biologically O O
active O O
HPV B-virus B-virus
rare O O
. O O

93 O O
patients O O
HNSCC O O
included O O
. O O

Sensitivity O O
specificity O O
brush O O
test O O
83 O O
% O O
( O O
95 O O
% O O
CI O O
: O O
67-92 O O
% O O
) O O
85 O O
% O O
( O O
95 O O
% O O
CI O O
: O O
72-93 O O
% O O
) O O
. O O

Results O O
p16 O O
IHC O O
concordant O O
FFPE O O
samples O O
DNA O O
determinations O O
73/93 O O
patients O O
. O O

In O O
53 O O
patients O O
( O O
57 O O
% O O
) O O
tumor O O
located O O
oropharynx O O
40 O O
patients O O
( O O
43 O O
% O O
) O O
tumor O O
located O O
non-oropharynx O O
region O O
. O O

Sensitivity O O
specificity O O
brush O O
test O O
patients O O
oropharyngeal O O
cancer O O
higher O O
86 O O
% O O
( O O
95 O O
% O O
CI O O
: O O
70-95 O O
% O O
) O O
89 O O
% O O
( O O
95 O O
% O O
CI O O
: O O
65-99 O O
% O O
) O O
. O O

Oncogenic O O
HPV B-virus B-virus
infection O O
found O O
19.23 O O
% O O
HNSCCs O O
, O O
genotype O O
16 O O
predominating O O
. O O

HPV-related B-virus B-virus
HNSCC O O
tended O O
occur O O
younger O O
age O O
compared O O
non-HPV-related B-virus B-virus
HNSCC O O
. O O

The O O
commonest O O
site O O
HPV-associated B-virus B-virus
HNSSC O O
Ghana O O
larynx O O
, O O
rather O O
oropharynx O O
reported O O
studies O O
. O O

Host O O
factors O O
may O O
responsible O O
site O O
difference O O
work O O
required O O
elucidate O O
. O O

In O O
cohort O O
patients O O
, O O
39.3 O O
% O O
could O O
safely O O
prescribed O O
unsupervised O O
exercise O O
6 O O
months O O
completing O O
definitive O O
therapy O O
. O O

On O O
multivariable O O
regression O O
, O O
older O O
age O O
, O O
BMI O O
> O O
30 O O
, O O
receipt O O
radiation O O
associated O O
increased O O
likelihood O O
requiring O O
evaluation O O
supervised O O
exercise O O
. O O

A O O
critical O O
review O O
applies O O
growth O O
utilization O O
interprofessional O O
education O O
( O O
IPE O O
) O O
interprofessional O O
collaboration O O
( O O
IPC O O
) O O
multi-disciplinary O O
models O O
addressing O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
oropharyngeal O O
cancers O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
oral O O
infection O O
related O O
several O O
factors O O
including O O
HIV B-virus B-virus
infection O O
, O O
cigarette O O
smoking O O
, O O
marijuana O O
consumption O O
number O O
sexual O O
partners O O
. O O

We O O
conducted O O
study O O
oral O O
HPV B-virus B-virus
prevalence O O
clearance O O
among O O
hosts O O
San O O
Patrignano O O
community O O
, O O
population O O
considered O O
`` O O
high-risk B-virus B-virus
'' O O
HPV E-virus E-virus
due O O
previous O O
habits O O
. O O

Immunoglobulin O O
G4 O O
( O O
IgG4 O O
) O O
#NAME? O O
disease O O
( O O
IgG4-RD O O
) O O
immune-mediated O O
condition O O
characterized O O
infiltration O O
involved O O
organs O O
IgG4-bearing O O
plasma O O
cells O O
. O O

The O O
prevalence O O
autoimmune O O
diseases O O
, O O
associated O O
occurring O O
patients O O
human B-virus B-virus
immunodeficiency I-virus I-virus
virus E-virus E-virus
( O O
HIV B-virus B-virus
) O O
infection O O
, O O
increasing O O
. O O

We O O
describe O O
58-year-old O O
man O O
undiagnosed O O
HIV B-virus B-virus
infection O O
, O O
presented O O
chronic O O
cervical O O
lymphadenopathy O O
elevated O O
serum O O
IgG4 O O
high O O
IgE O O
. O O

Histologically O O
, O O
lymph O O
nodes O O
showed O O
expanded O O
sinusoids O O
burnt-out O O
germinal O O
centers O O
increased O O
plasmacytic O O
infiltration O O
collagen O O
fiber O O
deposition O O
. O O

The O O
absolute O O
number O O
IgG4+ O O
plasma O O
cells O O
IgG4+/IgG+ O O
plasma O O
cell O O
ratio O O
increased O O
. O O

The O O
lymph O O
nodes O O
enlarged O O
clinically O O
patient O O
improved O O
steroid O O
treatment O O
. O O

Nine O O
months O O
later O O
, O O
diagnosed O O
acquired O O
immune O O
deficiency O O
syndrome O O
, O O
following O O
presentation O O
cavitary O O
left O O
lung O O
lesion O O
. O O

Immunohistochemical O O
studies O O
previously O O
resected O O
lymph O O
node O O
revealed O O
complete O O
absence O O
CD4+ O O
T-lymphocytes O O
increased O O
CD8+ O O
T-lymphocytes O O
. O O

The O O
pathologic O O
findings O O
met O O
criteria O O
HIV B-virus B-virus
infection O O
IgG4-related O O
lymphadenopathy O O
. O O

Our O O
case O O
demonstrates O O
investigations O O
underlying O O
HIV B-virus B-virus
infection O O
case O O
IgG4-RD O O
critical O O
, O O
especially O O
extremely O O
elevated O O
IgE O O
concomitantly O O
present O O
. O O

We O O
developed O O
virus B-virus B-virus
detection O O
discovery O O
computational O O
pipeline O O
, O O
Pickaxe O O
, O O
applied O O
NGS O O
databases O O
provided O O
The O O
Cancer O O
Genome O O
Atlas O O
( O O
TCGA O O
) O O
. O O

We O O
analyzed O O
collection O O
whole O O
genome O O
( O O
WGS O O
) O O
, O O
exome O O
( O O
WXS O O
) O O
, O O
RNA O O
( O O
RNA-Seq O O
) O O
sequencing O O
libraries O O
3052 O O
participants O O
across O O
22 O O
different O O
cancers O O
. O O

NGS O O
data O O
nearly O O
tumor O O
normal O O
tissues O O
examined O O
contained O O
contaminating O O
viral O O
sequences O O
. O O

Intensive O O
computational O O
manual O O
efforts O O
required O O
remove O O
artifacts O O
. O O

We O O
found O O
several O O
different O O
types O O
cancers O O
harbored O O
Herpesviruses O O
including O O
EBV B-virus B-virus
, O O
CMV B-virus B-virus
, O O
HHV1 B-virus B-virus
, O O
HHV2 B-virus B-virus
, O O
HHV6 B-virus B-virus
HHV7 B-virus B-virus
. O O

In O O
addition O O
reported O O
associations O O
Hepatitis B-virus B-virus
B I-virus I-virus
C I-virus I-virus
virus E-virus E-virus
( O O
HBV B-virus B-virus
& O O
HCV B-virus B-virus
) O O
liver O O
cancer O O
, O O
Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
cervical O O
cancer O O
subset O O
head O O
neck O O
cancers O O
, O O
found O O
additional O O
cases O O
HPV B-virus B-virus
integrated O O
small O O
number O O
bladder O O
cancers O O
. O O

Gene O O
expression O O
mutational O O
profiles O O
suggest O O
HPV B-virus B-virus
drives O O
tumorigenesis O O
cases O O
. O O

The O O
presence O O
HPV B-virus B-virus
16/18 O O
EBV B-virus B-virus
analysed O O
archival O O
pathological O O
specimens O O
collected O O
patients O O
undergone O O
surgery O O
salivary O O
gland O O
diseases O O
. O O

HPV B-virus B-virus
16/18 O O
DNA O O
detected O O
using O O
nested O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
confirmed O O
immunohistochemistry O O
. O O

EBV B-virus B-virus
DNA O O
detected O O
using O O
real-time O O
PCR O O
. O O

Oncolytic B-virus B-virus
viruses E-virus E-virus
( O O
OV B-virus B-virus
) O O
preferentially O O
kill O O
cancer O O
cells O O
due O O
part O O
defects O O
antiviral O O
responses O O
upon O O
exposure O O
type O O
I O O
interferons O O
( O O
IFNs O O
) O O
. O O

However O O
, O O
IFN O O
responsiveness O O
tumor O O
cells O O
confers O O
resistance O O
OV B-virus B-virus
treatment O O
. O O

The O O
human O O
type O O
I O O
IFNs O O
include O O
one O O
IFN-å°¾ O O
multiple O O
IFN-ä¼ª O O
subtypes O O
share O O
receptor O O
capable O O
differentially O O
inducing O O
biological O O
responses O O
. O O

The O O
role O O
individual O O
IFN O O
subtypes O O
promoting O O
tumor O O
cell O O
resistance O O
OV B-virus B-virus
addressed O O
. O O

Two O O
human O O
IFNs O O
produced O O
clinical O O
use O O
, O O
IFN-ä¼ª2a O O
IFN-å°¾ O O
, O O
compared O O
activity O O
protecting O O
human O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
lines O O
oncolysis B-virus B-virus
vesicular I-virus I-virus
stomatitis I-virus I-virus
virus E-virus E-virus
( O O
VSV B-virus B-virus
) O O
. O O

Susceptibility O O
HNSCC O O
lines O O
killing O O
VSV B-virus B-virus
varied O O
. O O

VSV B-virus B-virus
infection O O
induced O O
increased O O
production O O
IFN-å°¾ O O
resistant O O
HNSCC O O
cells O O
. O O

When O O
added O O
exogenously O O
, O O
IFN-å°¾ O O
significantly O O
effective O O
protecting O O
HNSCC O O
cells O O
VSV B-virus B-virus
oncolysis O O
IFN-ä¼ª2a O O
. O O

In O O
contrast O O
, O O
normal O O
keratinocytes O O
endothelial O O
cells O O
protected O O
equivalently O O
IFN O O
subtypes O O
. O O

Differential O O
responsiveness O O
tumor O O
cells O O
IFN-ä¼ª O O
#NAME? O O
supported O O
finding O O
autocrine O O
IFN-å°¾ O O
IFN-ä¼ª O O
promoted O O
survival O O
HNSCC O O
cells O O
persistent O O
VSV B-virus B-virus
infection O O
. O O

Therefore O O
, O O
IFN-ä¼ª O O
#NAME? O O
differentially O O
affect O O
VSV B-virus B-virus
oncolysis O O
, O O
justifying O O
evaluation O O
comparison O O
IFN O O
subtypes O O
use O O
combination O O
VSV B-virus B-virus
therapy O O
. O O

Pairing O O
VSV B-virus B-virus
IFN-ä¼ª2a O O
may O O
enhance O O
selectivity O O
oncolytic O O
VSV B-virus B-virus
therapy O O
HNSCC O O
inhibiting O O
VSV B-virus B-virus
replication O O
normal O O
cells O O
without O O
corresponding O O
inhibition O O
cancer O O
cells O O
. O O

Patients O O
HPV-related B-virus B-virus
OPSCC O O
pN3 O O
nodal O O
disease O O
treated O O
surgery O O
adjuvant O O
therapy O O
favorable O O
long-term O O
survival O O
regional O O
control O O
. O O

Patients O O
five O O
pathologically O O
positive O O
lymph O O
nodes O O
may O O
higher O O
risk O O
recurrence O O
. O O

A O O
retrospective O O
review O O
archival O O
HNSCC O O
specimens O O
patient O O
demographic O O
clinical O O
data O O
accessioned O O
January O O
, O O
2007 O O
December O O
, O O
2009 O O
Department O O
Pathology O O
, O O
Korle-Bu O O
Teaching O O
Hospital O O
, O O
Accra O O
, O O
Ghana O O
. O O

In O O
addition O O
traditional O O
risk O O
factors O O
smoking O O
habits O O
alcohol O O
consumption O O
, O O
certain O O
microbes O O
also O O
play O O
important O O
role O O
generation O O
head O O
neck O O
carcinomas O O
. O O

Infection O O
high-risk O B-virus
human B-virus I-virus
papillomavirus E-virus E-virus
types O O
strongly O O
associated O O
development O O
oropharyngeal O O
carcinoma O O
, O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
appears O O
indispensable O O
development O O
non-keratinizing O O
squamous O O
cell O O
carcinoma O O
nasopharynx O O
. O O

Other O O
viruses B-virus B-virus
including O O
torque B-virus B-virus
teno I-virus I-virus
virus E-virus E-virus
hepatitis B-virus B-virus
C I-virus I-virus
virus E-virus E-virus
may O O
act O O
co-carcinogens O O
, O O
increasing O O
risk O O
malignant O O
transformation O O
. O O

A O O
shift O O
composition O O
oral O O
microbiome O O
associated O O
development O O
oral O O
squamous O O
cell O O
carcinoma O O
, O O
although O O
causal O O
casual O O
role O O
oral O O
bacteria O O
remains O O
clarified O O
. O O

Conversion O O
ethanol O O
acetaldehyde O O
, O O
mutagenic O O
compound O O
, O O
members O O
oral O O
microflora O O
well O O
fungi O O
including O O
Candida O O
albicans O O
others O O
potential O O
mechanism O O
may O O
increase O O
oral O O
cancer O O
risk O O
. O O

In O O
addition O O
, O O
distinct O O
Candida O O
spp O O
. O O

also O O
produce O O
NBMA O O
( O O
N-nitrosobenzylmethylamine O O
) O O
, O O
potent O O
carcinogen O O
. O O

Inflammatory O O
processes O O
elicited O O
microbes O O
may O O
also O O
facilitate O O
tumorigenesis O O
head O O
neck O O
region O O
. O O

The O O
increasing O O
incidence O O
head O O
neck O O
cancer O O
( O O
HNSCC O O
) O O
highlights O O
need O O
better O O
understand O O
role O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
development O O
cancers O O
. O O

The O O
aims O O
study O O
conduct O O
systematic O O
review O O
meta-analysis O O
concerning O O
observational O O
studies O O
association O O
HPV B-virus B-virus
infection O O
HNSCC O O
quantify O O
association O O
, O O
thereby O O
obtaining O O
reliable O O
estimation O O
risk O O
HPV B-virus B-virus
infection O O
development O O
head O O
neck O O
cancer O O
. O O

Literature O O
searches O O
performed O O
using O O
PubMed O O
Scopus O O
databases O O
. O O

StatsDirect O O
2.7.8 O O
program O O
used O O
analysis O O
. O O

We O O
found O O
15 O O
case-control O O
studies O O
, O O
63 O O
prevalence O O
studies O O
, O O
cohort O O
studies O O
. O O

The O O
pooled O O
odds O O
ratio O O
( O O
OR O O
) O O
included O O
case-control O O
studies O O
resulted O O
value O O
1.63 O O
( O O
95 O O
% O O
CI O O
1.27-2.09 O O
; O O
P O O
< O O
0.0001 O O
) O O
. O O

The O O
highest O O
pooled O O
OR O O
resulted O O
analysis O O
studies O O
examined O O
HPV B-virus B-virus
16 O O
genotype O O
association O O
oral O O
cavity O O
( O O
OR O O
5.36 O O
; O O
95 O O
% O O
CI O O
1.4-20 O O
) O O
. O O

The O O
strong O O
evidence O O
association O O
HPV B-virus B-virus
infection O O
HNSCC O O
highlights O O
importance O O
introduction O O
specific O O
tests O O
cancer O O
prevention O O
practices O O
evaluate O O
presence O O
virus O B-virus
, O O
especially O O
oral O O
cavity O O
, O O
possibility O O
extension O O
vaccine O O
anti-HPV B-virus B-virus
male O O
population O O
. O O

Laboratory-based O O
translational O O
study O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
common O O
sexually O O
transmitted O O
viral O O
infection O O
. O O

Infection O O
certain O O
types O O
HPV B-virus B-virus
pose O O
major O O
public O O
health O O
risk O O
types O O
associated O O
multiple O O
human O O
cancers O O
, O O
including O O
cervical O O
cancer O O
, O O
anogenital O O
malignancies O O
increasing O O
number O O
head O O
neck O O
cancers O O
. O O

The O O
HPV B-virus B-virus
life O O
cycle O O
closely O O
tied O O
host O O
cell O O
differentiation O O
late O O
viral O O
events O O
structural O O
gene O O
expression O O
viral O O
genome O O
amplification O O
taking O O
place O O
upper O O
layers O O
stratified O O
epithelium O O
. O O

The O O
DNA O O
damage O O
response O O
( O O
DDR O O
) O O
elaborate O O
signaling O O
network O O
proteins O O
regulate O O
fidelity O O
replication O O
detecting O O
, O O
signaling O O
repairing O O
DNA O O
lesions O O
. O O

ATM O O
ATR O O
two O O
kinases O O
major O O
regulators O O
DNA O O
damage O O
detection O O
repair O O
. O O

A O O
multitude O O
studies O O
indicate O O
activation O O
ATM O O
( O O
Ataxia O O
telangiectasia O O
mutated O O
) O O
ATR O O
( O O
Ataxia O O
telangiectasia O O
Rad3-related O O
) O O
pathways O O
critical O O
HPV B-virus B-virus
productively O O
replicate O O
. O O

This O O
review O O
outlines O O
HPV B-virus B-virus
interfaces O O
ATM- O O
ATR-dependent O O
DNA O O
damage O O
responses O O
throughout O O
viral O O
life O O
cycle O O
create O O
environment O O
supportive O O
viral O O
replication O O
activation O O
pathways O O
could O O
impact O O
genomic O O
stability O O
. O O

The O O
significant O O
increase O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
oropharyngeal O O
carcinoma O O
( O O
OPC O O
) O O
recent O O
years O O
lead O O
surge O O
research O O
improved O O
understanding O O
disease O O
. O O

Most O O
patients O O
HPV-associated B-virus B-virus
OPC O O
present O O
cystic O O
nodal O O
metastases O O
small O O
primary O O
tumour O O
, O O
respond O O
well O O
treatment O O
modalities O O
including O O
primary O O
surgery O O
primary O O
chemoradiotherapy O O
. O O

Current O O
research O O
evaluating O O
treatment O O
de-escalation O O
reduce O O
long-term O O
treatment-associated O O
morbidities O O
. O O

Transoral O O
robotic O O
surgery O O
( O O
TORS O O
) O O
particularly O O
relevant O O
transoral O O
approach O O
allows O O
small O O
primary O O
tumours O O
removed O O
lower O O
morbidity O O
traditional O O
surgical O O
approaches O O
. O O

The O O
current O O
American O O
Joint O O
Committee O O
Cancer O O
staging O O
system O O
oropharyngeal O O
cancer O O
appropriately O O
stratify O O
HPV-associated B-virus B-virus
OPC O O
; O O
hence O O
, O O
alternative O O
risk O O
stratification O O
staging O O
classifications O O
proposed O O
. O O

Thirty-three O O
subjects O O
initiated O O
ART O O
diagnosed O O
cervical O O
lymph O O
node O O
mycobacteriosis O O
; O O
24 O O
Mycobacterium O O
tuberculosis O O
infection O O
nine O O
nontuberculous O O
disease O O
. O O

The O O
pattern O O
respiratory B-virus B-virus
virus E-virus E-virus
seasonality O O
found O O
nasal O O
mucosa O O
, O O
polyps O O
, O O
paranasal O O
sinus O O
samples O O
patients O O
CRS O O
reinforces O O
possibility O O
asymptomatic O O
respiratory O O
viral O O
infections O O
. O O

Recent O O
studies O O
revealed O O
important O O
intriguing O O
role O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
. O O

There O O
indications O O
prevalence O O
HPV-positive B-virus B-virus
HNSCC O O
recently O O
increased O O
, O O
genetic O O
analyses O O
point O O
completely O O
distinct O O
class O O
HNSCCs O O
. O O

Most O O
studies O O
suggest O O
patients O O
type O O
tumour O O
better O O
prognosis O O
argue O O
adjusted O O
therapeutic O O
approach O O
needed O O
. O O

One O O
crucial O O
point O O
research O O
HNSCC-HPV B-virus B-virus
involvement O O
often O O
neglected O O
, O O
lack O O
standardised O O
assay O O
detect O O
HPV B-virus B-virus
. O O

This O O
resulted O O
considerable O O
variation O O
frequency O O
HPV-positive B-virus B-virus
tumours O O
studies O O
reported O O
thus O O
far O O
. O O

Especially O O
PCR-based O O
tests O O
, O O
risk O O
exists O O
assay O O
sensitive O O
detects O O
virus B-virus B-virus
without O O
implying O O
causal O O
involvement O O
HNSCC O O
. O O

A O O
reliable O O
algorithm O O
detect O O
clinically O O
relevant O O
HPV B-virus B-virus
infection O O
formalin-fixed O O
paraffin O O
embedded O O
tissue O O
recently O O
become O O
available O O
. O O

Here O O
, O O
address O O
important O O
biological O O
analytical O O
aspects O O
HPV B-virus B-virus
involved O O
development O O
HNSCC O O
emphasised O O
standardised O O
HPV B-virus B-virus
assay O O
prerequisite O O
assessing O O
clinical O O
importance O O
HPV B-virus B-virus
infection O O
HNSCC O O
. O O

Cytological O O
samples O O
( O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
detection O O
) O O
laryngeal O O
secretions O O
( O O
immunoglobulin O O
assessment O O
) O O
obtained O O
31 O O
patients O O
laryngeal O O
disease O O
, O O
microscopic O O
laryngeal O O
surgery O O
. O O

On O O
histological O O
examination O O
, O O
12 O O
patients O O
squamous O O
cell O O
carcinoma O O
, O O
four O O
laryngeal O O
papilloma O O
15 O O
benign O O
laryngeal O O
disease O O
. O O

Cytological O O
samples O O
tested O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
DNA O O
using O O
Hybrid O O
Capture O O
2 O O
assay O O
. O O

Head O O
neck O O
cancers O O
constitute O O
multifactorial O O
global O O
disease O O
burden O O
associated O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
possible O O
risk O O
factor O O
. O O

The O O
aim O O
study O O
understand O O
relationship O O
HPV B-virus B-virus
development O O
head O O
neck O O
lesions O O
Indian O O
patients O O
. O O

To O O
end O O
, O O
frequency O O
HPV B-virus B-virus
assessed O O
relation O O
different O O
demographic O O
etiological O O
features O O
correlated O O
patient O O
survival O O
. O O

The O O
prevalence O O
HPV B-virus B-virus
significantly O O
increased O O
mild O O
dysplastic O O
lesions O O
( O O
43.6 O O
% O O
) O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
stage O O
IV O O
( O O
68.5 O O
% O O
) O O
HPV B-virus B-virus
16 O O
pre-dominant O O
dysplasia O O
( O O
43.8 O O
% O O
) O O
HNSCC O O
( O O
61.5 O O
% O O
) O O
. O O

Similar O O
trend O O
observed O O
increasing O O
grades O O
tumour O O
. O O

In O O
invasive O O
lesions O O
, O O
patients O O
aged O O
median O O
age O O
onset O O
showed O O
significantly O O
higher O O
occurrence O O
HPV B-virus B-virus
. O O

Patients O O
harbouring O O
HPV B-virus B-virus
showed O O
significantly O O
better O O
survival O O
irrespective O O
age O O
onset O O
. O O

Likewise O O
, O O
better O O
survival O O
observed O O
tobacco O O
habit O O
negative/HPV-positive B-virus B-virus
patients O O
, O O
reflected O O
univariate O O
multivariate O O
analysis O O
. O O

Majority O O
HPV B-virus B-virus
16-positive O O
samples O O
showed O O
moderate/high O O
nuclear O O
expression O O
HPV B-virus B-virus
E6 O O
E7 O O
proteins O O
tumours O O
respective O O
basal O O
layer O O
adjacent O O
normal O O
tissues O O
. O O

Thus O O
, O O
data O O
indicate O O
frequent O O
HPV B-virus B-virus
infection O O
, O O
along O O
tobacco O O
habit O O
, O O
pre-requisite O O
factor O O
development O O
HNSCC O O
Indian O O
patients O O
offers O O
better O O
survival O O
even O O
tobacco O O
usage O O
, O O
implicating O O
diagnostic O O
prognostic O O
importance O O
. O O

Viral O O
infections O O
, O O
including O O
cytomegalovirus B-virus B-virus
( O O
CMV B-virus B-virus
) O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
, O O
play O O
important O O
role O O
carcinogenesis O O
influence O O
patients O O
' O O
prognosis O O
condition O O
cancer O O
treatment.The O O
goal O O
study O O
investigate O O
CMV B-virus B-virus
EBV B-virus B-virus
infections O O
patients O O
receiving O O
radiotherapy O O
radiochemotherapy O O
due O O
head O O
neck O O
cancers O O
determine O O
influence O O
infections O O
risk O O
death O O
. O O

The O O
observation O O
period O O
2 O O
years.Of O O
41 O O
patients O O
enrolled O O
, O O
11 O O
received O O
radiotherapy O O
( O O
simultaneous-integrated O O
boost O O
intensity-modulated O O
radiation O O
therapy O O
[ O O
SIB-IMRT O O
] O O
, O O
2.25 O O
Gy/fraction O O
, O O
30 O O
fractions O O
, O O
[ O O
n O O
= O O
7 O O
] O O
IMRT O O
, O O
2 O O
Gy O O
per O O
fraction O O
, O O
35 O O
fractions O O
, O O
[ O O
n O O
= O O
4 O O
] O O
) O O
30 O O
received O O
radiochemotherapy O O
( O O
cisplatin O O
100 O O
mg/m O O
SIB-IMRT O O
[ O O
n O O
= O O
13 O O
] O O
IMRT O O
[ O O
n O O
= O O
17 O O
] O O
) O O
. O O

Plasma O O
CMV B-virus B-virus
EBV B-virus B-virus
DNA O O
levels O O
assessed O O
using O O
real-time O O
PCR O O
treatment O O
4 O O
weeks O O
posttreatment.The O O
risk O O
death O O
group O O
positive O O
plasma O O
CMV B-virus B-virus
EBV B-virus B-virus
deoxyribonucleic O O
acid O O
( O O
DNA O O
) O O
significantly O O
higher O O
compared O O
group O O
without O O
detectable O O
plasma O O
CMV B-virus B-virus
( O O
odd O O
ratio O O
[ O O
OR O O
] O O
: O O
7.5 O O
, O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
: O O
1.11-50.67 O O
) O O
EBV B-virus B-virus
DNA O O
( O O
OR O O
: O O
10.91 O O
, O O
95 O O
% O O
CI O O
: O O
1.135-104.8 O O
) O O
. O O

Results O O
confirmed O O
using O O
Bayesian O O
method O O
. O O

Plasma O O
positivity O O
CMV B-virus B-virus
EBV B-virus B-virus
DNA O O
associated O O
higher O O
risk O O
death O O
( O O
P O O
= O O
0.04 O O
) O O
.Viral O O
infections O O
negatively O O
affect O O
survival O O
patients O O
head O O
neck O O
cancers O O
. O O

Diagnosing O O
treating O O
viral O O
infections O O
patients O O
positive O O
results O O
considered O O
. O O

4 O O
. O O

Considering O O
adenoid O O
specimens O O
, O O
HBoV B-virus B-virus
found O O
frequent O O
virus B-virus B-virus
rate O O
43.1 O O
% O O
. O O

In O O
specimens O O
recurrent O O
tonsillitis O O
hypertrophic O O
tonsils O O
, O O
EBV B-virus B-virus
frequently O O
encountered O O
virus B-virus B-virus
( O O
53.8 O O
% O O
, O O
32 O O
% O O
, O O
respectively O O
) O O
. O O

In O O
children O O
hypertrophic O O
adenoids O O
, O O
HBoV B-virus B-virus
detected O O
positive O O
throughout O O
year O O
, O O
EBV B-virus B-virus
present O O
throughout O O
year O O
children O O
recurrent O O
tonsillitis O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infections O O
continue O O
one O O
common O O
sexually O O
transmitted O O
infections O O
worldwide O O
. O O

The O O
oncogenic O O
potential O O
virus O B-virus
well O O
established O O
anogenital O O
malignancies O O
oropharyngeal O O
cancers O O
. O O

Even O O
though O O
fall O O
cervical O O
cancer O O
rates O O
reported O O
worldwide O O
, O O
subsequent O O
rise O O
HPV-associated B-virus B-virus
head O O
neck O O
cancers O O
among O O
men O O
women O O
reported O O
developed O O
countries O O
, O O
necessitating O O
vaccination O O
adolescent O O
boys O O
well O O
. O O

The O O
objective O O
narrative O O
review O O
provide O O
update O O
current O O
status O O
HPV B-virus B-virus
vaccination O O
worldwide O O
. O O

This O O
helpful O O
clinicians O O
counseling O O
parents O O
guardians O O
vaccine O O
mainly O O
targets O O
sexually O O
naèŒ‚ve O O
preadolescents O O
. O O

An O O
electronic O O
search O O
databases O O
carried O O
retrieve O O
information O O
concerning O O
HPV B-virus B-virus
vaccine O O
implementation O O
July O O
2006 O O
2017 O O
, O O
special O O
emphasis O O
current O O
viewpoints O O
, O O
controversies O O
ethical O O
issues O O
. O O

Globally O O
, O O
74 O O
countries O O
implemented O O
HPV B-virus B-virus
vaccine O O
national O O
immunization O O
schedule O O
, O O
vaccine O O
listed O O
essential O O
medicine O O
WHO O O
. O O

About O O
60 O O
% O O
low- O O
lower-middle-income O O
countries O O
implemented O O
vaccine O O
financial O O
assistance O O
Gavi O O
WHO O O
. O O

The O O
HPV B-virus B-virus
vaccine O O
safe O O
vaccine O O
serious O O
adverse O O
effects O O
per O O
data O O
available O O
developed O O
nations O O
well O O
low/lower O O
middle/upper O O
middle-income O O
countries O O
. O O

However O O
, O O
long-term O O
follow-up O O
essential O O
substantiate O O
impact O O
vaccination O O
programs O O
cancer O O
prevention O O
. O O

Head O O
neck O O
cancers O O
( O O
HNC O O
) O O
, O O
90 O O
% O O
squamous O O
cell O O
carcinomas O O
( O O
SCC O O
) O O
, O O
rank O O
sixth O O
among O O
malignancies O O
worldwide O O
comprise O O
40-50 O O
% O O
total O O
number O O
malignancies O O
India O O
. O O

In O O
addition O O
alcohol O O
tobacco O O
usage O O
, O O
major O O
source O O
oral O O
carcinogens O O
, O O
viruses B-virus B-virus
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
may O O
also O O
contribute O O
development O O
malignancy O O
. O O

The O O
aim O O
study O O
identify O O
prevalence O O
HPV B-virus B-virus
head O O
neck O O
cancers O O
using O O
material O O
metastatic O O
site O O
. O O

A O O
total O O
111 O O
cases O O
neck O O
nodal O O
metastases O O
included O O
study O O
. O O

The O O
primary O O
identified O O
oral O O
cavity O O
, O O
oropharynx O O
nasopharynx O O
. O O

In O O
subset O O
, O O
primary O O
remained O O
`` O O
unknown O O
. O O
'' O O

Polymerase O O
chain O O
reaction O O
carried O O
detect O O
HPV B-virus B-virus
DNA O O
fine O O
needle O O
aspirates O O
. O O

HPV B-virus B-virus
detected O O
32.4 O O
% O O
cases O O
. O O

Maximum O O
positivity O O
observed O O
metastases O O
primary O O
oral O O
cavity O O
( O O
47.1 O O
% O O
) O O
tongue O O
( O O
55 O O
% O O
) O O
, O O
followed O O
oropharynx O O
( O O
25 O O
% O O
) O O
nasopharynx O O
( O O
5 O O
% O O
) O O
cases O O
. O O

In O O
unknown O O
primary O O
group O O
, O O
HPV B-virus B-virus
detected O O
52.9 O O
% O O
cases O O
. O O

Study O O
defines O O
association O O
HPV B-virus B-virus
HNC O O
population O O
northern O O
India O O
. O O

There O O
varied O O
association O O
HPV O B-virus
depending O O
site O O
primary O O
tumor O O
arising O O
mucosal O O
surfaces O O
head O O
neck O O
region O O
. O O

To O O
investigate O O
prevalence O O
, O O
genotypes O O
, O O
prognostic O O
values O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infections O O
Japanese O O
patients O O
different O O
types O O
head O O
neck O O
cancer O O
( O O
HNC O O
) O O
. O O

The O O
present O O
study O O
carried O O
determine O O
active O O
form O O
HPV-16 B-virus B-virus
using O O
combination O O
PCR O O
, O O
viral O O
load O O
determination O O
, O O
HPV-16 B-virus B-virus
E7 O O
mRNA O O
expression O O
, O O
p16 O O
, O O
p53 O O
, O O
pRB O O
immuno-histochemistry O O
( O O
IHC O O
) O O
. O O

There O O
considerable O O
debate O O
within O O
literature O O
significance O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
head O O
neck O O
squamous O O
cell O O
carcinoma O O
, O O
potential O O
influence O O
prevention O O
, O O
diagnosis O O
, O O
grading O O
, O O
treatment O O
prognosis O O
cancers O O
. O O

Cigarette O O
smoking O O
alcohol O O
consumption O O
traditionally O O
cited O O
main O O
risk O O
factors O O
head O O
neck O O
cancers O O
. O O

However O O
, O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
, O O
normally O O
associated O O
cervical O O
genital O O
carcinomas O O
, O O
emerged O O
possible O O
key O O
aetiological O O
factor O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
, O O
especially O O
oropharyngeal O O
cancers O O
. O O

These O O
cancers O O
pose O O
significant O O
financial O O
burden O O
health O O
resources O O
increasing O O
incidence O O
. O O

The O O
recent O O
introduction O O
vaccines O O
targeted O O
human B-virus B-virus
papilloma I-virus I-virus
virus I-virus E-virus
types I-virus I-virus
16 E-virus E-virus
18 E-virus E-virus
, O O
prevent O O
cervical O O
cancer O O
, O O
highlighted O O
need O O
ongoing O O
research O O
importance O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
head O O
neck O O
squamous O O
cell O O
carcinoma O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
oropharyngeal O O
cancer O O
generally O O
associated O O
excellent O O
response O O
therapy O O
, O O
HPV-positive B-virus B-virus
tumors O O
progress O O
despite O O
aggressive O O
therapy O O
. O O

The O O
purpose O O
study O O
evaluate O O
viral O O
oncogene O O
expression O O
viral O O
integration O O
sites O O
HPV16- B-virus B-virus
HPV18-positive B-virus B-virus
squamous O O
cell O O
carcinoma O O
lines O O
. O O

Real-time O O
quantitative O O
polymerase O O
chain O O
reaction O O
applied O O
detect O O
HPV16 B-virus B-virus
saliva O O
DNA O O
349 O O
screening O O
subjects O O
without O O
head O O
neck O O
cancer O O
( O O
HNC O O
) O O
, O O
156 O O
HNC O O
, O O
19 O O
controls O O
. O O

Cut O O
points O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
positivity O O
> O O
0 O O
> O O
0.001 O O
copy/cell O O
. O O

Proportions O O
compared O O
groups O O
using O O
exact O O

( O O
2 O O
) O O
Fisher O O
exact O O
tests O O
( O O
P O O
< O O
0.05 O O
) O O
. O O

Of O O
209 O O
HNC O O
patients O O
, O O
63 O O
( O O
30.1 O O
% O O
) O O
HPV B-virus B-virus
infection O O
, O O
HPV-16 B-virus B-virus
common O O
subtype O O
( O O
86.9 O O
% O O
) O O
. O O

HPV B-virus B-virus
E6/E7 O O
mRNA O O
expression O O
found O O
23 O O
60 O O
( O O
38.3 O O
% O O
) O O
HPV B-virus B-virus
DNA-positive O O
cases O O
detected O O
. O O

The O O
site O O
highest O O
prevalence O O
HPV B-virus B-virus
oropharynx O O
( O O
45.9 O O
% O O
) O O
. O O

Among O O
146 O O
( O O
69.9 O O
% O O
) O O
HNCs O O
EBV B-virus B-virus
DNA O O
identified O O
, O O
107 O O
( O O
73.3 O O
% O O
) O O
27 O O
( O O
18.5 O O
% O O
) O O
contained O O
types O O
A O O
B O O
, O O
respectively O O
, O O
124 O O
( O O
84.9 O O
% O O
) O O
showed O O
existence O O
del-LMP-1 O O
. O O

However O O
, O O
13 O O
( O O
6.2 O O
% O O
) O O
HNCs O O
positive O O
EBER O O
, O O
12 O O
( O O
92.3 O O
% O O
) O O
derived O O
nasopharynx O O
. O O

Co-infection O O
HPV B-virus B-virus
EBER O O
found O O
1 O O
% O O
HNCs O O
10 O O
% O O
NPCs O O
. O O

Kaplan-Meier O O
survival O O
analysis O O
showed O O
significantly O O
better O O
disease-specific O O
overall O O
survival O O
HPV B-virus B-virus
DNA+/mRNA+ O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OPC O O
) O O
patients O O
OPC O O
patients O O
( O O
P O O
= O O
0.027 O O
0.017 O O
, O O
respectively O O
) O O
. O O

Multivariate O O
analysis O O
showed O O
stage O O
T1-3 O O
( O O
P O O
= O O
0.002 O O
) O O
HPV B-virus B-virus
mRNA-positive O O
status O O
( O O
P O O
= O O
0.061 O O
) O O
independently O O
predicted O O
better O O
disease-specific O O
survival O O
. O O

No O O
significant O O
difference O O
disease-specific O O
survival O O
found O O
EBER-positive O O
#NAME? O O
NPC O O
patients O O
( O O
P O O
= O O
0.155 O O
) O O
. O O

A O O
case O O
EBVMCU B-virus B-virus
base O O
tongue O O
reported O O
retrospective O O
review O O
cases O O
EBVMCU B-virus B-virus
head O O
neck O O
single O O
academic O O
institution O O
conducted O O
January O O
1 O O
, O O
1986 O O
April O O
1 O O
, O O
2015 O O
. O O

The O O
MEDLINE O O
database O O
additionally O O
queried O O
January O O
1 O O
, O O
1950 O O
April O O
1 O O
, O O
2015 O O
reports O O
EBVMCU B-virus B-virus
head O O
neck O O
, O O
pertinent O O
clinical O O
data O O
extracted O O
. O O

There O O
significant O O
burden O O
HPV-associated B-virus B-virus
HNSCC O O
Bangladesh O O
, O O
particularly O O
oropharynx O O
also O O
oral O O
laryngeal O O
cancers O O
. O O

Whilst O O
combination O O
PCR-based O O
DNA O O
detection O O
p16 O O
IHC O O
useful O O
, O O
latter O O
excellent O O
specificity O O
, O O
acceptable O O
sensitivity O O
good O O
predictive O O
value O O
carriage O O
HPV B-virus B-virus
population O O
used O O
prognostic O O
evaluation O O
treatment O O
planning O O
HNSCC O O
patients O O
South O O
Asia O O
, O O
Western O O
world O O
. O O

In O O
study O O
, O O
Oropharyngeal O O
HPV B-virus B-virus
infection O O
rate O O
35 O O
% O O
, O O
followed O O
hypopharynx O O
30 O O
% O O
, O O
oropharyx O O
16 O O
% O O
. O O

The O O
overall O O
survival O O
rate O O
3 O O
years O O
5 O O
years O O
66.4 O O
% O O
, O O
39.2 O O
% O O
respectively O O
. O O

The O O
clinical O O
stage O O
, O O
N O O
stage O O
HPV B-virus B-virus
influencing O O
factors O O
prognosis O O
patients O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
P O O
< O O
0.05 O O
) O O
. O O

N O O
stage O O
HPV B-virus B-virus
independent O O
prognostic O O
factors O O
prognosis O O
patients O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
P O O
< O O
0.05 O O
) O O
. O O

Accurate O O
estimates O O
fraction O O
head O O
neck O O
cancer O O
( O O
HNC O O
) O O
attributable O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
essential O O
predict O O
effectiveness O O
interventions O O
based O O
vaccination O O
HPV B-virus B-virus
HPV-testing B-virus O
. O O

In O O
addition O O
, O O
supported O O
currently O O
on-going O O
clinical O O
trials O O
, O O
attribution O O
HNC O O
HPV B-virus B-virus
may O O
allow O O
better O O
less O O
toxic O O
treatments O O
. O O

Here O O
focused O O
studies O O
prevalence O O
molecular O O
serological O O
HPV B-virus B-virus
markers O O
similarly O O
assessed O O
oropharyngeal O O
non-oropharyngeal O O
HNC O O
. O O

Large O O
data O O
HPV B-virus B-virus
DNA O O
detection O O
PCR O O
p16 O O
expression O O
HNC O O
biopsies O O
suggests O O
probability O O
cancer O O
oral O O
cavity O O
, O O
larynx O O
, O O
hypopharynx O O
attributable O O
HPV B-virus B-virus
least O O
5-fold O O
lower O O
oropharyngeal O O
cancer O O
. O O

Seropositivity O O
HPV16 B-virus B-virus
E6 O O
E7 O O
shows O O
larger O O
differences O O
across O O
sites O O
, O O
findings O O
vary O O
studies O O
. O O

Because O O
HPV B-virus B-virus
DNA O O
p16 O O
detection O O
lack O O
specificity O O
, O O
E6 O O
E7 O O
antibody O O
detection O O
lacks O O
sensitivity O O
, O O
tests O O
totally O O
satisfactory O O
. O O

Limited O O
data O O
situ O O
hybridization O O
HPV B-virus B-virus
E6/E7 O O
mRNA O O
, O O
mainly O O
United O O
States O O
, O O
suggests O O
HPV-attributable B-virus B-virus
HNC O O
rare O O
oral O O
cavity O O
( O O
âˆ¼3 O O
% O O
) O O
, O O
larynx O O
( O O
âˆ¼7 O O
% O O
) O O
, O O
hypopharynx O O
( O O
âˆ¼0 O O
% O O
) O O
. O O

Data O O
HPV B-virus B-virus
rarer O O
HNCs O O
extremely O O
limited O O
essentially O O
negative O O
. O O

Available O O
data O O
allow O O
establishment O O
way O O
HPV B-virus B-virus
infection O O
tobacco O O
may O O
interact O O
non-oropharyngeal O O
HNC O O
. O O

The O O
exclusion O O
oropharynx O O
site O O
tumor O O
origin O O
identification O O
robust O O
fingerprints O O
HPV-driven B-virus B-virus
carcinogenesis O O
priorities O O
improve O O
estimate O O
HPV-attributable B-virus B-virus
non-oropharyngeal O O
HNC O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
induced O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
represents O O
distinct O O
tumor O O
subset O O
. O O

We O O
questioned O O
accurately O O
brushing O O
tumor O O
surface O O
detects O O
HPV B-virus B-virus
patients O O
HNSCC O O
. O O

There O O
great O O
deal O O
progress O O
development O O
oncolytic B-virus B-virus
viruses E-virus E-virus
. O O

However O O
, O O
major O O
problem O O
individual O O
cancers O O
vary O O
sensitivity O O
oncolytic B-virus B-virus
viruses E-virus E-virus
. O O

In O O
many O O
cases O O
due O O
differences O O
production O O
response O O
interferons O O
( O O
IFNs O O
) O O
. O O

The O O
experiments O O
described O O
compared O O
responses O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
cell O O
lines O O
two O O
IFN O O
subtypes O O
, O O
IFN-ä¼ª2a O O
IFN-å°¾ O O
, O O
protection O O
oncolytic B-virus B-virus
vesicular I-virus I-virus
stomatitis I-virus I-virus
virus E-virus E-virus
. O O

We O O
found O O
IFN-ä¼ª2a O O
significantly O O
less O O
protective O O
cancer O O
cells O O
IFN-å°¾ O O
, O O
whereas O O
normal O O
cells O O
equivalently O O
protected O O
IFNs O O
. O O

These O O
results O O
suggest O O
therapeutic O O
standpoint O O
, O O
selectivity O O
cancer O O
versus O O
normal O O
cells O O
may O O
enhanced O O
pairing O O
VSV B-virus B-virus
IFN-ä¼ª2a O O
. O O

To O O
analyze O O
current O O
status O O
research O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
cancers O O
China O O
using O O
national O O
international O O
references O O
. O O

From O O
March O O
2007 O O
September O O
2010 O O
subjects O O
submitted O O
oropharyngeal O O
brushing O O
saliva O O
collection O O
baseline O O
, O O
6 O O
, O O
12 O O
48 O O
months O O
( O O
subjects O O
HPV B-virus B-virus
positive O O
baseline O O
) O O
. O O

Samples O O
analyzed O O
detect O O
HPV B-virus B-virus
DNA B-virus B-virus
virus E-virus E-virus
genotypes O O
. O O

The O O
correlation O O
HPV B-virus B-virus
prevalence O O
demographic O O
, O O
behavioral O O
immunological O O
characteristics O O
assessed O O
. O O

Forty-six O O
patients O O
included O O
study O O
among O O
attending O O
head O O
neck O O
surgical O O
services O O
cities O O
BogotÃ¡ O O
, O O
Manizales O O
Bucaramanga O O
. O O

In O O
histopathological O O
report O O
study O O
samples O O
characterized O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
. O O

DNA O O
extraction O O
subsequently O O
performed O O
HPV B-virus B-virus
genotyping O O
determine O O
physical O O
state O O
viral O O
genome O O
, O O
well O O
RNA O O
determine O O
viral O O
transcripts O O
using O O
real-time O O
PCR O O
. O O

CMCSCC-1 O O
, O O
novel O O
oral O O
tongue O O
SCC O O
cell O O
line O O
, O O
established O O
. O O

It O O
help O O
elucidation O O
molecular O O
pathogenesis O O
HPV-negative B-virus B-virus
radiosensitive O O
tumors O O
. O O

Â© O O
2015 O O
Wiley O O
Periodicals O O
, O O
Inc. O O
Head O O
Neck O O
38 O O
: O O
E542-E551 O O
, O O
2015 O O
. O O

EBVMCU B-virus B-virus
tends O O
follow O O
indolent O O
self-limiting O O
clinical O O
course O O
, O O
responding O O
reduction O O
immunosuppression O O
conservative O O
treatment O O
. O O

It O O
imperative O O
clinicians O O
consider O O
EBVMCU B-virus B-virus
differential O O
diagnosis O O
mucocutaneous O O
ulcers O O
head O O
neck O O
avoid O O
excessive O O
treatment O O
. O O

Fifty-one O O
surgically O O
resected O O
HNSCCs O O
, O O
including O O
31 O O
HPV B-virus B-virus
+ E-virus E-virus
cancers O O
, O O
implanted O O
NOD/SCID/IL-2Ræ¬¾ O O

High-risk B-virus B-virus
human I-virus I-virus
papillomaviruses E-virus E-virus
( O O
HR-HPV B-virus B-virus
) O O
cause O O
ano-genital O O
cancers O O
fast O O
growing O O
subset O O
oropharyngeal O O
cancer O O
. O O

As O O
malignancies O O
occur O O
result O O
HPV- B-virus B-virus
infection O O
transmitted O O
intimate O O
contact O O
, O O
many O O
patients O O
HPV- B-virus B-virus
induced O O
cancer O O
partners O O
concerned O O
HPV-transmission B-virus B-virus
potential O O
partners O O
' O O
cancer O O
risk O O
. O O

Few O O
studies O O
addressed O O
issue O O
whether O O
HPV-related B-virus B-virus
cancer O O
risk O O
partners O O
patients O O
HPV-related B-virus B-virus
cancers O O
comparable O O
greater O O
general O O
population O O
. O O

Infection O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
necessary O O
development O O
cervical O O
carcinoma O O
. O O

By O O
contrast O O
, O O
role O O
HPV B-virus B-virus
pathogenesis O O
malignancies O O
, O O
head O O
neck O O
cancers O O
, O O
less O O
well O O
characterised O O
. O O

This O O
study O O
aimed O O
address O O
key O O
information O O
gaps O O
conducting O O
systematic O O
review O O
meta-analysis O O
prevalence O O
HPV B-virus B-virus
infection O O
head O O
neck O O
cancers O O
, O O
focusing O O
data O O
European O O
populations O O
. O O

Paraffin-embedded O O
tumor O O
specimens O O
available O O
59 O O
patients O O
NPC O O
diagnosed O O
1996 O O
2015 O O
. O O

We O O
detected O O
virus B-virus B-virus
status O O
p16 O O
immunohistochemistry O O
, O O
HPV B-virus B-virus
PCR O O
, O O
situ O O
hybridization O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
#NAME? O O
RNA O O
. O O

Kaplan-Meier O O
curves O O
used O O
compare O O
overall O O
survival O O
viral O O
status O O
. O O

A O O
total O O
226 O O
HNC O O
patients O O
enrolled O O
present O O
study O O
. O O

Sixty-seven O O
( O O
29.7 O O
% O O
) O O
HNC O O
cases O O
found O O
HPV B-virus B-virus
DNA O O
positive O O
. O O

Thirty-two O O
( O O
14 O O
% O O
) O O
cases O O
HPV-16 B-virus B-virus
DNA O O
positive O O
20 O O
( O O
9 O O
% O O
) O O
cases O O
expressed O O
HPV-16 B-virus B-virus
E7 O O
mRNA O O
. O O

HPV-16 B-virus B-virus
mRNA/p16 O O
positive O O
cases O O
significantly O O
increased O O
viral O O
load O O
integrated O O
HPV-16 B-virus B-virus
DNA O O
. O O

In O O
summary O O
, O O
total O O
HNC O O
patients O O
, O O
6 O O
% O O
cases O O
positive O O
HPV-16 B-virus B-virus
DNA O O
p16 O O
, O O
5 O O
% O O
positive O O
E7 O O
mRNA O O
p16 O O
IHC O O
. O O

We O O
observed O O
similar O O
HPV-16 B-virus B-virus
DNA/E7mRNA O O
prevalence O O
oropharynx O O
oral O O
cavity O O
sites O O
, O O
however O O
, O O
oropharynx O O
SCC O O
significantly O O
higher O O
viral O O
load O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
causally O O
associated O O
benign O O
malignant O O
diseases O O
upper O O
airway O O
, O O
including O O
respiratory O O
papillomatosis O O
oropharyngeal O O
cancer O O
. O O

Low-risk B-virus B-virus
HPV E-virus E-virus
types O O
6 O O
11 O O
predominant O O
cause O O
papillomatosis O O
, O O
whereas O O
HPV16 B-virus B-virus
definitively O O
satisfies O O
molecular O O
epidemiological O O
causal O O
criteria O O
carcinogenic O O
high-risk O O
type O O
upper O O
airway O O
. O O

HPV16 B-virus B-virus
E6/E7 O O
mRNA O O
expression O O
integration O O
observed O O
predominantly O O
among O O
oropharyngeal O O
cancers O O
, O O
experimental O O
models O O
shown O O
E6/E7 O O
expression O O
necessary O O
initiation O O
maintenance O O
malignant O O
phenotype O O
cancers O O
. O O

From O O
epidemiological O O
perspective O O
, O O
strong O O
consistent O O
association O O
markers O O
HPV16 B-virus B-virus
exposure O O
oropharyngeal O O
cancer O O
demonstrated O O
numerous O O
case-control O O
studies O O
. O O

HPV-positive B-virus B-virus
oropharyngeal O O
cancers O O
also O O
shown O O
distinct O O
HPV-negative B-virus B-virus
head O O
neck O O
squamous O O
cell O O
cancers O O
regard O O
risk-factor O O
profiles O O
, O O
molecular O O
genetic O O
alterations O O
, O O
population-level O O
incidence O O
trends O O
time O O
, O O
prognosis O O
. O O

Tumor O O
HPV B-virus B-virus
status O O
( O O
determined O O
certain O O
HPV16 B-virus B-virus
situ O O
hybridization O O
assays O O
certain O O
p16 O O
immunohistochemistry O O
assays O O
) O O
strongest O O
determinant O O
survival O O
patients O O
local-regionally O O
advanced O O
oropharyngeal O O
cancer O O
: O O
patients O O
HPV-positive B-virus B-virus
cancer O O
least O O
50 O O
% O O
improvement O O
overall O O
survival O O
5 O O
years O O
, O O
equivalent O O
approximate O O
30 O O
% O O
difference O O
absolute O O
survival O O
. O O

Thus O O
, O O
HPV B-virus B-virus
status O O
determination O O
part O O
routine O O
diagnostic O O
evaluation O O
prognostication O O
. O O

Preliminary O O
evidence O O
indicates O O
small O O
proportion O O
head O O
neck O O
cancers O O
may O O
caused O O
additional O O
HPV B-virus B-virus
types O O
( O O
e.g. O O
, O O
18 E-virus E-virus
, O O
31 E-virus E-virus
, O O
33 E-virus E-virus
, O O
35 E-virus E-virus
) O O
HPV-caused B-virus B-virus
cancers O O
may O O
rarely O O
arise O O
non-oropharyngeal O O
sites O O
( O O
e.g. O O
, O O
oral O O
cavity O O
, O O
nasopharynx O O
, O O
larynx O O
) O O
. O O

Whether O O
HPV B-virus B-virus
vaccination O O
potential O O
prevent O O
oral O O
HPV B-virus B-virus
infections O O
lead O O
cancer O O
papillomatosis O O
upper O O
airway O O
currently O O
unknown O O
, O O
potential O O
secondary O O
prevention O O
HPV B-virus B-virus
detection O O
. O O

This O O
article O O
forms O O
part O O
special O O
supplement O O
entitled O O
`` O O
Comprehensive O O
Control O O
HPV B-virus B-virus
Infections O O
Related O O
Diseases O O
'' O O
Vaccine O O
Volume O O
30 O O
, O O
Supplement O O
5 O O
, O O
2012 O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
accounts O O
common O O
cause O O
virus-associated O O
human O O
cancers O O
. O O

Here O O
, O O
describe O O
first O O
graphic O O
user O O
interface O O
( O O
GUI O O
) O O
#NAME? O O
automated O O
tool O O
'HPVDetector B-virus B-virus
' O O
, O O
non-computational O O
biologists O O
, O O
exclusively O O
detection O O
annotation O O
HPV B-virus B-virus
genome O O
based O O
next-generation O O
sequencing O O
data O O
sets O O
. O O

Recent O O
studies O O
showed O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
integration O O
contributes O O
genomic O O
instability O O
seen O O
HPV-associated B-virus B-virus
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HPV-HNSCC B-virus O
) O O
. O O

However O O
, O O
epigenetic O O
alterations O O
induced O O
HPV B-virus B-virus
integration O O
remains O O
unclear O O
. O O

To O O
identify O O
molecular O O
details O O
HPV16 B-virus B-virus
DNA O O
integration O O
ensuing O O
patterns O O
methylation O O
HNSCC O O
, O O
performed O O
next-generation O O
sequencing O O
using O O
target-enrichment O O
method O O
effective O O
identification O O
HPV16 B-virus B-virus
integration O O
breakpoints O O
well O O
characterization O O
genomic O O
sequences O O
adjacent O O
HPV16 B-virus B-virus
integration O O
breakpoints O O
three O O
HPV16-related B-virus B-virus
HNSCC O O
cell O O
lines O O
. O O

The O O
DNA O O
methylation O O
levels O O
integrated O O
HPV16 B-virus B-virus
genome O O
adjacent O O
human O O
genome O O
also O O
analyzed O O
bisulfite O O
pyrosequencing O O
. O O

We O O
found O O
various O O
integration O O
loci O O
, O O
including O O
novel O O
integration O O
sites O O
. O O

Integration O O
loci O O
located O O
predominantly O O
intergenic O O
region O O
, O O
significant O O
enrichment O O
microhomologous O O
sequences O O
human O O
HPV16 B-virus B-virus
genomes O O
integration O O
breakpoints O O
. O O

Furthermore O O
, O O
various O O
levels O O
methylation O O
within O O
human O O
genome O O
integrated O O
HPV B-virus B-virus
genome O O
integration O O
breakpoints O O
integrant O O
observed O O
. O O

Allele-specific O O
methylation O O
analysis O O
suggested O O
HPV16 B-virus B-virus
integrants O O
remained O O
hypomethylated O O
flanking O O
host O O
genome O O
hypomethylated O O
. O O

After O O
integration O O
highly O O
methylated O O
human O O
genome O O
regions O O
, O O
however O O
, O O
HPV16 B-virus B-virus
DNA O O
became O O
methylated O O
. O O

In O O
conclusion O O
, O O
found O O
novel O O
integration O O
sites O O
methylation O O
patterns O O
HPV-HNSCC B-virus B-virus
using O O
unique O O
method O O
. O O

These O O
findings O O
may O O
provide O O
insights O O
understanding O O
viral O O
integration O O
mechanism O O
virus-associated O B-virus
carcinogenesis O O
HPV-HNSCC B-virus B-virus
. O O

These O O
results O O
suggest O O
local O O
laryngeal O O
immune O O
response O O
activated O O
infection O O
carcinogenesis O O
due O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
. O O

The O O
findings O O
strongly O O
suggest O O
secretory O O
IgA O O
inhibitory O O
activity O O
infection O O
carcinogenesis O O
associated O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
larynx O O
. O O

Head O O
neck O O
carcinoma O O
( O O
HNC O O
) O O
occupy O O
sixth O O
place O O
frequent O O
type O O
cancer O O
worldwide O O
. O O

Next O O
alcohol O O
tobacco O O
intoxication O O
, O O
risk O O
factors O O
( O O
RF O O
) O O
suspected O O
, O O
including O O
human B-virus B-virus
papilloma I-virus I-virus
viruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
. O O

The O O
aim O O
study O O
highlight O O
prevalence O O
HPVs B-virus B-virus
histo-epidemiological O O
characteristics O O
HNC O O
HPV+ B-virus B-virus
Senegal O O
. O O

This O O
prospective O O
, O O
multicenter O O
preliminary O O
study O O
18 O O
months O O
( O O
January O O
1 O O
, O O
2012-June O O
30 O O
, O O
2014 O O
) O O
. O O

The O O
cases O O
HNC O O
histologically O O
confirmed O O
Senegal O O
sent O O
bio-pathology O O
department O O
Curie O O
Institute O O
Paris O O
search O O
HPVs B-virus B-virus
. O O

In O O
90 O O
included O O
cases O O
, O O
PCR O O
technique O O
successful O O
54 O O
cases O O
( O O
60 O O
% O O
) O O
. O O

HPVs B-virus B-virus
found O O
seven O O
cases O O
, O O
, O O
prevalence O O
13 O O
% O O
. O O

HPVs B-virus B-virus
associated O O
5 O O
cases O O
hypopharyngeal O O
carcinoma O O
2 O O
cases O O
carcinoma O O
oral O O
cavity O O
. O O

Patients O O
HNC O O
HPV+ B-virus B-virus
median O O
age O O
42 O O
years O O
49 O O
years O O
HPV-patients B-virus B-virus
. O O

Three O O
patients O O
( O O
42.8 O O
% O O
) O O
HPV+ B-virus B-virus
carcinomas O O
smokers O O
. O O

Of O O
47 O O
HPV-patients B-virus O
, O O
40 O O
patients O O
( O O
87.1 O O
% O O
) O O
alcohol O O
intoxication O O
and/or O O
smoking O O
. O O

The O O
concept O O
oral O O
sex O O
refuted O O
patients O O
. O O

Squamous O O
cell O O
carcinoma O O
histological O O
type O O
found O O
. O O

HPV+ B-virus B-virus
cell O O
carcinoma O O
showed O O
specific O O
histological O O
appearance O O
. O O

HPVs B-virus B-virus
another O O
certain O O
RF O O
HNC O O
Senegal O O
. O O

The O O
major O O
therapeutic O O
prognostic O O
impact O O
HPVinduced O O
cancers O O
requires O O
systematic O O
search O O
viruses B-virus B-virus
PCR O O
technique O O
. O O

In O O
present O O
study O O
, O O
comprehensively O O
analyzed O O
prevalence O O
transcriptionally O O
active O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
tissue O O
samples O O
Indian O O
patients O O
leukoplakia O O
, O O
predominantly O O
hyperplastic O O
lesions O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
. O O

In O O
addition O O
, O O
saliva O O
samples O O
patients O O
HNSCC O O
screened O O
HPV B-virus B-virus
detection O O
. O O

This O O
article O O
discusses O O
risk O O
factors O O
, O O
incidence O O
trends O O
, O O
prognostic O O
considerations O O
head O O
neck O O
cancer O O
( O O
HNC O O
) O O
. O O

The O O
primary O O
causes O O
HNC O O
tobacco O O
alcohol O O
use O O
, O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
. O O

Tobacco-related O O
HNC O O
incidence O O
rates O O
decreasing O O
countries O O
tobacco O O
use O O
declined O O
. O O

HPV-HNC B-virus B-virus
, O O
occurs O O
primarily O O
oropharynx O O
associated O O
sexual O O
behaviors O O
, O O
increasing O O
past O O
several O O
decades O O
, O O
among O O
white O O
men O O
particular O O
. O O

The O O
prognosis O O
HNC O O
overall O O
improved O O
slightly O O
since O O
1990s O O
, O O
influenced O O
site O O
, O O
stage O O
, O O
HPV B-virus B-virus
status O O
. O O

Prognosis O O
HPV-HNC B-virus O
significantly O O
better O O
HPV-negative B-virus B-virus
disease O O
. O O

31 O O
150 O O
( O O
20.7 O O
% O O
) O O
HNSCCs O O
HPV B-virus B-virus
positive O O
. O O

Inverted O O
papillomas O O
benign O O
sinonasal O O
tumor O O
propensity O O
recurrence O O
malignant O O
transformation O O
. O O

Although O O
many O O
investigations O O
made O O
nature O O
disease O O
, O O
etiology O O
causes O O
malignant O O
transformation O O
yet O O
fully O O
elucidated O O
. O O

It O O
authors O O
' O O
objective O O
present O O
review O O
management O O
disease O O
evaluate O O
present O O
relationship O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
inverted O O
papilloma O O
. O O

There O O
high O O
rate O O
HPV B-virus B-virus
infection O O
oropharynx O O
head O O
neck O O
cancer O O
. O O

HPV B-virus B-virus
positive O O
protective O O
factor O O
prognosis O O
head O O
neck O O
cancer O O
, O O
risk O O
death O O
patients O O
HPV B-virus B-virus
3æœˆ5æ—¥ O O
lower O O
HPV B-virus B-virus
negative O O
patients O O
. O O

HPV B-virus B-virus
viral O O
load O O
may O O
positively O O
related O O
total O O
survival O O
rate O O
. O O

N O O
stage O O
risk O O
factor O O
prognosis O O
head O O
neck O O
cancer O O
. O O

Different O O
nationalities O O
little O O
influence O O
prognosis O O
. O O

At O O
cut O O
point O O
> O O
0 O O
, O O
group O O
overall O O
HPV B-virus B-virus
prevalence O O
5 O O
% O O
, O O
higher O O
prevalence O O
30.8 O O
% O O
HNC O O
patient O O
group O O
. O O

At O O
cut O O
point O O
> O O
0.001 O O
, O O
prevalence O O
lower O O
: O O
0 O O
% O O
control O O
, O O
1.2 O O
% O O
screening O O
, O O
16.7 O O
% O O
HNC O O
group O O
. O O

In O O
latter O O
, O O
cut O O
points O O
, O O
HPV B-virus B-virus
prevalence O O
different O O
across O O
sites O O
( O O
< O O
0.001 O O
) O O
significantly O O
higher O O
oropharynx O O
larynx O O
site O O
Hochberg O O
's O O
adjustment O O
. O O

At O O
> O O
0 O O
, O O
women O O
screening O O
group O O
higher O O
prevalence O O
HPV B-virus B-virus
men O O
( O O
P O O
= O O
0.01 O O
) O O
, O O
> O O
0.001 O O
, O O
prevalence O O
higher O O
men O O
HNC O O
group O O
women O O
( O O
P O O
= O O
0.035 O O
) O O
. O O

In O O
screening O O
group O O
, O O
> O O
0 O O
, O O
African O O
Americans O O
higher O O
prevalence O O
Caucasian O O
Americans O O
( O O
P O O
= O O
0.025 O O
) O O
. O O

Biopsies O O
squamous O O
cell O O
carcinomas O O
oropharynx O O
, O O
nasopharynx O O
, O O
larynx O O
hypopharynx O O
112 O O
South O O
African O O
patients O O
screened O O
using O O
three O O
PCR O O
assays O O
targeting O O
L1 O O
E6 O O
regions O O
HPV B-virus B-virus
p16 O O
immunohistochemical O O
staining O O
. O O

Much O O
current O O
literature O O
regarding O O
molecular O O
pathophysiology O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
focused O O
virus B-virus B-virus
's O O
effect O O
cell O O
cycle O O
modulation O O
cell O O
proliferation O O
. O O

A O O
second O O
mechanism O O
pathogenicity O O
employed O O
HPV B-virus B-virus
, O O
dysregulation O O
cellular O O
DNA O O
repair O O
processes O O
, O O
sparsely O O
studied O O
. O O

The O O
purpose O O
review O O
describe O O
current O O
understanding O O
effect O O
HPV B-virus B-virus
DNA O O
repair O O
HNSCC O O
, O O
taking O O
cues O O
cervical O O
cancer O O
literature O O
. O O

HPV B-virus B-virus
affects O O
DNA-damage O O
response O O
pathways O O
interacting O O
many O O
proteins O O
, O O
including O O
ATM O O
, O O
ATR O O
, O O
MRN O O
, O O
æ¬¾-H2AX O O
, O O
Chk1 O O
, O O
Chk2 O O
, O O
p53 O O
, O O
BRCA1 O O
, O O
BRCA2 O O
, O O
RAD51 O O
, O O
Rb-related O O
proteins O O
107 O O
130 O O
, O O
Tip60 O O
, O O
p16INK4A O O
. O O

Further O O
elucidation O O
pathways O O
could O O
lead O O
development O O
targeted O O
therapies O O
improvement O O
current O O
treatment O O
protocols O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
recently O O
recognised O O
carcinogenic O O
factor O O
subset O O
head O O
neck O O
cancers O O
( O O
HNC O O
) O O
. O O

In O O
Europe O O
, O O
France O O
one O O
highest O O
incidence O O
rates O O
HNC O O
. O O

The O O
aim O O
study O O
explore O O
changes O O
HNC O O
incidence O O
France O O
, O O
potentially O O
relation O O
infection O O
HPV B-virus B-virus
. O O

HNC O O
classified O O
two O O
anatomical O O
groups O O
: O O
potentially O O
HPV-related B-virus B-virus
HPV-unrelated B-virus B-virus
. O O

Trends O O
period O O
1980-2012 O O
analysed O O
age-period-cohort O O
model O O
based O O
data O O
eleven O O
French O O
cancer O O
registries O O
. O O

Among O O
men O O
, O O
age-standardised O O
incidence O O
rate O O
( O O
ASR O O
) O O
HNC O O
decreased O O
groups O O
, O O
less O O
HPV-related B-virus B-virus
sites O O
compared O O
unrelated O O
sites O O
, O O
especially O O
recent O O
years O O
( O O
annual O O
percentage O O
change O O
[ O O
APC O O
] O O
period O O
2005-2012 O O
: O O
-3.5 O O
% O O
vs. O O
-5.4 O O
% O O
) O O
. O O

Among O O
women O O
, O O
ASR O O
increased O O
groups O O
, O O
rapidly O O
HPV-related B-virus B-virus
compared O O
unrelated O O
sites O O
( O O
APC O O
period O O
2005-2012 O O
: O O
1.9 O O
% O O
vs. O O
-0.4 O O
% O O
) O O
. O O

This O O
preferential O O
growth O O
HPV-related B-virus B-virus
versus O O
unrelated O O
HNC O O
observed O O
cohorts O O
born O O
1930 O O
1935 O O
. O O

The O O
differences O O
trends O O
possible O O
HPV-related B-virus B-virus
HPV-unrelated B-virus B-virus
sites O O
suggest O O
increasing O O
incidence O O
HNC O O
due O O
HPV B-virus B-virus
infection O O
. O O

The O O
difference O O
less O O
marked O O
men O O
compared O O
women O O
, O O
likely O O
higher O O
contamination O O
HPV-related B-virus B-virus
group O O
cancers O O
due O O
tobacco O O
alcohol O O
consumption O O
. O O

The O O
pattern O O
observed O O
consistent O O
observations O O
made O O
countries O O
, O O
studies O O
HPV B-virus B-virus
prevalence O O
HNC O O
evolution O O
sexual O O
behaviour O O
France O O
. O O

Tissue O O
samples O O
40 O O
Warthin O O
's O O
tumors O O
parotid O O
gland O O
investigated O O
PCR O O
followed O O
situ O O
hybridization O O
. O O

The O O
immunohistochemical O O
expression O O
p16 O O
dual O O
immunostaining O O
p16 O O
Ki-67 O O
evaluated O O
samples O O
. O O

Retrospective O O
case O O
series O O
chart O O
review O O
. O O

Mucosal O O
high-risk O O
( O O
HR O O
) O O
human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
cause O O
subset O O
head O O
neck O O
cancers O O
( O O
HNC O O
) O O
. O O

The O O
HPV-attributable B-virus B-virus
fraction O O
HNC O O
varies O O
substantially O O
countries O O
. O O

Although O O
HNC O O
high O O
incidence O O
Indian O O
subcontinent O O
, O O
information O O
contribution O O
HPV B-virus B-virus
infection O O
limited O O
. O O

Here O O
, O O
evaluated O O
HPV-attributable B-virus O
fraction O O
HNC O O
( O O
N O O
= O O
364 O O
) O O
collected O O
central O O
region O O
India O O
. O O

HNC O O
three O O
different O O
anatomical O O
subsites O O
included O O
, O O
namely O O
, O O
oral O O
cavity O O
( O O
n O O
= O O
252 O O
) O O
, O O
oropharynx O O
( O O
n O O
= O O
53 O O
) O O
hypopharynx/larynx O O
( O O
n O O
= O O
59 O O
) O O
. O O

In O O
retrospective O O
study O O
, O O
HPV-driven B-virus B-virus
HNC O O
defined O O
presence O O
viral O O
DNA O O
RNA O O
. O O

Overexpression O O
p16 O O

To O O
discuss O O
effect O O
limited O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
status O O
prognosis O O
different O O
nationalities O O
Xinjiang O O
. O O

We O O
included O O
ART-naive O O
subjects O O
least O O
one O O
follow-up O O
ear O O
, O O
nose O O
, O O
throat O O
examination O O
, O O
diagnosed O O
lymph O O
node O O
mycobacterial O O
infection O O
first O O
3 O O
months O O
ART O O
initiation O O
. O O

Mycobacterial-associated O O
IRIS O O
cervical O O
lymph O O
nodes O O
determined O O
retrospectively O O
clinical O O
case O O
definition O O
medical O O
chart O O
review O O
. O O

We O O
performed O O
systematic O O
review O O
published O O
literature O O
addressing O O
issue O O
. O O

Out O O
1055 O O
references O O
screened O O
, O O
53 O O
articles O O
found O O
eligible O O
inclusion O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
positive O O
( O O
HPV+ B-virus B-virus
) O O
tumors O O
represent O O
large O O
proportion O O
anal O O
, O O
vulvar O O
, O O
vaginal O O
, O O
cervical O O
head O O
neck O O
squamous O O
carcinomas O O
( O O
HNSCC O O
) O O
late O O
stage O O
invasive O O
disease O O
thought O O
originate O O
premalignant O O
state O O
. O O

Cyclic O O
dinucleotides O O
activate O O
STimulator O O
INterferon O O
Genes O O
( O O
STING O O
) O O
shown O O
cause O O
rapid O O
regression O O
range O O
advanced O O
tumors O O
. O O

We O O
aimed O O
investigate O O
STING O O
ligands O O
novel O O
treatment O O
papilloma O O
. O O

We O O
tested O O
therapies O O
spontaneous O O
mouse O O
model O O
papilloma O O
face O O
anogenital O O
region O O
histologically O O
resembles O O
human O O
HPV-associated B-virus B-virus
papilloma O O
. O O

We O O
demonstrate O O
STING O O
ligands O O
cause O O
rapid O O
regression O O
papilloma O O
, O O
associated O O
T O O
cell O O
infiltration O O
, O O
significantly O O
effective O O
Imiquimod O O
, O O
current O O
immunotherapy O O
papilloma O O
. O O

In O O
humans O O
, O O
show O O
STING O O
expressed O O
basal O O
layer O O
normal O O
skin O O
lost O O
keratinocyte O O
differentiation O O
. O O

We O O
found O O
STING O O
expressed O O
HPV-associated B-virus B-virus
cervical O O
anal O O
dysplasia O O
strongly O O
expressed O O
cancer O O
cells O O
HPV+ B-virus B-virus
HNSCC O O
HPV-unrelated B-virus B-virus
HNSCC O O
. O O

We O O
found O O
strong O O
association O O
STING O O
expression O O
progressive O O
disease O O
non-HPV B-virus B-virus
oral O O
dysplasia O O
oral O O
pre-malignancies O O
HPV-related B-virus B-virus
. O O

These O O
data O O
demonstrate O O
STING O O
expressed O O
basal O O
cells O O
skin O O
retained O O
HPV+ B-virus B-virus
pre-malignancies O O
advanced O O
cancers O O
, O O
HPV-unrelated B-virus B-virus
HNSCC O O
. O O

However O O
, O O
using O O
murine O O
HNSCC O O
model O O
express O O
STING O O
, O O
demonstrate O O
STING O O
ligands O O
effective O O
therapy O O
regardless O O
expression O O
STING O O
cancer O O
cells O O
. O O

Delineate O O
factors O O
impacting O O
creation O O
use O O
patient-derived O O
xenografts O O
( O O
PDXs O O
) O O
human B-virus B-virus
papilloma I-virus I-virus
virus-related E-virus E-virus
( O O
HPV+ B-virus B-virus
) O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCCs O O
) O O
. O O

Cross-sectional O O
prospective O O
study O O
. O O

Despite O O
clear O O
differences O O
United O O
States O O
terms O O
tobacco O O
use O O
, O O
increase O O
OPSCC O O
incidence O O
European O O
population O O
also O O
mainly O O
attributed O O
HPV B-virus B-virus
, O O
HPV B-virus B-virus
status O O
significantly O O
affected O O
prognosis O O
. O O

For O O
clinical O O
trial O O
design O O
important O O
consider O O
large O O
group O O
smokers O O
within O O
HPV-induced B-virus B-virus
OPSCC O O
. O O

The O O
aim O O
study O O
identify O O
presence O O
frequency O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
nucleic O O
acid O O
p16-positive O O
oral O O
squamous O O
cell O O
carcinomas O O
( O O
OSCCs O O
) O O
, O O
assess O O
whether O O
virus B-virus B-virus
transcriptionally O O
active O O
assess O O
utility O O
p16 O O
overexpression O O
surrogate O O
marker O O
HPV B-virus B-virus
OSCC O O
. O O

Previous O O
investigations O O
studying O O
association O O
DNA B-virus B-virus
viruses E-virus E-virus
salivary O O
gland O O
tumors O O
( O O
SGTs O O
) O O
led O O
conflicting O O
results O O
. O O

The O O
aim O O
study O O
determine O O
prevalence O O
different O O
DNA B-virus B-virus
viruses E-virus E-virus
using O O
highly O O
sensitive O O
assay O O
multi-center O O
series O O
100 O O
fresh O O
frozen O O
salivary O O
gland O O
samples O O
. O O

High B-virus B-virus
risk I-virus I-virus
Human I-virus I-virus
Papilloma I-virus I-virus
virus E-virus E-virus
( O O
HR-HPV B-virus B-virus
) O O
associated O O
oropharyngeal O O
cancers O O
increase O O
. O O

Although O O
, O O
scientific O O
community O O
aware O O
importance O O
Human B-virus B-virus
Papilloma I-virus I-virus
Virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
testing O O
, O O
consensus O O
assays O O
required O O
reliably O O
identify O O
HR-HPV B-virus B-virus
related O O
tumors O O
. O O

A O O
wide O O
range O O
methods O O
developed O O
. O O

The O O
widely O O
used O O
techniques O O
include O O
viral O O
DNA O O
detection O O
, O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
In O O
Situ O O
Hybridization O O
, O O
p16 O O
detected O O
immunohistochemistry O O
. O O

However O O
, O O
tests O O
provide O O
different O O
information O O
specific O O
limitations O O
. O O

In O O
review O O
, O O
summarize O O
different O O
techniques O O
, O O
light O O
recent O O
literature O O
. O O

p16 O O
Overexpression O O
, O O
indirect O O
marker O O
HPV B-virus B-virus
infection O O
, O O
considered O O
many O O
head O O
neck O O
oncologists O O
important O O
marker O O
patient O O
stratification O O
. O O

We O O
describe O O
frequent O O
lack O O
concordance O O
marker O O
assays O O
possible O O
reasons O O
. O O

The O O
latest O O
developments O O
HPV B-virus B-virus
testing O O
also O O
reported O O
, O O
RNAscopeê½“ O O
HPV B-virus B-virus
test O O
, O O
fit O O
existing O O
framework O O
techniques O O
. O O

HPV B-virus B-virus
testing O O
must O O
considered O O
isolation O O
, O O
important O O
interactions O O
parameters O O
, O O
tobacco O O
exposure O O
. O O

This O O
important O O
rapidly O O
evolving O O
field O O
likely O O
become O O
pivotal O O
staging O O
choice O O
treatment O O
oropharyngeal O O
carcinoma O O
future O O
. O O

One O O
risk O O
factors O O
squamous O O
cell O O
oropharyngeal O O
carcinoma O O
infection O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
, O O
prevalences O O
vary O O
depending O O
geographical O O
region O O
. O O

DNA O O
isolated O O
84 O O
SGTs O O
( O O
80 O O
parotid O O
tumors O O
4 O O
submandibular O O
gland O O
tumors O O
) O O
28 O O
normal O O
salivary O O
tissue O O
samples O O
85 O O
patients O O
Northeast O O
Italy O O
. O O

Using O O
highly O O
sensitive O O
type-specific O O
multiplex O O
genotyping O O
assay O O
, O O
analyzed O O
samples O O
presence O O
DNA O O
62 O O
different O O
viruses B-virus B-virus
including O O
47 O O
papillomaviruses B-virus B-virus
, O O
10 O O
polyomaviruses B-virus B-virus
, O O
5 O O
herpesviruses B-virus B-virus
. O O

Superficial O O
brushes O O
tumor O O
surface O O
may O O
used O O
identify O O
HPV B-virus B-virus
positive O O
HNSCC O O
. O O

HPV16 B-virus B-virus
present O O
one O O
OSCC O O
( O O
3 O O
% O O
) O O
. O O

TP53 O O
mutations O O
found O O
14 O O
( O O
45 O O
% O O
) O O
OSCC O O
: O O
five O O
missense O O
nine O O
resulted O O
truncated O O
protein O O
. O O

Six O O
latter O O
insertions O O
deletions O O
one O O
nucleotides O O
leading O O
frameshift O O
, O O
one O O
splice O O
site O O
two O O
resulted O O
stop O O
codon O O
. O O

The O O
percentage O O
truncating O O
mutations O O
( O O
64 O O
% O O
mutations O O
) O O
higher O O
observed O O
institute O O
's O O
reference O O
group O O
( O O
44 O O
% O O
, O O
P O O
= O O
0.23 O O
) O O
independent O O
reference O O
group O O
( O O
24 O O
% O O
, O O
P O O
= O O
0.002 O O
) O O
. O O

At O O
1 O O
year O O
complete O O
HPV B-virus B-virus
clearance O O
observed O O
could O O
related O O
adoption O O
healthier O O
lifestyles O O
participants O O
. O O

New O O
HPV B-virus B-virus
infections O O
detected O O
even O O
absence O O
recognized O O
declared O O
risky O O
behavioral O O
factors O O
, O O
suggesting O O
re-expression O O
latent O O
infection O O
. O O

This O O
study O O
aimed O O
clarify O O
local O O
immune O O
status O O
larynx O O
presence O O
infection O O
carcinogenesis O O
associated O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
. O O

The O O
frequency O O
HPV B-virus B-virus
OSCC O O
low O O
North-India O O
majority O O
cases O O
associated O O
tobacco O O
habit O O
. O O

It O O
appears O O
tobacco O O
shows O O
confounding O O
effect O O
HPV B-virus B-virus
positive O O
cases O O
use O O
p16 O O
protein O O
reliable O O
marker O O
assess O O
potential O O
etiological O O
role O O
HPV B-virus B-virus
OSCC O O
population O O
suggested O O
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
comprise O O
diverse O O
group O O
, O O
different O O
epithelial O O
tropisms O O
life-cycle O O
strategies O O
. O O

Many O O
HPVs B-virus B-virus
classified O O
low-risk O O
, O O
rarely O O
associated O O
neoplasia O O
cancer O O
general O O
population O O
. O O

These O O
HPVs B-virus B-virus
typically O O
cause O O
inapparent/inconspicuous O O
infections O O
, O O
benign O O
papillomas O O
, O O
persist O O
months O O
years O O
, O O
eventually O O
resolved O O
host O O
's O O
immune O O
system O O
. O O

Low-risk B-virus B-virus
HPVs E-virus E-virus
difficult O O
manage O O
immunosuppressed O O
people O O
individuals O O
genetic O O
predispositions O O
, O O
give O O
rise O O
papillomatosis O O
, O O
rare O O
instances O O
, O O
cancer O O
. O O

The O O
high-risk B-virus B-virus
HPV E-virus E-virus
types O O
, O O
contrast O O
, O O
cause O O
several O O
important O O
human O O
cancers O O
, O O
including O O
almost O O
cases O O
cervical O O
cancer O O
, O O
large O O
proportion O O
anogenital O O
cancers O O
growing O O
number O O
head O O
neck O O
tumours O O
. O O

The O O
high-risk B-virus B-virus
HPV E-virus E-virus
types O O
constitute O O
subset O O
genus O O
Alphapapillomavirus B-virus B-virus
prevalent O O
general O O
population O O
, O O
individuals O O
cause O O
inconspicuous O O
oral O O
genital O O
lesions O O
. O O

Cancer O O
progression O O
associated O O
persistent O O
high-risk B-virus B-virus
HPV E-virus E-virus
infection O O
deregulated O O
viral O O
gene O O
expression O O
, O O
leads O O
excessive O O
cell O O
proliferation O O
, O O
deficient O O
DNA O O
repair O O
, O O
accumulation O O
genetic O O
damage O O
infected O O
cell O O
. O O

Although O O
life-cycle O O
organisation O O
broadly O O
similar O O
low-risk B-virus B-virus
HPV E-virus E-virus
types O O
, O O
two O O
groups O O
differ O O
significantly O O
capacity O O
drive O O
cell O O
cycle O O
entry O O
cell O O
proliferation O O
basal/parabasal O O
cell O O
layers O O
. O O

This O O
thought O O
linked O O
, O O
least O O
part O O
, O O
different O O
abilities O O
high- O O
low-risk O O
E6 O O
proteins O O
modulate O O
activity O O
p53 O O
PDZ-domain O O
proteins O O
, O O
differential O O
ability O O
E7 O O
proteins O O
target O O
several O O
different O O
members O O
retinoblastoma O O
protein O O
family O O
. O O

This O O
article O O
forms O O
part O O
special O O
supplement O O
entitled O O
`` O O
Comprehensive O O
Control O O
HPV B-virus B-virus
Infections O O
Related O O
Diseases O O
'' O O
Vaccine O O
Volume O O
30 O O
, O O
Supplement O O
5 O O
, O O
2012 O O
. O O

DNA O O
expressions O O
EBV B-virus B-virus
, O O
HBoV B-virus B-virus
, O O
polyomaviruses B-virus B-virus
KIPyV B-virus B-virus
WUPyV B-virus B-virus
investigated O O
children O O
chronic O O
tonsillar O O
adenoidal O O
diseases O O
using O O
real-time O O
polymerase O O
chain O O
reaction O O
. O O

The O O
patients O O
grouped O O
follows O O
: O O
adenoid O O
, O O
recurrent O O
tonsillitis O O
hypertrophic O O
tonsillitis O O
group O O
. O O

The O O
relationships O O
expressions O O
viruses B-virus B-virus
age O O
, O O
gender O O
, O O
recurrent O O
infection O O
airway O O
obstruction O O
also O O
analyzed O O
. O O

Seasonal O O
variations O O
rates O O
detection O O
viruses O B-virus
adenoid O O
tonsil O O
tissues O O
also O O
investigated O O
. O O

The O O
detection O O
HBoV B-virus B-virus
EBV B-virus B-virus
throughout O O
year O O
samples O O
children O O
asymptomatic O O
chronic O O
adenotonsillar O O
diseases O O
may O O
indicate O O
viruses B-virus B-virus
may O O
remain O O
persistently O O
lymphoepithelial O O
tissues O O
upper O O
respiratory O O
tract O O
. O O

Virus B-virus B-virus
persistence O O
may O O
pathogenetic O O
potential O O
development O O
lymphoid O O
hypertrophy O O
chronic O O
stimulatory O O
effect O O
inflammation O O
. O O

The O O
prevalence O O
HPV B-virus B-virus
infection O O
European O O
patients O O
head O O
neck O O
cancers O O
high O O
varies O O
different O O
anatomical O O
sites O O
malignancies O O
. O O

There O O
appears O O
association O O
HPV B-virus B-virus
type O O
geographical O O
setting O O
, O O
type O O
samples O O
analysed O O
type O O
primer O O
used O O
analyse O O
samples O O
cancers O O
. O O

During O O
last O O
decades O O
, O O
phenotypically O O
distinct O O
type O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
SCC O O
) O O
, O O
etiologically O O
related O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
, O O
emerged O O
, O O
prevalence O O
continues O O
increase O O
. O O

The O O
tumors O O
site-specific O O
special O O
predilection O O
oropharynx O O
. O O

They O O
morphologically O O
molecularly O O
distinct O O
responsive O O
different O O
types O O
treatment O O
modalities O O
, O O
excellent O O
clinical O O
outcome O O
, O O
spite O O
early O O
lymph O O
node O O
metastasis O O
. O O

Microscopically O O
, O O
carcinomas O O
nonkeratinizing O O
SCCs O O
. O O

More O O
recently O O
, O O
variants O O
believed O O
etiologically O O
related O O
HPV B-virus B-virus
reported O O
. O O

As O O
result O O
, O O
several O O
clinical O O
pathologic O O
questions O O
emerged O O
. O O

Importantly O O
, O O
whether O O
virus B-virus B-virus
biologically O O
active O O
tumors O O
involved O O
pathogenesis O O
, O O
second O O
, O O
clinical O O
implications O O
regard O O
patient O O
management O O
outcome O O
HPV-related B-virus B-virus
variants O O
. O O

This O O
review O O
attempt O O
answer O O
questions O O
based O O
information O O
derived O O
available O O
yet O O
limited O O
number O O
publications O O
. O O

The O O
variants O O
discussed O O
include O O
nonkeratinizing O O
SCC O O
( O O
NKSCC O O
) O O
, O O
NKSCC O O
maturation O O
( O O
hybrid O O
type O O
) O O
, O O
keratinizing O O
SCC O O
( O O
KSSC O O
) O O
, O O
basaloid O O
squamous O O
carcinoma O O
( O O
BSCC O O
) O O
, O O
undifferentiated O O
carcinoma O O
( O O
UC O O
) O O
, O O
papillary O O
SCC O O
( O O
PSCC O O
) O O
, O O
small O O
cell O O
carcinoma O O
, O O
adenosquamous O O
carcinoma O O
( O O
AdSCC O O
) O O
, O O
spindle O O
cell O O
( O O
sarcomatoid O O
) O O
carcinoma O O
. O O

We O O
aimed O O
reveal O O
prevalence O O
pattern O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
p53 O O
mutations O O
among O O
Japanese O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
patients O O
relation O O
clinicopathological O O
parameters O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
DNA O O
p53 O O
mutations O O
examined O O
493 O O
HNSCCs O O
subset O O
283 O O
HNSCCs O O
. O O

Oropharyngeal O O
carcinoma O O
frequently O O
HPV-positive B-virus B-virus
non-oropharyngeal O O
carcinoma O O
( O O
34.4 O O
% O O
vs O O
3.6 O O
% O O
, O O
P O O
< O O
0.001 O O
) O O
, O O
HPV16 B-virus B-virus
accounted O O
91.1 O O
% O O
HPV-positive B-virus B-virus
tumors O O
. O O

In O O
oropharyngeal O O
carcinoma O O
, O O
showed O O
increasing O O
trend O O
HPV B-virus B-virus
prevalence O O
time O O
( O O
P O O
< O O
0.001 O O
) O O
, O O
HPV B-virus B-virus
infection O O
inversely O O
correlated O O
tobacco O O
smoking O O
, O O
alcohol O O
drinking O O
, O O
p53 O O
mutations O O
, O O
disruptive O O
mutation O O
( O O
P O O
= O O
0.003 O O
, O O
< O O
0.001 O O
, O O
< O O
0.001 O O
, O O
< O O
0.001 O O
, O O
respectively O O
) O O
. O O

The O O
prevalence O O
p53 O O
mutations O O
differed O O
significantly O O
virus-unrelated B-virus B-virus
HNSCC O O
virus-related B-virus B-virus
HNSCC O O
consisting O O
nasopharyngeal O O
HPV-positive B-virus B-virus
oropharyngeal O O
carcinomas O O
( O O
48.3 O O
% O O
vs O O
7.1 O O
% O O
, O O
P O O
< O O
0.001 O O
) O O
. O O

Although O O
p53 O O
mutations O O
associated O O
tobacco O O
smoking O O
alcohol O O
drinking O O
, O O
association O O
disappeared O O
virus-unrelated B-virus B-virus
HNSCC O O
. O O

A O O
disruptive O O
mutation O O
never O O
found O O
virus-related B-virus B-virus
HNSCC O O
, O O
whereas O O
independently O O
associated O O
primary O O
site O O
, O O
oropharynx O O
hypopharynx O O
( O O
P O O
= O O
0.01 O O
0.03 O O
, O O
respectively O O
) O O
, O O
virus-unrelated B-virus B-virus
HNSCC O O
. O O

Moreover O O
, O O
virus-unrelated B-virus B-virus
HNSCC O O
, O O
G O O
: O O
C O O
T O O
: O O
A O O
transversions O O
frequent O O
ever-smokers O O
never-smokers O O
( O O
P O O
= O O
0.04 O O
) O O
, O O
whereas O O
G O O
: O O
C O O
A O O
: O O
T O O
transitions O O
CpG O O
sites O O
less O O
frequent O O
ever-smokers O O
never-smokers O O
( O O
P O O
= O O
0.04 O O
) O O
. O O

In O O
conclusion O O
, O O
HNSCC O O
etiologically O O
classified O O
virus-related B-virus B-virus
virus-unrelated B-virus B-virus
subgroups O O
. O O

In O O
virus-related B-virus B-virus
HNSCC O O
, O O
p53 O O
mutations O O
uncommon O O
absence O O
disruptive O O
mutation O O
, O O
whereas O O
virus-unrelated B-virus B-virus
HNSCC O O
, O O
p53 O O
mutations O O
common O O
, O O
disruptive O O
mutagenesis O O
p53 O O
related O O
oropharyngeal O O
hypopharyngeal O O
carcinoma O O
. O O

Over O O
past O O
30 O O
years O O
, O O
human B-virus B-virus
papilloma E-virus I-virus
virus I-virus E-virus
( O O
HPV B-virus B-virus
) O O
shown O O
play O O
role O O
development O O
various O O
cancers O O
. O O

Most O O
notably O O
, O O
HPV B-virus B-virus
linked O O
malignant O O
progression O O
neoplasms O O
anogenital O O
region O O
. O O

However O O
, O O
high-risk B-virus B-virus
HPV E-virus E-virus
also O O
suggested O O
play O O
significant O O
role O O
development O O
cancers O O
anatomic O O
locations O O
, O O
head O O
neck O O
, O O
lung O O
, O O
breast O O
bladder O O
. O O

In O O
2006 O O
, O O
first O O
vaccine O O
HPV B-virus B-virus
, O O
Gardasil O O
, O O
approved O O
prevention O O
subtypes O O
6 O O
, O O
11 O O
, O O
16 O O
18 O O
. O O

A O O
years O O
later O O
, O O
Cevarix O O
approved O O
prevention O O
subtypes O O
16 O O
18 O O
, O O
HPV B-virus B-virus
subtypes O O
frequently O O
implicated O O
malignant O O
progression O O
. O O

Although O O
increased O O
awareness O O
vaccination O O
could O O
drastically O O
decrease O O
incidence O O
HPV-positive B-virus B-virus
cancers O O
, O O
approaches O O
benefit O O
patients O O
already O O
contracted O O
HPV B-virus B-virus
developed O O
cancer O O
result O O
. O O

For O O
reason O O
, O O
researchers O O
need O O
continue O O
developing O O
treatment O O
modalities O O
, O O
targeted O O
immunotherapies O O
, O O
HPV-positive B-virus B-virus
lesions O O
. O O

Here O O
, O O
review O O
potential O O
evidence O O
linking O O
HPV B-virus B-virus
infection O O
development O O
non-anogenital O O
cancers O O
potential O O
role O O
immunotherapy O O
prevention O O
eradication O O
HPV B-virus B-virus
infection O O
oncogenic O O
sequela O O
. O O

Oncogenic O O
viral O O
infections O O
detected O O
12 O O
cases O O
( O O
54 O O
% O O
total O O
; O O
2 O O
HPV18 B-virus B-virus
, O O
5 O O
HPV16 B-virus B-virus
, O O
2 O O
EBV B-virus B-virus
infection O O
, O O
3 O O
EBV/HPV16 B-virus B-virus
coinfections O O
) O O
. O O

The O O
frequent O O
primarily O O
involved O O
neck O O
level O O
series O O
IIA O O
( O O
70 O O
% O O
) O O
, O O
highest O O
prevalence O O
viral O O
infection O O
( O O
66 O O
% O O
) O O
. O O

We O O
find O O
significant O O
correlations O O
virus B-virus B-virus
detection O O
clinicopathologic O O
parameters O O
prognosis O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
causes O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OPSCC O O
) O O
, O O
although O O
strongly O O
divergent O O
results O O
reported O O
regarding O O
prevalence O O
HPV16 B-virus B-virus
different O O
countries O O
, O O
whether O O
represents O O
important O O
differences O O
etiology O O
remains O O
unclear O O
. O O

Applying O O
rigorous O O
protocols O O
sample O O
processing O O
, O O
centrally O O
evaluated O O
1,420 O O
head O O
neck O O
tumors O O
( O O
533 O O
oropharynx O O
, O O
395 O O
oral O O
cavity O O
482 O O
larynx O O
) O O
studies O O
conducted O O
US O O
, O O
Europe O O
Brazil O O
mucosal O O
HPV B-virus B-virus
DNA O O
p16 O O

To O O
identify O O
frequent O O
HPV B-virus B-virus
viral O O
types O O
oropharyngeal O O
cancer O O
, O O
levels O O
expression O O
physical O O
condition O O
viral O O
genome O O
. O O

TTV B-virus B-virus
prevalence O O
higher O O
HNCC O O
patients O O
( O O
saliva O O
: O O
27/71 O O
, O O
38 O O
% O O
; O O
tumor O O
biopsy O O
: O O
22/74 O O
, O O
30 O O
% O O
) O O
controls O O
( O O
saliva O O
: O O
8/56 O O
, O O
14 O O
% O O
; O O
oral O O
mucosa O O
: O O
1æœˆ19æ—¥ O O
, O O
5 O O
% O O
) O O
. O O

TTV B-virus B-virus
prevalence O O
also O O
high O O
patients O O
premalignant O O
lesions O O
oral O O
carcinoma O O
( O O
saliva O O
: O O
9æœˆ18æ—¥ O O
, O O
50 O O
% O O
; O O
biopsy O O
: O O
5æœˆ21æ—¥ O O
, O O
24 O O
% O O
) O O
. O O

By O O
phylogenetic O O
analysis O O
, O O
TTV B-virus B-virus
belonging O O
mostly O O
genotypes O O
1 O O
2 O O
found O O
HNCC O O
patients O O
. O O

In O O
cases O O
, O O
identical O O
TTV B-virus B-virus
strains O O
present O O
biopsy O O
salivary O O
sample O O
HNCC O O
patient O O
. O O

In O O
addition O O
, O O
TTV B-virus B-virus
strain O O
detected O O
2 O O
laryngeal O O
carcinoma O O
biopsies O O
obtained O O
2 O O
independent O O
patients O O
. O O

Among O O
patients O O
evaluated O O
, O O
78 O O
% O O
male O O
. O O

The O O
average O O
age O O
group O O
58 O O
years O O
. O O

Risk O O
factors O O
, O O
smoking O O
( O O
78 O O
% O O
) O O
alcohol O O
consumption O O
( O O
70.8 O O
% O O
) O O
recorded O O
group O O
. O O

HPV B-virus B-virus
DNA O O
detected O O
21 O O
cases O O
( O O
25.6 O O
% O O
; O O
95 O O
% O O
confidence O O
interval O O
16.9-36.6 O O
) O O
33.3 O O
% O O
HPV16 B-virus B-virus
14.3 O O
% O O
HPV18 B-virus B-virus
. O O

The O O
presence O O
lymph O O
node O O
metastases O O
registered O O
deaths O O
less O O
frequent O O
human B-virus B-virus
papilomavirus E-virus E-virus
positive O O
tumors O O
, O O
suggesting O O
better O O
prognosis O O
cases O O
; O O
however O O
, O O
differences O O
groups O O
statistically O O
significant O O
. O O

Squamous O O
cell O O
carcinoma O O
head O O
neck O O
( O O
HNSCC O O
) O O
long O O
regarded O O
disease O O
entity O O
remarkable O O
incidence O O
worldwide O O
fairly O O
onerous O O
prognosis O O
; O O
thus O O
encouraging O O
research O O
factors O O
might O O
modify O O
disease O O
outcome O O
. O O

Squamous O O
cell O O
carcinomas O O
encompass O O
least O O
90 O O
% O O
oral O O
malignancies O O
. O O

Several O O
factors O O
like O O
tobacco O O
tobacco-related O O
products O O
, O O
alcohol O O
, O O
genetic O O
predisposition O O
hormonal O O
factors O O
suspected O O
possible O O
causative O O
factors O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
, O O
causal O O
agent O O
cervical O O
cancer O O
also O O
appears O O
involved O O
aetiology O O
oral O O
oropharyngeal O O
cancer O O
. O O

HPVpositive B-virus O
squamous O O
cell O O
carcinoma O O
( O O
SCC O O
) O O
seems O O
differ O O
HPV-negative B-virus B-virus
SCC O O
. O O

Many O O
questions O O
natural O O
history O O
oral O O
HPV B-virus B-virus
infection O O
remain O O
investigation O O
. O O

The O O
aim O O
review O O
highlight O O
current O O
understanding O O
HPV-associated B-virus B-virus
oral O O
cancer O O
emphasis O O
prognosis O O
, O O
detection O O
management O O
. O O

Thirty-nine O O
publications O O
met O O
inclusion O O
criteria O O
. O O

The O O
prevalence O O
HPV B-virus B-virus
type O O
3,649 O O
patients O O
head O O
neck O O
cancers O O
40 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
34.6 O O
% O O
45.5 O O
% O O
) O O
, O O
highest O O
tonsillar O O
cancer O O
( O O
66.4 O O
% O O
) O O
lowest O O
pharyngeal O O
( O O
15.3 O O
% O O
) O O
tongue O O
( O O
25.7 O O
% O O
) O O
cancers O O
. O O

There O O
statistically O O
significant O O
associations O O
HPV B-virus B-virus
types O O
analysed O O
geographical O O
setting O O
, O O
type O O
sample O O
analysed O O
type O O
primer O O
used O O
analyse O O
samples O O
head O O
neck O O
cancers O O
. O O

In O O
human B-virus B-virus
papilloma I-virus I-virus
virus-related E-virus E-virus
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
, O O
patients O O
solid O O
lymph O O
node O O
metastases O O
higher O O
risk O O
treatment O O
failure O O
worse O O
disease-free O O
survival O O
. O O

Solid O O
lymph O O
nodes O O
may O O
serve O O
imaging O O
biomarker O O
tailor O O
individual O O
treatment O O
regimens O O
. O O

The O O
genetic O O
differences O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
#NAME? O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCC O O
) O O
remain O O
largely O O
unknown O O
. O O

To O O
identify O O
differential O O
biology O O
novel O O
therapeutic O O
targets O O
entities O O
, O O
determined O O
mutations O O
copy-number O O
aberrations O O
large O O
cohort O O
locoregionally O O
advanced O O
HNSCC O O
. O O

A O O
collaborative O O
practice O O
model O O
related O O
Human B-virus B-virus
Papilloma I-virus I-virus
Virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
associated O O
oropharyngeal O O
cancer O O
highlights O O
role O O
dental O O
hygienist O O
addressing O O
condition O O
. O O

Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
ubiquitous O O
: O O
90 O O
% O O
adult O O
population O O
infected O O
virus B-virus B-virus
. O O

EBV B-virus B-virus
capable O O
infecting O O
B O O
lymphocytes O O
epithelial O O
cells O O
throughout O O
body O O
including O O
head O O
neck O O
region O O
. O O

Transmission O O
occurs O O
mainly O O
exchange O O
saliva O O
. O O

The O O
infection O O
asymptomatic O O
mild O O
children O O
, O O
adolescents O O
young O O
adults O O
, O O
causes O O
infectious O O
mononucleosis O O
, O O
self-limiting O O
disease O O
characterized O O
lethargy O O
, O O
sore O O
throat O O
, O O
fever O O
lymphadenopathy O O
. O O

Once O O
established O O
, O O
virus B-virus B-virus
often O O
remains O O
latent O O
people O O
become O O
lifelong O O
carriers O O
without O O
experiencing O O
disease O O
. O O

However O O
, O O
people O O
, O O
latent O O
virus B-virus B-virus
capable O O
causing O O
malignant O O
tumours O O
, O O
nasopharyngeal O O
carcinoma O O
various O O
B- O O
T-cell O O
lymphomas O O
, O O
sites O O
including O O
head O O
, O O
neck O O
oropharyngeal O O
region O O
. O O

As O O
lymphoma O O
second-most O O
common O O
malignant O O
disease O O
head O O
, O O
neck O O
oral O O
region O O
squamous O O
cell O O
carcinoma O O
, O O
oral O O
health O O
care O O
workers O O
including O O
dentists O O
specialists O O
responsibility O O
carry O O
thorough O O
clinical O O
examination O O
anatomical O O
region O O
view O O
identifying O O
diagnosing O O
lesions O O
may O O
represent O O
lymphomas O O
. O O

Early O O
detection O O
allows O O
early O O
treatment O O
resulting O O
better O O
prognosis O O
. O O

The O O
focus O O
review O O
morphology O O
, O O
transmission O O
carcinogenic O O
properties O O
EBV B-virus B-virus
clinical O O
diagnostic O O
aspects O O
range O O
EBV-associated B-virus B-virus
malignancies O O
occurring O O
head O O
, O O
neck O O
oral O O
region O O
. O O

As O O
carcinogenic O O
agents O O
, O O
viruses B-virus B-virus
contribute O O
significant O O
proportion O O
global O O
cancer O O
burden O O
: O O
approximately O O
15 O O
% O O
human O O
cancers O O
, O O
worldwide O O
, O O
attributable O O
viruses.1,2 B-virus B-virus
Serologic O O
epidemiologic O O
studies O O
providing O O
mounting O O
evidence O O
etiologic O O
association O O
viruses B-virus B-virus
head O O
neck O O
malignancies.3 O O
To O O
update O O
oral O O
maxillofacial O O
surgeons O O
oral O O
medicine O O
specialists O O
raise O O
awareness O O
association O O
, O O
recently O O
reviewed O O
evidence O O
etiologic O O
role O O
human B-virus B-virus
papillomavirus E-virus E-virus
oral O O
disease.4 O O
In O O
paper O O
, O O
review O O
current O O
state O O
knowledge O O
association O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
malignant O O
diseases O O
head O O
neck O O
region O O
. O O

Between O O
1998 O O
2011 O O
incidence O O
OPSCC O O
non-OPSCC O O
increased O O
. O O

An O O
increase O O
HPV B-virus B-virus
prevalence O O
( O O
% O O
HPV+ B-virus O
cases O O
2004-2006 O O
versus O O
2012-2013 O O
: O O
27 O O
% O O
versus O O
59 O O
% O O
, O O
P=0.0004 O O
) O O
accompanied O O
moderate O O
decrease O O
portion O O
current O O
smokers O O
observed O O
OPSCC O O
non-OPSCC O O
. O O

The O O
change O O
disease O O
epidemiology O O
OPSCC O O
associated O O
significant O O
improvement O O
overall O O
survival O O
. O O

Increased O O
HPV B-virus B-virus
prevalence O O
OPSCC O O
( O O
48 O O
% O O
) O O
compared O O
non-OPSCC O O
( O O
11 O O
% O O
) O O
confirmed O O
cohort O O
2 O O
. O O

In O O
attempt O O
improve O O
prognosis O O
patients O O
head O O
neck O O
cancer O O
, O O
could O O
necessary O O
identify O O
biomarkers O O
homogeneous O O
subgroups O O
patients O O
head O O
neck O O
cancer O O
. O O

Mycobacterial O O
infections O O
leading O O
cause O O
morbidity O O
mortality O O
among O O
human B-virus B-virus
immunodeficiency I-virus I-virus
virus E-virus E-virus
( O O
HIV B-virus B-virus
) O O
#NAME? O O
individuals O O
worldwide O O
. O O

Cervical O O
lymph O O
nodes O O
frequently O O
affected O O
extrapulmonary O O
sites O O
. O O

Despite O O
substantial O O
reduction O O
complications O O
HIV-tuberculosis B-virus B-virus
coinfection O O
, O O
proportion O O
individuals O O
develop O O
immune O O
reconstitution O O
inflammatory O O
syndrome O O
( O O
IRIS O O
) O O
, O O
term O O
used O O
clinical O O
deterioration O O
following O O
initiation O O
antiretroviral O O
therapy O O
( O O
ART O O
) O O
. O O

The O O
objective O O
study O O
describe O O
mycobacterial-associated O O
IRIS O O
cervical O O
lymph O O
nodes O O
HIV-infected B-virus B-virus
individuals O O
receiving O O
ART O O
. O O

HPV B-virus B-virus
identified O O
7 O O
( O O
6.3 O O
% O O
) O O
tumours O O
, O O
22 O O
( O O
19.6 O O
% O O
) O O
positive O O
p16 O O
immunohistochemical O O
staining O O
. O O

There O O
concordance O O
results O O
obtained O O
using O O
three O O
PCR O O
assays O O
. O O

There O O
substantial O O
agreement O O
results O O
molecular O O
tests O O
p16 O O
immunohistochemistry O O
hypopharyngeal O O
carcinomas O O
, O O
fair O O
agreement O O
laryngeal O O
oropharyngeal O O
carcinomas O O
. O O

The O O
general O O
prevalence O O
HPV B-virus B-virus
34.05 O O
% O O
among O O
civil O O
patients O O
head O O
neck O O
cancers O O
. O O

Our O O
analysis O O
different O O
clinical O O
pathological O O
indices O O
affect O O
HPV-associated B-virus B-virus
oral O O
squamous O O
cell O O
carcinomas O O
revealed O O
non-smoking O O
non-drinking O O
groups O O
higher O O
HPV B-virus B-virus
infection O O
rates O O
compared O O
smoking O O
( O O
P=0.002 O O
) O O
drinking O O
( O O
P O O
< O O
0.005 O O
) O O
groups O O
. O O

In O O
addition O O
, O O
N2-N3 O O
stage O O
patients O O
higher O O
detectable O O
rates O O
N0-N1 O O
stage O O
patients O O
( O O
P=0.027 O O
) O O
. O O

MEDLINE O O
, O O
Embase O O
grey O O
literature O O
sources O O
systematically O O
searched O O
primary O O
studies O O
published O O
English O O
July O O
2002 O O
July O O
2012 O O
, O O
reported O O
prevalence O O
HPV B-virus B-virus
infection O O
head O O
neck O O
cancers O O
European O O
populations O O
. O O

Studies O O
non-European O O
populations O O
, O O
published O O
English O O
, O O
assessing O O
patients O O
co-infected O O
human B-virus B-virus
immunodeficiency I-virus I-virus
virus E-virus E-virus
excluded O O
. O O

Eligible O O
studies O O
combined O O
meta-analysis O O
. O O

In O O
addition O O
, O O
potential O O
statistical O O
association O O
head O O
neck O O
cancers O O
certain O O
HPV B-virus B-virus
types O O
investigated O O
. O O

Tertiary O O
hospital O O
. O O

A O O
retrospective O O
study O O
performed O O
150 O O
samples O O
patients O O
diagnosed O O
HNSCCs O O
. O O

HPV B-virus B-virus
status O O
determined O O
using O O
p16INK4A O O
. O O

A O O
model O O
related O O
HPV B-virus B-virus
associated O O
oropharyngeal O O
cancer O O
addresses O O
oral O O
systemic O O
condition O O
supports O O
inclusion O O
dental O O
hygienist O O
collaborative O O
teams O O
addressing O O
prevention O O
, O O
detection O O
, O O
treatment O O
cure O O
OPC O O
. O O

A O O
subset O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
, O O
mainly O O
arise O O
crypt O O
epithelium O O
palatine O O
lingual O O
tonsils O O
, O O
may O O
caused O O
high-risk B-virus B-virus
human I-virus I-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infections O O
. O O

This O O
topographical O O
restriction O O
together O O
overlapping O O
clinical O O
features O O
led O O
investigators O O
suspect O O
HPV B-virus B-virus
plays O O
role O O
squamous O O
cell O O
carcinoma O O
unknown O O
primary O O
( O O
SCCUP O O
) O O
site O O
metastatic O O
neck O O
lymph O O
nodes O O
. O O

We O O
performed O O
systematic O O
review O O
articles O O
listed O O
PubMed O O
identify O O
studies O O
testing O O
HPV B-virus B-virus
and/or O O
p16 O O
( O O
INK4a O O
) O O
status O O
( O O
p16 O O
) O O
tissue O O
samples O O
initial O O
definitive O O
SCCUP O O
. O O

The O O
prevalence O O
HPV-related B-virus B-virus
( O O
HPV B-virus B-virus
DNA-positive O O
and/or O O
p16 O O
positive O O
) O O
SCCUP O O
calculated O O
SCCUP O O
, O O
initial O O
SCCUP O O
, O O
suspected O O
definitive O O
SCCUP O O
, O O
TRUE O O
definitive O O
SCCUP O O
whenever O O
minimum O O
10 O O
cases O O
category O O
identified O O
. O O

In O O
addition O O
, O O
data O O
concerning O O
patients O O
' O O
diagnostic O O
work-up O O
, O O
HPV B-virus B-virus
detection O O
methods O O
, O O
correlations O O
HPV-status B-virus B-virus
, O O
localization O O
occult O O
primary O O
tumor O O
, O O
clinical O O
outcome O O
also O O
extracted O O
. O O

Eighteen O O
retrospective O O
cohort O O
studies O O
, O O
assessing O O
total O O
659 O O
patients O O
, O O
met O O
inclusion O O
criteria O O
. O O

The O O
overall O O
median O O
prevalences O O
HPV-DNA B-virus B-virus
( O O
pos O O
) O O
, O O
p16 O O
( O O
pos O O
) O O
, O O
positivity O O
HPV B-virus B-virus
markers O O
, O O
respectively O O
, O O
37 O O
, O O
48.5 O O
, O O
36 O O
% O O
. O O

Patients O O
diagnosis O O
initial O O
SCCUP O O
overall O O
median O O
prevalences O O
HPV-DNA B-virus B-virus
( O O
pos O O
) O O
, O O
p16 O O
( O O
pos O O
) O O
, O O
positivity O O
HPV B-virus B-virus
markers O O
, O O
respectively O O
, O O
81.8 O O
, O O
86.2 O O
, O O
80.8 O O
% O O
. O O

The O O
data O O
uncovered O O
systematic O O
review O O
confirm O O
SCCUP O O
frequently O O
causally O O
associated O O
HPV-driven B-virus B-virus
oropharyngeal O O
squamous O O
cell O O
carcinomas O O
. O O

This O O
finding O O
supports O O
view O O
HPV-status B-virus B-virus
could O O
routinely O O
assessed O O
SCCUP O O
patients O O
may O O
lead O O
identifying O O
primary O O
tumor O O
decision O O
de-escalate O O
treatment O O
. O O

To O O
report O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
genotypes O O
involved O O
HNSCC O O
. O O

Evidence O O
exists O O
suggesting O O
HPV B-virus B-virus
infection O O
plays O O
role O O
progression O O
inverted O O
papilloma O O
confers O O
increased O O
risk O O
recurrence O O
malignant O O
transformation O O
. O O

PCR O O
preferred O O
detection O O
method O O
, O O
fresh O O
frozen O O
specimens O O
ideal O O
source O O
tissue O O
evaluation O O
. O O

Although O O
multiple O O
studies O O
detected O O
association O O
HPV B-virus B-virus
inverted O O
papilloma O O
( O O
recurrent O O
malignant O O
transformation O O
) O O
, O O
studies O O
necessary O O
elucidate O O
underlying O O
molecular O O
pathways O O
association O O
changed O O
causation O O
. O O

Respiratory B-virus B-virus
viruses E-virus E-virus
frequently O O
detected O O
association O O
chronic O O
tonsillar O O
hypertrophy O O
absence O O
symptoms O O
acute O O
respiratory O O
infection O O
( O O
ARI O O
) O O
. O O

The O O
present O O
analysis O O
done O O
follow-up O O
previous O O
clinical O O
study O O
done O O
group O O
. O O

Nasopharyngeal O O
washes O O
( O O
NPWs O O
) O O
obtained O O
83 O O
120 O O
individuals O O
variable O O
times O O
post O O
adenotonsillectomy O O
, O O
absence O O
ARI O O
symptoms O O
. O O

A O O
look O O
back O O
virus B-virus B-virus
detection O O
results O O
NPWs O O
83 O O
individuals O O
time O O
tonsillectomy O O
revealed O O
73.5 O O
% O O
( O O
61/83 O O
) O O
positive O O
one O O
viruses B-virus B-virus
. O O

The O O
overall O O
frequency O O
respiratory B-virus B-virus
virus E-virus E-virus
detection O O
post-tonsillectomy O O
NPWs O O
58.8 O O
% O O
. O O

Rhinovirus B-virus B-virus
( O O
RV B-virus B-virus
) O O
agent O O
frequently O O
detected O O
, O O
38 O O
83 O O
subjects O O
( O O
45.8 O O
% O O
) O O
, O O
followed O O
enterovirus B-virus B-virus
7 O O
( O O
8.4 O O
% O O
) O O
, O O
human B-virus B-virus
metapneumovirus E-virus E-virus
6 O O
( O O
7.2 O O
% O O
) O O
, O O
human B-virus B-virus
respiratory I-virus I-virus
syncytial I-virus I-virus
virus E-virus E-virus
3 O O
( O O
3.6 O O
% O O
) O O
human B-virus B-virus
coronavirus E-virus E-virus
1 O O
( O O
1.2 O O
% O O
) O O
. O O

Remarkably O O
, O O
detection O O
adenovirus B-virus B-virus
( O O
HAdV B-virus B-virus
) O O
human B-virus B-virus
bocavirus E-virus E-virus
( O O
HBoV B-virus B-virus
) O O
asymptomatic O O
individuals O O
follow-up O O
adenotonsillectomy O O
. O O

In O O
keeping O O
persistence O O
respiratory B-virus B-virus
DNA O B-virus
viruses E-virus E-virus
human O O
tonsils O O
, O O
tonsillectomy O O
significantly O O
reduces O O
asymptomatic O O
shedding O O
HAdV B-virus B-virus
HBoV B-virus B-virus
NPWs O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
carcinoma O O
quite O O
heterogeneous O O
tumors O O
arise O O
oral O O
cavity O O
, O O
oropharynx O O
, O O
hypopharynx O O
larynx O O
. O O

HPV B-virus B-virus
recently O O
recognized O O
emerging O O
risk O O
factor O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OSCC O O
) O O
. O O

HPV B-virus B-virus
( I-virus I-virus
+ I-virus I-virus
) E-virus E-virus
tumors O O
represent O O
5æœˆ20æ—¥ O O
% O O
head O O
neck O O
squamous-cell O O
carcinomas O O
( O O
HNSCCs O O
) O O
40-90 O O
% O O
arising O O
oropharynx O O
, O O
widely O O
variable O O
rates O O
depending O O
geographic O O
area O O
, O O
population O O
, O O
relative O O
prevalence O O
environment-related O O
SCC O O
detection O O
assay O O
. O O

Different O O
carcinogenic O O
mechanisms O O
likely O O
implicated O O
cervical O O
oropharyngeal O O
carcinogenesis O O
. O O

The O O
certain O O
carcinogenic O O
genotype O O
head O O
neck O O
region O O
common O O
high-risk B-virus B-virus
HPV E-virus E-virus
genotype O O
, O O
HPV-16 B-virus B-virus
, O O
frequently O O
detected O O
OSCC O O
. O O

A O O
combination O O
p16INK4A O O
expression O O
molecular O O
detection O O
HPV B-virus B-virus
DNA O O
gold O O
standard O O
viral O O
identification O O
tissue O O
exfoliated O O
cell O O
samples O O
. O O

Differences O O
biology O O
HPV B-virus B-virus
( I-virus I-virus
+ I-virus I-virus
) E-virus I-virus
HPV B-virus B-virus
( I-virus I-virus
- I-virus I-virus
) E-virus E-virus
OSCC O O
may O O
implications O O
management O O
patients O O
. O O

New O O
immunotherapy O O
drugs O O
based O O
release O O
co-inhibitory O O
receptors O O
, O O
cytotoxic O O
T-lymphocyte-associated O O
antigen O O
4 O O
( O O
CTLA-4 O O
) O O
programmed-death O O
1 O O
( O O
PD-1 O O
) O O
currently O O
emerged O O
. O O

The O O
goal O O
therapeutic O O
cancer O O
vaccination O O
inculcation O O
persistent O O
, O O
tumor O O
antigen-specific O O
T O O
cell O O
response O O
kills O O
tumor O O
cells O O
. O O

The O O
efficacy O O
current O O
HPV B-virus B-virus
vaccines O O
, O O
Cervarix O O
Gardasil O O
, O O
preventing O O
HPV-related B-virus B-virus
HNSCC O O
present O O
unknown O O
. O O

Treatment O O
de-escalation O O
recommended O O
current O O
management O O
HPV-induced B-virus B-virus
HNSCCs O O
. O O

Surgically O O
removed O O
palatine O O
tonsils O O
provide O O
conveniently O O
accessible O O
source O O
T O O
B O O
lymphocytes O O
study O O
interplay O O
foreign O O
pathogens O O
host O O
immune O O
system O O
. O O

In O O
study O O
characterised O O
distribution O O
human B-virus B-virus
adenovirus E-virus E-virus
( O O
HAdV B-virus B-virus
) O O
, O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
human B-virus B-virus
cytomegalovirus E-virus E-virus
( O O
HCMV B-virus B-virus
) O O
purified O O
tonsillar O O
T O O
B O O
cell-enriched O O
fractions O O
isolated O O
three O O
patient O O
age O O
groups O O
diagnosed O O
tonsillar O O
hypertrophy O O
chronic/recurrent O O
tonsillitis O O
. O O

HAdV B-virus B-virus
DNA O O
detected O O
93 O O
111 O O
patients O O
( O O
84 O O
% O O
) O O
, O O
EBV B-virus B-virus
DNA O O
detected O O
58 O O
patients O O
( O O
52 O O
% O O
) O O
. O O

The O O
abundant O O
adenovirus O O
type O O
HAdV-5 B-virus O
( O O
68 O O
% O O
) O O
. O O

None O O
patients O O
positive O O
HCMV B-virus B-virus
. O O

Furthermore O O
, O O
43 O O
patients O O
( O O
39 O O
% O O
) O O
showed O O
co-infection O O
HAdV B-virus B-virus
EBV B-virus B-virus
. O O

The O O
majority O O
young O O
patients O O
diagnosed O O
tonsillar O O
hypertrophy O O
positive O O
HAdV B-virus B-virus
, O O
whereas O O
adult O O
patients O O
diagnosed O O
chronic/recurrent O O
tonsillitis O O
positive O O
either O O
HAdV B-virus B-virus
EBV B-virus B-virus
. O O

Most O O
tonsils O O
patients O O
diagnosed O O
either O O
tonsillar O O
hypertrophy O O
chronic/recurrent O O
tonsillitis O O
showed O O
higher O O
HAdV B-virus B-virus
DNA O O
copy O O
number O O
T O O
compared O O
B O O
cell-enriched O O
fraction O O
. O O

Interestingly O O
, O O
majority O O
tonsils O O
patients O O
chronic/recurrent O O
tonsillitis O O
HAdV B-virus B-virus
DNA O O
detected O O
T O O
cells O O
, O O
whereas O O
hypertrophic O O
tonsils O O
demonstrated O O
HAdV B-virus B-virus
DNA O O
T O O
B O O
cell-enriched O O
fractions O O
. O O

In O O
contrast O O
, O O
majority O O
EBV B-virus B-virus
positive O O
tonsils O O
revealed O O
preference O O
EBV B-virus B-virus
DNA O O
accumulation O O
B O O
cell-enriched O O
fraction O O
compared O O
T O O
cell O O
fraction O O
irrespective O O
patients O O
' O O
age O O
. O O

The O O
prevalence O O
HPV B-virus B-virus
associated O O
oropharyngeal O O
carcinoma O O
among O O
Colombian O O
study O O
population O O
21.7 O O
% O O
, O O
relatively O O
low O O
. O O

The O O
frequent O O
viral O O
type O O
HPV-16 B-virus B-virus
, O O
found O O
mixed O O
form O O
low O O
expression O O
E7 O O
, O O
possibly O O
indicating O O
poor O O
prognosis O O
patients O O
. O O

HPV B-virus B-virus
integration O O
cancer-related O O
genes O O
occurred O O
7 O O
9 O O
HPV-positive B-virus B-virus
cell O O
lines O O
6 O O
tumors O O
progressed O O
. O O

HPV B-virus B-virus
integration O O
cancer-related O O
genes O O
may O O
secondary O O
carcinogenic O O
driver O O
HPV-driven B-virus B-virus
tumors O O
. O O

Â© O O
2017 O O
Wiley O O
Periodicals O O
, O O
Inc. O O
Head O O
Neck O O
39 O O
: O O
840-852 O O
, O O
2017 O O
. O O

Subclinical O O
oral O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
persists O O
decades O O
likely O O
precede O O
HPV-driven B-virus B-virus
squamous O O
cell O O
carcinoma O O
head O O
neck O O
, O O
little O O
known O O
natural O O
history O O
oral O O
HPV B-virus B-virus
. O O

We O O
systematically O O
reviewed O O
abstracted O O
data O O
nine O O
manuscripts O O
examined O O
human O O
immunodeficiency O O
virus-negative O O
cancer-free O O
subjects O O
oral O O
HPV B-virus B-virus
DNA O O
determine O O
pooled O O
baseline O O
prevalence O O
incidence O O
newly O O
acquired O O
oral O O
HPV B-virus B-virus
infections O O
, O O
specifically O O
HPV-16 B-virus B-virus
. O O

We O O
also O O
documented O O
clearance O O
rate O O
median O O
time O O
clearance O O
, O O
data O O
existed O O
. O O

Of O O
3762 O O
individuals O O
, O O
7.5 O O
% O O
oral O O
infection O O
HPV B-virus B-virus
type O O
( O O
1.6 O O
% O O
HPV-16 B-virus B-virus
) O O
. O O

Meta-regression O O
analysis O O
estimated O O
12-month O O
cumulative O O
incidence O O
4.8 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
3.2-7.3 O O
% O O
) O O
. O O

The O O
overall O O
oral O O
HPV B-virus B-virus
clearance O O
reported O O
0-80 O O
% O O
studies O O
, O O
median O O
time O O
clearance O O
6.5 O O
18 O O
months O O
. O O

Oral O O
HPV-16 B-virus B-virus
clearance O O
43-83 O O
% O O
, O O
median O O
time O O
clearance O O
HPV-16 B-virus B-virus
7æœˆ22æ—¥ O O
months O O
. O O

Oral O O
HPV B-virus B-virus
prevalence O O
, O O
incidence O O
clearance O O
vary O O
considerably O O
published O O
studies O O
different O O
geographical O O
regions O O
. O O

Further O O
research O O
required O O
identify O O
predictors O O
persistent O O
oral O O
HPV B-virus B-virus
infection O O
. O O

Measurable O O
baseline O O
prevalence O O
observed O O
studies O O
, O O
well O O
non-trivial O O
incidence O O
newly O O
acquired O O
oral O O
HPV B-virus B-virus
infections O O
incomplete O O
clearance O O
. O O

Cases O O
58 O O
males O O
20 O O
females O O
included O O
29 O O
oral O O
cavity O O
, O O
33 O O
larynx O O
, O O
11 O O
pharynx O O
5 O O
parotid O O
gland O O
. O O

HPV B-virus B-virus
DNA O O
found O O
15 O O
( O O
19.23 O O
% O O
) O O
tumors O O
12 O O
HPV-16 B-virus B-virus
, O O
2 O O
HPV-18 B-virus B-virus
1 O O
dual O O
infection O O
HPV-16 B-virus B-virus
HPV-18 B-virus B-virus
, O O
giving O O
HPV-16 B-virus B-virus
prevalence O O
86.7 O O
% O O
. O O

Higher O O
prevalence O O
HPV B-virus B-virus
DNA O O
found O O
males O O
females O O
. O O

There O O
trend O O
towards O O
subjects O O
younger O O
58 O O
years O O
likely O O
HPV-positive B-virus B-virus
tumors.The O O
15 O O
HPV-positive B-virus B-virus
cases O O
distributed O O
location O O
8 O O
33 O O
( O O
24.2 O O
% O O
) O O
larynx O O
, O O
4 O O
29 O O
( O O
13.8 O O
% O O
) O O
oral O O
cavity O O
, O O
2 O O
11 O O
( O O
18.2 O O
% O O
) O O
pharynx O O
1 O O
5 O O
( O O
20 O O
% O O
) O O
parotid O O
gland O O
. O O

Head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
sixth O O
common O O
cancer O O
annual O O
incidence O O
approximately O O
400,000 O O
worldwide O O
. O O

Although O O
principal O O
risk O O
factors O O
head O O
neck O O
cancer O O
remain O O
tobacco O O
alcohol O O
use O O
, O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
recently O O
found O O
etiologically O O
associated O O
20 O O
25 O O
% O O
HNSCC O O
, O O
mostly O O
oropharynx O O
. O O

HPV B-virus B-virus
causes O O
human O O
cancers O O
expressing O O
two O O
viral O O
oncoproteins O O
, O O
E6 O O
E7 O O
. O O

These O O
oncoproteins O O
degrade O O
destabilize O O
two O O
major O O
tumor O O
suppressor O O
proteins O O
, O O
p53 O O
pRb O O
, O O
ubiquitination O O
. O O

Additional O O
studies O O
shown O O
E6 O O
E7 O O
directly O O
bind O O
multiple O O
host O O
proteins O O
p53 O O
pRb O O
( O O
e.g. O O
, O O
Bak O O
p21 O O
( O O
Cip1 O O
) O O
) O O
, O O
contributing O O
genetic O O
instability O O
. O O

However O O
, O O
expression O O
E6 O O
E7 O O
alone O O
sufficient O O
cellular O O
transformation O O
, O O
additional O O
genetic O O
alterations O O
necessary O O
malignant O O
progression O O
setting O O
virus-induced B-virus B-virus
genomic O O
instability O O
unknown O O
. O O

In O O
addition O O
etiological O O
differences O O
, O O
HPV-positive B-virus B-virus
cancers O O
clinically O O
distinct O O
compared O O
HPV-negative B-virus B-virus
cancers O O
regard O O
treatment O O
response O O
survival O O
outcome O O
, O O
tumor O O
HPV-positivity B-virus B-virus
favorable O O
prognostic O O
biomarker O O
. O O

Further O O
understanding O O
carcinogenesis O O
clinical O O
behavior O O
HPV-positive B-virus B-virus
cancers O O
improve O O
disease O O
prevention O O
, O O
patient O O
care O O
, O O
surveillance O O
strategies O O
HNSCC O O
patients O O
. O O

We O O
evaluated O O
fresh O O
samples O O
consecutive O O
series O O
22 O O
neck O O
dissections O O
metastases O O
unknown O O
primary O O
squamous O O
cell O O
carcinoma O O
obtained O O
2010 O O
2012 O O
single O O
institution O O
. O O

The O O
samples O O
tested O O
presence O O
HPV B-virus B-virus
E6 O O
E7 O O
mRNA O O
EBV B-virus B-virus
DNA O O
. O O

The O O
lack O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
sequences O O
well O O
potential O O
HPV-activated B-virus B-virus
cells O O
cells O O
would O O
p16- O O
Ki-67 O O
positive O O
support O O
role O O
HPV B-virus B-virus
pathogenesis O O
lesion O O
. O O

The O O
identification O O
HPV B-virus B-virus
status-specific O O
significant O O
gene O O
set O O
necessary O O
. O O

It O O
expected O O
HPV B-virus B-virus
status-specific O O
biomarkers O O
helpful O O
deciding O O
therapeutic O O
methods O O
patients O O
head O O
neck O O
cancer O O
, O O
biological O O
validation O O
large O O
prospective O O
trials O O
. O O

Because O O
torque B-virus B-virus
teno I-virus I-virus
virus E-virus E-virus
( O O
TTV B-virus B-virus
) O O
implicated O O
tumorigenesis O O
cocarcinogen O O
, O O
studied O O
TTV B-virus B-virus
prevalence O O
saliva O O
biopsy O O
samples O O
head O O
neck O O
cancer O O
( O O
HNCC O O
) O O
patients O O
, O O
patients O O
premalignant O O
lesions O O
oral O O
cancer O O
, O O
controls O O
. O O

We O O
also O O
wished O O
determine O O
TTV B-virus B-virus
genotypes O O
HNCC O O
patients O O
. O O

The O O
purpose O O
study O O
present O O
clinicopathological O O
features O O
series O O
patients O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
second O O
primary O O
tumors O O
. O O

One O O
hundred O O
eighty-three O O
patients O O
included O O
mean O O
follow-up O O
38 O O
months O O
. O O

In O O
univariate O O
analysis O O
, O O
following O O
variables O O
statistically O O
significant O O
association O O
treatment O O
failure O O
: O O
solid-versus-cystic O O
lymph O O
nodes O O
, O O
clinical O O
T-stage O O
, O O
clinical O O
N-stage O O
, O O
radiologic O O
evidence O O
extracapsular O O
spread O O
. O O

The O O
multivariate O O
Cox O O
proportional O O
hazard O O
model O O
resulted O O
model O O
included O O
solid-versus-cystic O O
lymph O O
nodes O O
, O O
T-stage O O
, O O
radiologic O O
evidence O O
extracapsular O O
spread O O
independent O O
predictors O O
treatment O O
failure O O
. O O

Patients O O
cystic O O
nodal O O
metastasis O O
staging O O
significantly O O
better O O
disease-free O O
survival O O
patients O O
solid O O
lymph O O
nodes O O
. O O

Our O O
findings O O
indicate O O
co-infection O O
HPV B-virus B-virus
EBV B-virus B-virus
rare O O
HNC O O
. O O

Oropharyngeal O O
SCC O O
active O O
HPV B-virus B-virus
infection O O
related O O
highly O O
favorable O O
outcome O O
, O O
EBV B-virus B-virus
status O O
prognostic O O
NPC O O
cohort O O
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
necessary O O
cause O O
anogenital O O
squamous O O
cell O O
carcinomas O O
( O O
SCC O O
) O O
subgroup O O
head O O
neck O O
SCC O O
, O O
i.e. O O
, O O
originating O O
oropharynx O O
. O O

The O O
key O O
events O O
high-risk B-virus B-virus
HPV E-virus E-virus
( O O
HRHPV B-virus B-virus
) O O
#NAME? O O
neoplastic O O
progression O O
include O O
persistent O O
infection O O
, O O
deregulated O O
expression O O
virus B-virus B-virus
early O O
genes O O
basal O O
epithelial O O
cells O O
, O O
local O O
immune O O
suppression O O
accumulation O O
chromosomal O O
alterations O O
. O O

Evidence O O
events O O
particularly O O
comes O O
studies O O
uterine O O
cervical O O
carcinogenesis O O
; O O
primary O O
premalignant O O
HRHPV-positive B-virus B-virus
lesions O O
head O O
neck O O
mucosa O O
seldomly O O
detected O O
. O O

Integration O O
virus B-virus B-virus
DNA O O
host O O
chromosomes O O
considered O O
important O O
driver O O
carcinogenesis O O
observed O O
40 O O
90 O O
% O O
uterine O O
cervical O O
SCC O O
( O O
UCSCC O O
) O O
oropharyngeal O O
SCC O O
( O O
OPSCC O O
) O O
, O O
dependent O O
integration O O
detection O O
method O O
used O O
HRHPV B-virus B-virus
type O O
. O O

In O O
OPSCC O O
, O O
> O O
90 O O
% O O
HPV-positive B-virus B-virus
tumors O O
infected O O
HPV16 B-virus B-virus
. O O

Ten O O
60 O O
% O O
HPV-positive B-virus B-virus
tumors O O
thus O O
contain O O
extrachromosomal B-virus B-virus
( O O
episomal B-virus B-virus
) O O
virus E-virus E-virus
. O O

In O O
chapter O O
, O O
causes O O
consequences O O
HPV B-virus B-virus
integration O O
summarized O O
literature O O
, O O
special O O
focus O O
site O O
HPV B-virus B-virus
integration O O
cellular O O
genome O O
, O O
effect O O
expression O O
viral O O
oncogenes O O
( O O
particularly O O
E6 O O
E7 O O
) O O
, O O
human O O
( O O
tumor O O
) O O
gene O O
expression O O
deregulation O O
cell O O
proliferation O O
, O O
apoptosis O O
cell O O
signaling O O
pathways O O
. O O

Also O O
data O O
DNA O O
methylation O O
, O O
viral O O
load O O
clinical O O
outcome O O
relation O O
HPV B-virus B-virus
integration O O
provided O O
. O O

One O O
hundred O O
ninety O O
six O O
archival O O
HNSCC O O
tissue O O
samples O O
analysed O O
presence O O
HPV B-virus B-virus
DNA O O
. O O

The O O
DNA O O
quality O O
assured O O
, O O
amplified O O
using O O
nested O O
PCR O O
approach O O
. O O

The O O
typing O O
HPV B-virus B-virus
performed O O
automated O O
DNA O O
sequencing O O
. O O

Cellular O O
markers O O
p53 O O
, O O
Cyclin O O
D1 O O
pRb O O
tested O O
samples O O
immunohistochemistry O O
( O O
IHC O O
) O O
, O O
well O O
p16 O O
putative O O
surrogate O O
detection O O
HPV B-virus B-virus
. O O

Development O O
referral O O
systems O O
essential O O
enhance O O
survivorship O O
outcomes O O
patients O O
completed O O
treatment O O
. O O

The O O
identified O O
gene O O
set O O
distinguishing O O
head O O
neck O O
cancer O O
head O O
neck O O
normal O O
, O O
accurately O O
discriminate O O
HPV B-virus B-virus
specific O O
patients O O
head O O
neck O O
cancer O O
head O O
neck O O
normal O O
group O O
. O O

Also O O
, O O
demonstrated O O
HPV-positive B-virus B-virus
( O O
HPV+ B-virus B-virus
) O O
head O O
neck O O
cancer-specific O O
genes O O
may O O
significant O O
HPV-negative B-virus B-virus
( O O
HPV- B-virus B-virus
) O O
head O O
neck O O
cancer O O
patients O O
. O O

The O O
identified O O
HPV B-virus B-virus
specific O O
gene O O
sets O O
showed O O
good O O
performance O O
validation O O
datasets O O
. O O

The O O
HPV+ B-virus B-virus
head O O
neck O O
cancer-specific O O
gene O O
set O O
included O O
various O O
metabolism-related O O
pathways O O
, O O
HPV- B-virus B-virus
head O O
neck O O
cancer-specific O O
gene O O
set O O
included O O
several O O
pathways O O
; O O
fibroblast O O
, O O
collagen O O
degradation O O
, O O
actin-binding O O
, O O
actin O O
cytoskeleton O O
. O O

A O O
causal O O
relationship O O
HPV B-virus B-virus
pathogenesis O O
progression O O
inverted O O
papilloma O O
posited O O
since O O
1980s O O
. O O

Although O O
widely O O
varied O O
HPV B-virus B-virus
detection O O
rates O O
reported O O
, O O
recent O O
studies O O
noted O O
substantial O O
increase O O
recurrence O O
malignant O O
transformation O O
HPV-infected B-virus B-virus
inverted O O
papillomas O O
. O O

However O O
, O O
exact O O
cellular O O
mechanisms O O
infection O O
leads O O
subsequent O O
recurrence O O
development O O
carcinoma O O
yet O O
elucidated O O
. O O

Neck O O
metastasis O O
unknown O O
primary O O
squamous O O
cell O O
carcinoma O O
could O O
another O O
virus-related O B-virus
malignancy O O
head O O
neck O O
region O O
, O O
along O O
nasopharyngeal O O
oropharyngeal O O
carcinoma O O
. O O

An O O
evaluation O O
impact O O
viral O O
infection O O
patient O O
prognosis O O
sensitivities O O
different O O
treatment O O
modalities O O
could O O
modify O O
prognostic O O
assessments O O
treatment O O
planning O O
. O O

Furthermore O O
, O O
virus B-virus B-virus
detection O O
would O O
decisive O O
impact O O
diagnostic/decisional O O
algorithms O O
, O O
especially O O
detection O O
methods O O
implemented O O
cytologic O O
samples O O
( O O
e.g. O O
, O O
thin O O
prep O O
) O O
. O O

A O O
standardized O O
assay O O
determine O O
HPV B-virus B-virus
status O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
specimens O O
yet O O
established O O
, O O
particularly O O
cytologic O O
samples O O
. O O

The O O
goal O O
study O O
determine O O
whether O O
hybrid O O
capture-2 O O
( O O
HC-2 O O
) O O
assay O O
, O O
already O O
widely O O
used O O
detection O O
high B-virus B-virus
risk I-virus I-virus
HPV E-virus E-virus
cervical O O
brushings O O
, O O
applicable O O
cytologic O O
specimens O O
obtained O O
patients O O
suspected O O
HNSCCs O O
. O O

HPV B-virus B-virus
presence O O
confirmed O O
23/250 O O
( O O
9.2 O O
% O O
) O O
OSCC O O
cases O O
, O O
30.4 O O
% O O
HPV B-virus B-virus
16 O O
infection O O
, O O
17.4 O O
% O O
positive O O
HPV B-virus B-virus
18 O O
26.1 O O
% O O
co-infections O O
. O O

HPV B-virus B-virus
presence O O
significantly O O
associated O O
male O O
gender O O
( O O
p=0.02 O O
) O O
habit O O
pan O O
masala O O
chewing O O
( O O
p=0.01 O O
) O O
. O O

HPV B-virus B-virus
positive O O
cases O O
also O O
history O O
tobacco O O
consumption O O
91.3 O O
% O O
cases O O
. O O

p16 O O
expression O O
observed O O
39.1 O O
% O O
HPV B-virus B-virus
positive O O
cases O O
significantly O O
different O O
negative O O
cases O O
( O O
p=0.54 O O
) O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
postulated O O
risk O O
factor O O
etiology O O
specific O O
mucosal O O
pathologies O O
head O O
neck O O
regions O O
. O O

Despite O O
frequent O O
use O O
p16 O O
( O O
INK4a O O
) O O
surrogate O O
marker O O
HPV-infection B-virus B-virus
, O O
still O O
controversy O O
respect O O
reliability O O
. O O

This O O
study O O
undertaken O O
assess O O
potential O O
role O O
p16 O O
( O O
INK O O
4a O O
) O O
Ki-67 O O
expression O O
HPV-related B-virus B-virus
lesions O O
. O O

The O O
study O O
conducted O O
71 O O
specimens O O
oral O O
, O O
tonsillar O O
laryngeal O O
lesions O O
comprised O O
25 O O
dysplasia O O
46 O O
papilloma O O
specimens O O
. O O

Specimens O O
immunohistochemically O O
stained O O
p16 O O
( O O
INK4A O O
) O O
Ki-67 O O
proteins O O
. O O

HPV B-virus B-virus
DNA O O
determined O O
one O O
step O O
multiplex O O
polymerase O O
chain O O
reaction O O
. O O

HPV B-virus B-virus
DNA O O
detected O O
33.8 O O
% O O
lesions O O
. O O

Tonsil O O
larynx O O
lesions O O
showed O O
significant O O
differences O O
oral O O
lesions O O
HPV B-virus B-virus
positivity O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

p16 O O
( O O
INK O O
4a O O
) O O
over-expression O O
seen O O
56.5 O O
% O O
papilloma O O
60 O O
% O O
dysplasia O O
specimens O O
. O O

HPV B-virus B-virus
status O O
showed O O
positive O O
correlation O O
p16 O O
( O O
INK O O
4a O O
) O O
expression O O
tonsillar O O
dysplasias O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

p16 O O
( O O
INK O O
4a O O
) O O
expression O O
may O O
value O O
marker O O
high O O
risk O O
HPV B-virus B-virus
induced O O
dysplasias O O
, O O
low O O
risk O O
infected O O
lesions O O
. O O

The O O
proliferation O O
index O O
related O O
HPV-induced B-virus B-virus
lesions O O
may O O
evaluated O O
independent O O
marker O O
head O O
neck O O
premalignant O O
lesions O O
. O O

This O O
review O O
examines O O
general O O
cellular O O
molecular O O
underpinnings O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
carcinogenesis O O
context O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
focuses O O
HPV-positive B-virus B-virus
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
areas O O
specific O O
data O O
available O O
. O O

It O O
covers O O
major O O
pathways O O
dysregulated O O
HPV-positive B-virus B-virus
HNSCC O O
genome-wide O O
changes O O
associated O O
disease O O
. O O

HPV B-virus B-virus
EBV B-virus B-virus
DNA O O
, O O
EBV B-virus B-virus
genotypes O O
LMP-1 O O
variants O O
, O O
HPV B-virus B-virus
mRNA O O
expression O O
detected O O
PCR O O
fresh-frozen O O
HNC O O
samples O O
. O O

HPV B-virus B-virus
genotypes O O
determined O O
direct O O
sequencing O O
, O O
EBV B-virus B-virus
encoded O O
RNA O O
( O O
EBER O O
) O O
examined O O
situ O O
hybridization O O
. O O


On O O
basis O O
evaluation O O
116 O O
whole-exome O O
, O O
23 O O
whole-transcriptome O O
2 O O
whole-genome O O
data O O
, O O
able O O
identify O O
presence O O
HPV B-virus B-virus
20 O O
exomes O O
4 O O
transcriptomes O O
cervical O O
head O O
neck O O
cancer O O
tumour O O
samples O O
. O O

Using O O
inbuilt O O
annotation O O
module O O
HPVDetector B-virus B-virus
, O O
found O O
predominant O O
integration O O
viral O O
gene O O
E7 O O
, O O
known O O
oncogene O O
, O O
known O O
17q21 O O
, O O
3q27 O O
, O O
7q35 O O
, O O
Xq28 O O
novel O O
sites O O
integration O O
human O O
genome O O
. O O

Furthermore O O
, O O
co-infection O O
high-risk B-virus B-virus
HPVs E-virus E-virus
16 O O
31 O O
found O O
mutually O O
exclusive O O
compared O O
low-risk B-virus B-virus
HPV71 E-virus E-virus
. O O

Approximately O O
1æœˆ9æ—¥ O O
% O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
neck O O
metastases O O
clinically O O
undetectable O O
primary O O
tumors O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
proven O O
carcinogenic O O
factors O O
associated O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
nasopharyngeal O O
carcinoma O O
, O O
respectively O O
. O O

In O O
present O O
study O O
, O O
evaluated O O
prevalence O O
viruses O B-virus
neck O O
metastases O O
unknown O O
primary O O
squamous O O
cell O O
carcinoma O O
. O O

The O O
long-term O O
survival O O
rates O O
surgically O O
treated O O
oropharyngeal O O
cancer O O
patients O O
comparable O O
studies O O
. O O

Variables O O
including O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
status O O
tumour O O
stage O O
associated O O
survival O O
patients O O
treated O O
primary O O
surgery O O
; O O
however O O
, O O
nodal O O
stage O O
presence O O
extracapsular O O
spread O O
non-prognostic O O
. O O

This O O
study O O
investigated O O
long-term O O
survival O O
outcomes O O
surgically O O
treated O O
oropharyngeal O O
cancer O O
patients O O
known O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
status O O
. O O

This O O
study O O
conducted O O
1998 O O
2013 O O
included O O
patients O O
HPV-related B-virus B-virus
OPSCC O O
treated O O
surgery O O
without O O
adjuvant O O
therapy O O
pN3 O O
nodal O O
disease O O
. O O

The O O
primary O O
outcome O O
disease-specific O O
survival O O
( O O
DSS O O
) O O
. O O

Secondary O O
outcomes O O
included O O
overall O O
survival O O
( O O
OS O O
) O O
, O O
disease-free O O
survival O O
( O O
DFS O O
) O O
, O O
adverse O O
events O O
, O O
gastrostomy O O
tube O O
rates O O
. O O

To O O
evaluate O O
outcomes O O
patients O O
pathological O O
N3 O O
( O O
pN3 O O
) O O
neck O O
disease O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OPSCC O O
) O O
determine O O
variables O O
predictive O O
survival O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
changed O O
face O O
head O O
neck O O
cancer O O
past O O
2 O O
decades O O
. O O

No O O
longer O O
solely O O
disease O O
older O O
patients O O
history O O
heavy O O
tobacco O O
alcohol O O
use O O
. O O

Patients O O
HPV-related B-virus B-virus
head O O
neck O O
cancers O O
tend O O
younger O O
, O O
healthier O O
, O O
improved O O
prognosis O O
, O O
compared O O
HPV-negative B-virus B-virus
tumors O O
. O O

As O O
patients O O
diagnosed O O
HPV-related B-virus B-virus
head O O
neck O O
cancer O O
, O O
physicians O O
important O O
topics O O
consider O O
. O O

These O O
include O O
prevalence O O
, O O
transmission O O
, O O
natural O O
history O O
HPV B-virus B-virus
, O O
role O O
screening O O
, O O
vaccines O O
, O O
HPV B-virus B-virus
testing O O
head O O
neck O O
cancer O O
. O O

This O O
article O O
continues O O
series O O
developed O O
American O O
Head O O
Neck O O
Society O O
's O O
Education O O
Committee O O
entitled O O
`` O O
Do O O
know O O
guidelines O O
? O O
'' O O

intended O O
provide O O
guidance O O
navigating O O
common O O
questions O O
concerns O O
patients O O
may O O
HPV B-virus B-virus
infection O O
HPV-related B-virus B-virus
head O O
neck O O
cancer O O
. O O

Â© O O
2017 O O
Wiley O O
Periodicals O O
, O O
Inc. O O
Head O O
Neck O O
39 O O
: O O
833-839 O O
, O O
2017 O O
. O O

We O O
searched O O
bibliographies O O
electronic O O
databases O O
Sichuan O O
University O O
, O O
including O O
Chinese O O
Biological O O
Medical O O
Database O O
( O O
CBM O O
) O O
, O O
China O O
Science O O
Technology O O
Journal O O
Database O O
( O O
VIP O O
) O O
, O O
Wanfang O O
Journal O O
Database O O
. O O

Then O O
, O O
data O O
selected O O
extracted O O
analyze O O
basic O O
characteristics O O
HPV-related B-virus B-virus
head O O
neck O O
cancers O O
, O O
general O O
prevalence O O
HPV B-virus B-virus
, O O
effects O O
various O O
clinic O O
pathological O O
indicators O O
HPV B-virus B-virus
patients O O
. O O

Cancer O O
unknown O O
primary O O
head O O
neck O O
challenging O O
entity O O
oncologist O O
. O O

The O O
role O O
human B-virus B-virus
papilloma I-virus I-virus
virus/p16 E-virus E-virus
carcinogenesis O O
prognosis O O
well O O
established O O
certain O O
HNSCC O O
especially O O
oropharynx O O
. O O

In O O
case O O
occult O O
primary O O
head O O
neck O O
role O O
HPV/p16 B-virus B-virus
positivity O O
well O O
defined O O
regarding O O
prognosis O O
localization O O
primary O O
. O O

An O O
independent O O
review O O
PubMed O O
ScienceDirect O O
database O O
performed O O
May O O
2014 O O
using O O
combinations O O
terms O O
`` O O
occult O O
primary O O
head O O
neck O O
'' O O
, O O
`` O O
CUP O O
head O O
neck O O
'' O O
`` O O
metastatic O O
cervical O O
squamous O O
cell O O
carcinoma O O
unknown O O
primary O O
'' O O
, O O
`` O O
HPV B-virus B-virus
'' O O
`` O O
HPV B-virus B-virus
head O O
neck O O
cancer O O
'' O O
. O O

Literature O O
review O O
shows O O
strong O O
association O O
HPV/p16 B-virus B-virus
positivity O O
primary O O
location O O
oropharynx O O
patients O O
CUP O O
head O O
neck O O
well O O
better O O
clinical O O
outcome O O
. O O

HPV B-virus B-virus
positivity O O
p16 O O
overexpression O O
could O O
used O O
surrogate O O
markers O O
search O O
primary O O
site O O
patients O O
CUP O O
head O O
neck O O
therefore O O
maybe O O
guiding O O
treatment O O
decisions O O
. O O

Elucidation O O
tumor-DNA B-virus B-virus
virus E-virus E-virus
associations O O
many O O
cancer O O
types O O
enhanced O O
knowledge O O
fundamental O O
oncogenesis O O
mechanisms O O
provided O O
basis O O
cancer O O
prevention O O
initiatives O O
. O O

RNA-Seq O O
novel O O
tool O O
comprehensively O O
assess O O
associations O O
. O O

We O O
interrogated O O
RNA-Seq O O
data O O
3,775 O O
malignant O O
neoplasms O O
The O O
Cancer O O
Genome O O
Atlas O O
database O O
presence O O
viral O O
sequences O O
. O O

Viral O O
integration O O
sites O O
also O O
detected O O
expressed O O
transcripts O O
using O O
novel O O
approach O O
. O O

The O O
detection O O
capacity O O
RNA-Seq O O
compared O O
available O O
clinical O O
laboratory O O
data O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
transcripts O O
detected O O
using O O
RNA-Seq O O
analysis O O
head-and-neck O O
squamous O O
cell O O
carcinoma O O
, O O
uterine O O
endometrioid O O
carcinoma O O
, O O
squamous O O
cell O O
carcinoma O O
lung O O
. O O

Detection O O
HPV B-virus B-virus
RNA-Seq O O
correlated O O
detection O O
situ O O
hybridization O O
immunohistochemistry O O
squamous O O
cell O O
carcinoma O O
tumors O O
head O O
neck O O
. O O

Hepatitis B-virus B-virus
B I-virus I-virus
virus E-virus E-virus
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
detected O O
using O O
RNA-Seq O O
hepatocellular O O
carcinoma O O
gastric O O
carcinoma O O
tumors O O
, O O
respectively O O
. O O

Integration O O
sites O O
viral O O
genes O O
oncogenes O O
detected O O
cancers O O
harboring O O
HPV B-virus B-virus
hepatitis B-virus B-virus
B I-virus I-virus
virus E-virus E-virus
EBV-positive B-virus B-virus
gastric O O
carcinoma O O
. O O

Integration O O
sites O O
expressed O O
viral O O
transcripts O O
frequently O O
involved O O
known O O
coding O O
areas O O
host O O
genome O O
. O O

No O O
DNA B-virus B-virus
virus E-virus E-virus
transcripts O O
detected O O
acute O O
myeloid O O
leukemia O O
, O O
cutaneous O O
melanoma O O
, O O
low- O O
high-grade O O
gliomas O O
brain O O
, O O
adenocarcinomas O O
breast O O
, O O
colon O O
rectum O O
, O O
lung O O
, O O
prostate O O
, O O
ovary O O
, O O
kidney O O
, O O
thyroid O O
. O O

In O O
conclusion O O
, O O
study O O
provides O O
large-scale O O
overview O O
landscape O O
DNA B-virus B-virus
viruses E-virus E-virus
human O O
malignant O O
cancers O O
. O O

While O O
validation O O
necessary O O
specific O O
cancer O O
types O O
, O O
findings O O
highlight O O
utility O O
RNA-Seq O O
detecting O O
tumor-associated O O
DNA B-virus B-virus
viruses E-virus E-virus
identifying O O
viral O O
integration O O
sites O O
may O O
unravel O O
novel O O
mechanisms O O
cancer O O
pathogenesis O O
. O O

Epstein-Barr B-virus B-virus
( O O
EBV B-virus B-virus
) O O
infection O O
presence O O
nasopharyngeal O O
cancer O O
( O O
NPC O O
) O O
case O O
family O O
increases O O
risk O O
developing O O
NPC O O
. O O

Aberrant O O
anti-EBV B-virus B-virus
immunoglobulin O O
A O O
( O O
IgA O O
) O O
antibodies O O
( O O
EBV-IgA B-virus B-virus
) O O
may O O
present O O
sera O O
non-cancer O O
individuals O O
predict O O
NPC O O
. O O

Limited O O
studies O O
report O O
presence O O
EBV-IgA B-virus B-virus
antibodies O O
within O O
non-cancer O O
individuals O O
Indonesia O O
disease O O
prevalent O O
. O O

This O O
study O O
aimed O O
exploring O O
whether O O
EBV-IgA B-virus B-virus
found O O
frequently O O
among O O
first O O
degree O O
relatives O O
NPC O O
patients O O
individuals O O
presenting O O
chronic O O
symptoms O O
head O O
neck O O
area O O
compared O O
healthy O O
controls O O
. O O

A O O
total O O
967 O O
non-cancer O O
subjects O O
recruited O O
, O O
including O O
509 O O
family O O
members O O
NPC O O
cases O O
, O O
196 O O
individuals O O
chronic O O
complaints O O
head O O
neck O O
region O O
, O O
262 O O
healthy O O
donors O O
local O O
blood O O
bank O O
. O O

Sera O O
analyzed O O
using O O
standardized O O
peptide-based O O
EBV-IgA B-virus B-virus
ELISA O O
. O O

Overall O O
, O O
61.6 O O
% O O
individuals O O
anti-EBV B-virus B-virus
IgA O O
reactivity O O
equal O O
cut O O
value O O
( O O
CoV O O
) O O
. O O

Seroreactivity O O
CoV O O
significantly O O
higher O O
females O O
( O O
38.7 O O
% O O
) O O
compared O O
males O O
( O O
28.7 O O
% O O
) O O
( O O
p O O
= O O
0.001 O O
) O O
. O O

Older O O
individuals O O
seroreactivity O O
CoV O O
( O O
42.5 O O
% O O
) O O
younger O O
ones O O
( O O
26.4 O O
% O O
) O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

Seroprevalence O O
significantly O O
higher O O
family O O
members O O
NPC O O
patients O O
( O O
41.7 O O
% O O
) O O
, O O
compared O O
32.7 O O
% O O
individuals O O
chronic O O
head O O
neck O O
problems O O
( O O
p O O
= O O
0.028 O O
) O O
16.4 O O
% O O
healthy O O
blood O O
donors O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

As O O
conclusion O O
, O O
study O O
showed O O
significant O O
higher O O
seroprevalence O O
healthy O O
family O O
members O O
NPC O O
cases O O
subjects O O
presenting O O
chronic O O
symptoms O O
head O O
neck O O
area O O
compared O O
healthy O O
individuals O O
general O O
community O O
. O O

This O O
finding O O
indicates O O
groups O O
elevated O O
risk O O
developing O O
NPC O O
may O O
serve O O
targets O O
regional O O
NPC O O
screening O O
program O O
. O O

To O O
report O O
clinical O O
presentation O O
, O O
treatment O O
, O O
management O O
outcomes O O
patients O O
Epstein-Barr B-virus B-virus
virus-positive E-virus E-virus
mucocutaneous O O
ulcer O O
( O O
EBVMCU B-virus B-virus
) O O
head O O
neck O O
, O O
newly O O
characterized O O
pathologic O O
entity O O
aggressive O O
morphology O O
follows O O
indolent O O
, O O
self-limiting O O
clinical O O
course O O
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
etiological O O
factors O O
many O O
benign O O
malignant O O
lesions O O
localized O O
skin O O
mucous O O
membranes O O
region O O
urogenital O O
organs O O
head O O
neck O O
. O O

Currently O O
, O O
assays O O
detection O O
HPV B-virus B-virus
based O O
detecting O O
presence O O
viral O O
nucleic O O
acids O O
, O O
mostly O O
viral O O
DNA O O
. O O

These O O
molecular O O
techniques O O
divided O O
: O O
1 O O
) O O
methods O O
based O O
targeted O O
, O O
selective O O
amplification O O
nucleic O O
acids O O
, O O
2 O O
) O O
signal O O
amplification O O
methods O O
, O O
3 O O
) O O
nucleic O O
acid O O
hybridization O O
assays O O
. O O

This O O
paper O O
presents O O
explains O O
number O O
different O O
HPV B-virus B-virus
detection O O
methods O O
provides O O
examples O O
commonly O O
available O O
commercial O O
tests O O
. O O

We O O
performed O O
massively O O
parallel O O
sequencing O O
617 O O
cancer-associated O O
genes O O
120 O O
matched O O
tumor/normal O O
samples O O
( O O
42.5 O O
% O O
HPV-positive B-virus B-virus
) O O
. O O

Mutations O O
copy-number O O
aberrations O O
determined O O
results O O
validated O O
secondary O O
method O O
. O O

Oncogenic B-virus B-virus
human I-virus I-virus
papillomaviruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
closely O O
linked O O
major O O
human O O
malignancies O O
, O O
including O O
cervical O O
head O O
neck O O
cancers O O
. O O

It O O
widely O O
assumed O O
HPV-positive B-virus B-virus
cancer O O
cells O O
selection O O
pressure O O
continuously O O
express O O
viral O O
E6/E7 O O
oncogenes O O
, O O
intracellular O O
p53 O O
levels O O
reconstituted O O
E6/E7 O O
repression O O
, O O
E6/E7 O O
inhibition O O
phenotypically O O
results O O
cellular O O
senescence O O
. O O

Here O O
show O O
hypoxic O O
conditions O O
, O O
often O O
found O O
subregions O O
cervical O O
head O O
neck O O
cancers O O
, O O
enable O O
HPV-positive B-virus B-virus
cancer O O
cells O O
escape O O
regulatory O O
principles O O
: O O
E6/E7 O O
efficiently O O
repressed O O
, O O
yet O O
, O O
p53 O O
levels O O
increase O O
. O O

Moreover O O
, O O
E6/E7 O O
repression O O
hypoxia O O
result O O
cellular O O
senescence O O
, O O
owing O O
hypoxia-associated O O
impaired O O
mechanistic O O
target O O
rapamycin O O
( O O
mTOR O O
) O O
signaling O O
via O O
inhibitory O O
REDD1/TSC2 O O
axis O O
. O O

Instead O O
, O O
reversible O O
growth O O
arrest O O
induced O O
overcome O O
reoxygenation O O
. O O

Impairment O O
mTOR O O
signaling O O
also O O
interfered O O
senescence O O
response O O
hypoxic O O
HPV-positive B-virus B-virus
cancer O O
cells O O
toward O O
prosenescent O O
chemotherapy O O
vitro O O
. O O

Collectively O O
, O O
findings O O
indicate O O
hypoxic O O
HPV-positive B-virus B-virus
cancer O O
cells O O
induce O O
reversible O O
state O O
dormancy O O
, O O
decreased O O
viral O O
antigen O O
synthesis O O
increased O O
therapeutic O O
resistance O O
, O O
may O O
serve O O
reservoirs O O
tumor O O
recurrence O O
reoxygenation O O
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
cause O O
range O O
serious O O
diseases O O
, O O
including O O
vast O O
majority O O
cervical O O
cancers O O
, O O
anal O O
cancers O O
around O O
half O O
head O O
neck O O
cancers O O
. O O

They O O
also O O
responsible O O
troublesome O O
benign O O
epithelial O O
lesions O O
, O O
including O O
genital O O
warts O O
laryngeal O O
papillomas O O
, O O
individuals O O
HPVs B-virus B-virus
lead O O
recurrent O O
respiratory O O
papillomatosis O O
difficult-to-manage O O
diseases O O
. O O

As O O
result O O
, O O
great O O
need O O
model O O
systems O O
accurately O O
mimic O O
papillomavirus B-virus B-virus
infections O O
humans O O
. O O

This O O
complicated O O
diverse O O
variety O O
HPVs B-virus B-virus
, O O
number O O
200 O O
types O O
, O O
different O O
strategies O O
evolved O O
persist O O
population O O
. O O

The O O
well-developed O O
models O O
involve O O
culture O O
HPV-containing B-virus B-virus
keratinocytes O O
organotypic O O
raft O O
culture O O
, O O
approach O O
appears O O
accurately O O
mimic O O
life O O
cycle O O
several O O
high-risk O O
cancer-associated O O
HPV B-virus B-virus
types O O
. O O

Included O O
amongst O O
HPV16 B-virus B-virus
18 O O
, O O
cause O O
majority O O
cervical O O
cancers O O
. O O

The O O
low-risk O B-virus
HPV B-virus E-virus
types O O
persist O O
less O O
well O O
tissue-culture O O
models O O
, O O
ability O O
study O O
productive O O
life O O
cycle O O
viruses O B-virus
limited O O
. O O

Although O O
ongoing O O
research O O
likely O O
improve O O
situation O O
, O O
animal O O
models O O
papillomavirus B-virus B-virus
disease O O
provide O O
considerable O O
basic O O
information O O
lesions O O
form O O
, O O
regress O O
controlled O O
immune O O
system O O
. O O

The O O
best O O
studied O O
cottontail O O
rabbit B-virus B-virus
papillomavirus E-virus E-virus
, O O
rabbit O O
oral B-virus B-virus
papillomavirus E-virus E-virus
, O O
recently O O
, O O
mouse B-virus B-virus
papillomavirus E-virus E-virus
( O O
MmuPV B-virus B-virus
) O O
, O O
last O O
providing O O
exciting O O
new O O
insights O O
viral O O
tropisms O O
immune O O
control O O
. O O

In O O
addition O O
, O O
transgenic O O
models O O
disease O O
helped O O
us O O
understand O O
consequences O O
persistent O O
viral O O
gene O O
expression O O
importance O O
co-factors O O
hormones O O
UV O O
irradiation O O
development O O
neoplasia O O
cancer O O
. O O

It O O
hoped O O
disease O O
models O O
eventually O O
lead O O
us O O
better O O
understanding O O
better O O
treatments O O
human O O
disease O O
. O O

Oral O O
squamous O O
cell O O
carcinoma O O
( O O
OSCC O O
) O O
prevalent O O
malignancy O O
among O O
males O O
India O O
. O O

While O O
tobacco O O
alcohol O O
main O O
aetiological O O
factors O O
, O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
presence O O
surprisingly O O
increased O O
head O O
neck O O
Squamous O O
Cell O O
Carcinoma O O
( O O
HNSCC O O
) O O
past O O
two O O
decade O O
frequency O O
OSCCS O O
still O O
uncertain O O
. O O

We O O
aim O O
explore O O
frequency O O
HPV B-virus B-virus
major O O
genotypes O O
North O O
Indian O O
patients O O
association O O
clinicopathological O O
histopathological O O
features O O
p16 O O
expression O O
pattern O O
. O O

Over O O
half O O
patients O O
HPV-related B-virus B-virus
HNC O O
would O O
benefit O O
referral O O
physical O O
therapy O O
exercise O O
professional O O
evaluation O O
determine O O
appropriate O O
level O O
exercise O O
supervision O O
, O O
based O O
upon O O
current O O
guidelines O O
. O O

Squamous O O
cell O O
carcinoma O O
originating O O
oral O O
cavity O O
, O O
lip O O
, O O
larynx O O
pharynx O O
grouped O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCC O O
) O O
. O O

A O O
seminested O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
amplifying O O
N22 O O
region O O
TTV B-virus B-virus
genome O O
, O O
well O O
direct O O
sequencing O O
PCR O O
fragments O O
, O O
used O O
. O O

Head O O
neck O O
cancer O O
sixth O O
common O O
malignancy O O
worldwide O O
. O O

Tobacco O O
smoking O O
alcohol O O
consumption O O
two O O
well O O
known O O
behavioral O O
risk O O
factors O O
associated O O
head O O
neck O O
cancer O O
. O O

Recently O O
, O O
evidence O O
mounting O O
infection O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
, O O
commonly O O
human B-virus B-virus
papilloma I-virus I-virus
virus-16 E-virus E-virus
responsible O O
subset O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
especially O O
tumors O O
tonsillar O O
origin O O
. O O

The O O
molecular O O
pathway O O
used O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
trigger O O
malignant O O
transformation O O
tissue O O
different O O
well O O
known O O
risk O O
factors O O
, O O
i.e O O
. O O

smoking O O
alcohol O O
, O O
associated O O
squamous O O
cell O O
carcinoma O O
. O O

Apparently O O
, O O
subsets O O
patients O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
positive O O
tumor O O
likely O O
better O O
prognosis O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
negative O O
tumor O O
. O O

Considering O O
fact O O
, O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
infection O O
determined O O
oropharyngeal O O
cancers O O
since O O
major O O
impact O O
decision O O
making O O
process O O
treatment O O
. O O

When O O
deciding O O
treat O O
patients O O
squamous O O
cell O O
carcinoma O O
head O O
neck O O
( O O
SCCHN O O
) O O
, O O
several O O
factors O O
taken O O
account O O
: O O
disease O O
factors O O
, O O
patient O O
factors O O
, O O
treatment O O
factors O O
, O O
wish O O
patient O O
. O O

This O O
symposium O O
article O O
summarizing O O
information O O
HPV B-virus B-virus
( O O
p16 E-virus E-virus
) O O
context O O
decision O O
making O O
SCCHN O O
patients O O
locoregionally O O
advanced O O
disease O O
recurrent/metastatic O O
disease O O
. O O

The O O
literature O O
data O O
suggest O O
HPV B-virus B-virus
( O O
p16 E-virus E-virus
) O O
prognostic O O
significance O O
, O O
locoregionally O O
advanced O O
disease O O
( O O
particular O O
, O O
oropharynx O O
cancer O O
) O O
recurrent/metastatic O O
disease O O
, O O
limited O O
data O O
predictive O O
significance O O
. O O

Results O O
HPV B-virus B-virus
( O O
p16 E-virus E-virus
) O O
testing O O
change O O
management O O
outside O O
clinical O O
trials O O
. O O

There O O
dramatic O O
rise O O
incidence O O
Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
- O O
associated O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
world O O
, O O
considerable O O
variation O O
geography O O
, O O
gender O O
ethnicity O O
. O O

Little O O
known O O
situation O O
Bangladesh O O
, O O
tobacco- O O
areca O O
nut-related O O
head O O
neck O O
cancers O O
( O O
HNCs O O
) O O
common O O
cancers O O
men O O
. O O

We O O
aimed O O
determine O O
prevalence O O
HPV B-virus B-virus
HNSCC O O
Bangladesh O O
explore O O
possible O O
value O O
cell O O
cycle O O
markers O O
clinical O O
diagnostic O O
settings O O
. O O

HPV B-virus B-virus
status O O
cervical O O
lymph O O
node O O
metastases O O
correctly O O
classified O O
using O O
HC-2 O O
assay O O
84 O O
% O O
( O O
21/25 O O
) O O
cases O O
. O O

Accuracy O O
improved O O
100 O O
% O O
cytologic O O
evaluation O O
confirmed O O
presence O O
cancer O O
cells O O
test O O
samples O O
. O O

The O O
estimated O O
cost O O
savings O O
CMS O O
using O O
HC-2 O O
assay O O
ranged O O
$ O O
113.74 O O
$ O O
364.63 O O
per O O
patient O O
. O O

HPV B-virus B-virus
prevalence O O
tumors O O
21.74 O O
% O O
( O O
n=10 O O
) O O
common O O
viral O O
type O O
HPV-16 B-virus B-virus
( O O
nine O O
cases O O
) O O
. O O

Viral O O
expression O O
HPV-16 B-virus B-virus
low O O
( O O
one O O
11 O O
copies O O
) O O
predominant O O
physical O O
state O O
virus B-virus B-virus
mixed O O
( O O
eight O O
cases O O
) O O
, O O
disruption O O
observed O O
E1 O O
- O O
E2 O O
binding O O
site O O
( O O
2525 O O
- O O
3720 O O
nucleotides O O
) O O
. O O

Eleven O O
patients O O
identified O O
: O O
5 O O
synchronous O O
6 O O
metachronous O O
HPV-positive B-virus B-virus
second O O
primary O O
tumors O O
, O O
latter O O
demonstrating O O
mean O O
time O O
interval O O
5 O O
years O O
. O O

There O O
13 O O
second O O
primary O O
tumors O O
: O O
11 O O
oropharyngeal O O
, O O
1 O O
nasopharyngeal O O
, O O
1 O O
floor O O
mouth O O
. O O

Nine O O
10 O O
genotyped O O
patients O O
harbored O O
HPV-16 O B-virus
, O O
1 O O
patient O O
HPV-33 O O
3 O O
synchronous O O
tumors O O
. O O

The O O
results O O
obtained O O
present O O
study O O
, O O
respect O O
presence O O
high-risk B-virus B-virus
HPV16 E-virus E-virus
HPV18 E-virus E-virus
genotypes O O
, O O
highlight O O
importance O O
human B-virus B-virus
papilomavirus E-virus E-virus
vaccination O O
control O O
oral O O
cavity O O
oropharynx O O
carcinomas O O
. O O

The O O
study O O
group O O
comprised O O
250 O O
histologically O O
proven O O
cases O O
OSCC O O
. O O

HPV B-virus B-virus
detected O O
real O O
time O O
PCR O O
tumor O O
biopsy O O
specimens O O
confirmed O O
conventional O O
PCR O O
PGMY09/ O O
PGMY11 O O
primers O O
. O O

Genotyping O O
high-risk O O
types O O
16/ O O
18 O O
conducted O O
type O O
specific O O
PCR O O
. O O

p16 O O
expression O O
assessed O O
immunohistochemsitry O O
. O O

Nasopharyngeal O O
carcinoma O O
uncommon O O
United O O
States O O
, O O
0.2 O O
0.5 O O
cases O O
per O O
100,00 O O
people O O
; O O
contrast O O
southern O O
China O O
Hong O O
Kong O O
, O O
incidence O O
25 O O
50 O O
per O O
100,000 O O
people O O
. O O

There O O
potential O O
link O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
development O O
nasopharyngeal O O
carcinoma O O
. O O

Radiotherapy O O
alone O O
single O O
modality O O
leads O O
similar O O
10-year O O
survival O O
rates O O
United O O
States O O
, O O
Denmark O O
, O O
Hong O O
Kong O O
( O O
34 O O
% O O
, O O
37 O O
% O O
, O O
43 O O
% O O
, O O
respectively O O
) O O
. O O

Multiple O O
studies O O
shown O O
advantage O O
concurrent O O
chemoradiation O O
treatment O O
advanced O O
disease O O
. O O

Radiation O O
therapy O O
remains O O
mainstay O O
salvage O O
therapy O O
, O O
modern O O
techniques O O
allowed O O
clinicians O O
achieve O O
adequate O O
local O O
control O O
without O O
excessive O O
toxicity O O
. O O

We O O
aimed O O
investigate O O
seasonal O O
disturbations O O
rates O O
detection O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
, O O
Human B-virus B-virus
Bocavirus E-virus E-virus
( O O
HBoV B-virus B-virus
) O O
, O O
polyomaviruses B-virus B-virus
KI E-virus E-virus
WU E-virus E-virus
( O O
KIPyV B-virus B-virus
WUPyV B-virus B-virus
) O O
adenoid O O
tonsil O O
tissues O O
absence O O
acute O O
infection O O
symptoms O O
. O O

Head O O
neck O O
cancer O O
( O O
HNC O O
) O O
currently O O
affects O O
approximately O O
11 O O
200 O O
people O O
UK O O
, O O
increasing O O
proportion O O
known O O
caused O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
. O O

We O O
undertook O O
systematic O O
review O O
studies O O
measuring O O
psychosocial O O
impact O O
HPV-related B-virus B-virus
HNC O O
also O O
studies O O
measuring O O
knowledge O O
link O O
HPV B-virus B-virus
HNC O O
among O O
different O O
populations O O
. O O

Searches O O
conducted O O
MEDLINE O O
, O O
Embase O O
, O O
PsycINFO O O
, O O
CINAHL O O
Plus O O
Web O O
Science O O
, O O
reference O O
forward O O
citation O O
searches O O
also O O
carried O O
included O O
studies O O
. O O

Studies O O
selected O O
( O O
) O O
original O O
peer-reviewed O O
research O O
( O O
qualitative O O
quantitative O O
) O O
, O O
( O O
ii O O
) O O
mentioned O O
HPV B-virus B-virus
HNC O O
, O O
( O O
iii O O
) O O
measured O O
aspect O O
psychosocial O O
impact O O
diagnosis O O
HPV-related B-virus B-virus
HNC O O
dependent O O
variable O O
and/or O O
( O O
iv O O
) O O
measured O O
knowledge O O
association O O
HPV B-virus B-virus
HNC O O
. O O

In O O
total O O
, O O
51 O O
papers O O
met O O
inclusion O O
criteria O O
; O O
10 O O
measuring O O
psychosocial O O
aspects O O
41 O O
measuring O O
knowledge O O
link O O
HPV B-virus B-virus
HNC O O
. O O

Quality O O
life O O
HPV-positive B-virus B-virus
HNC O O
found O O
higher O O
, O O
lower O O
equivalent O O
HPV-negative B-virus B-virus
HNC O O
. O O

Longitudinal O O
studies O O
found O O
quality O O
life O O
patients O O
lowest O O
2æœˆ3æ—¥ O O
months O O
diagnosis O O
studies O O
found O O
quality O O
life O O
almost O O
returned O O
baseline O O
levels O O
12 O O
months O O
. O O

Knowledge O O
link O O
HPV B-virus B-virus
HNC O O
measured O O
among O O
different O O
populations O O
, O O
lowest O O
knowledge O O
general O O
population O O
highest O O
medical O O
dental O O
professionals O O
. O O

Due O O
limited O O
studies O O
carried O O
patients O O
measuring O O
psychosocial O O
impact O O
diagnosis O O
HPV-positive B-virus B-virus
HNC O O
, O O
future O O
work O O
needed O O
partners O O
HPV-positive B-virus B-virus
HNC O O
patients O O
health O O
professionals O O
caring O O
patients O O
. O O

The O O
limited O O
knowledge O O
association O O
HPV B-virus B-virus
HNC O O
among O O
general O O
population O O
also O O
indicates O O
need O O
research O O
explore O O
information O O
populations O O
receiving O O
. O O

This O O
systematic O O
review O O
suggests O O
small O O
trend O O
increase O O
risk O O
HPV-associated B-virus B-virus
cancers O O
among O O
spouses O O
patients O O
HPV-related B-virus B-virus
cancer O O
. O O

HPVDetector B-virus B-virus
simple O O
yet O O
precise O O
robust O O
tool O O
detecting O O
HPV B-virus B-virus
tumour O O
samples O O
using O O
variety O O
next-generation O O
sequencing O O
platforms O O
including O O
whole O O
genome O O
, O O
whole O O
exome O O
transcriptome O O
. O O

Two O O
different O O
modes O O
( O O
quick O O
detection O O
integration O O
mode O O
) O O
along O O
GUI O O
widen O O
usability O O
HPVDetector B-virus B-virus
biologists O O
clinicians O O
minimal O O
computational O O
knowledge O O
. O O

4 O O
. O O

Laryngoscope O O
, O O
127:2033-2037 O O
, O O
2017 O O
. O O

Oral O O
cancer O O
eleventh O O
common O O
cancer O O
globally O O
, O O
well-established O O
major O O
risk O O
factors O O
tobacco O O
, O O
areca O O
nut O O
, O O
alcohol O O
, O O
high-risk B-virus B-virus
human I-virus I-virus
papillomavirus E-virus E-virus
( O O
HR-HPV B-virus B-virus
) O O
types O O
16 O O
18 O O
. O O

HR-HPV16/18 B-virus B-virus
etiologic O O
agents O O
cervical O O
cancers O O
proportion O O
oropharyngeal O O
cancers O O
. O O

HPV-associated B-virus B-virus
oropharyngeal O O
oral O O
cancers O O
show O O
better O O
prognosis O O
response O O
therapy O O
. O O

However O O
, O O
picture O O
HR-HPV16/18 B-virus B-virus
clinical O O
implications O O
oral O O
cancers O O
clear O O
majority O O
reports O O
combining O O
oral O O
cancer O O
data O O
head O O
neck O O
cancers O O
. O O

The O O
current O O
review O O
compiles O O
global O O
prevalence O O
HR-HPV16/18 B-virus B-virus
oral O O
cancers O O
, O O
highlighting O O
unique O O
clinical O O
molecular O O
pathologic O O
features O O
, O O
prognosis O O
therapeutic O O
strategies O O
prevention O O
management O O
HPV-positive B-virus B-virus
oral O O
cancers O O
. O O

The O O
potential O O
use O O
de-intensified O O
therapy O O
prophylactic O O
prevention O O
HPV-positive B-virus B-virus
oral O O
cancer O O
patients O O
highlighted O O
. O O

We O O
explored O O
necessity O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
status-specific O O
biomarkers O O
patients O O
head O O
neck O O
cancer O O
identified O O
HPV B-virus B-virus
status-specific O O
gene O O
set O O
. O O

The O O
identified O O
gene O O
set O O
validated O O
external O O
microarray O O
datasets O O
. O O

For O O
purpose O O
, O O
used O O
4 O O
microarray O O
datasets O O
obtained O O
public O O
database O O
. O O

One O O
dataset O O
used O O
identifying O O
HPV B-virus B-virus
status O O
specific O O
gene O O
set O O
, O O
datasets O O
used O O
validation O O
. O O

Squamous O O
cell O O
carcinoma O O
head O O
neck O O
, O O
particularly O O
basaloid O O
squamous O O
cell O O
carcinoma O O
, O O
may O O
difficult O O
distinguish O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
. O O

Evidence O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
, O O
particularly O O
HPV B-virus B-virus
16 O O
, O O
frequently O O
found O O
non-keratinizing O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
. O O

Immunoreactivity O O
p16 O O
, O O
surrogate O O
marker O O
HPV B-virus B-virus
infection O O
, O O
often O O
parallels O O
HPV B-virus B-virus
infection O O
status O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
. O O

However O O
, O O
incidence O O
correlation O O
p16 O O
expression O O
HPV B-virus B-virus
infection O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
unknown O O
. O O

Sixteen O O
cases O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
, O O
three O O
cases O O
dedifferentiated O O
adenoid O O
cystic O O
carcinoma O O
eight O O
cases O O
low-/intermediate-grade O O
adenoid O O
cystic O O
carcinoma O O
identified O O
inclusion O O
study O O
. O O

All O O
cases O O
tested O O
immunohistochemistry O O
p16 O O
expression O O
situ O O
hybridization O O
high- B-virus O
low-risk I-virus B-virus
HPV E-virus E-virus
. O O

Eight O O
cases O O
( O O
100 O O
% O O
) O O
low-to-intermediate-grade O O
adenoid O O
cystic O O
carcinoma O O
focally O O
positive O O
p16 O O
, O O
negative O O
HPV B-virus B-virus
. O O

In O O
, O O
14 O O
16 O O
cases O O
( O O
88 O O
% O O
) O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
three O O
cases O O
( O O
100 O O
% O O
) O O
dedifferentiated O O
adenoid O O
cystic O O
carcinoma O O
positive O O
p16 O O
; O O
strong O O
diffuse O O
staining O O
noted O O
three O O
cases O O
( O O
3 O O
19 O O
, O O
16 O O
% O O
) O O
. O O

Two O O
cases O O
( O O
11 O O
% O O
) O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
, O O
also O O
diffusely O O
positive O O
p16 O O
, O O
showed O O
presence O O
high-risk B-virus B-virus
HPV E-virus E-virus
. O O

These O O
findings O O
suggest O O
presence O O
HPV B-virus B-virus
infection O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
infrequent O O
, O O
even O O
presence O O
p16 O O
immunostaining O O
. O O

Nevertheless O O
, O O
HPV B-virus B-virus
positivity O O
used O O
exclude O O
possibility O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
differential O O
diagnosis O O
includes O O
squamous O O
cell O O
carcinoma O O
. O O

Moreover O O
, O O
although O O
p16 O O
overexpression O O
often O O
used O O
surrogate O O
marker O O
HPV B-virus B-virus
squamous O O
cell O O
carcinoma O O
, O O
used O O
manner O O
high-grade O O
adenoid O O
cystic O O
carcinoma O O
. O O

Most O O
tumours O O
head O O
neck O O
attributable O O
smoking O O
alcohol O O
use O O
, O O
increasing O O
proportion O O
head O O
neck O O
tumours O O
caused O O
human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPVs B-virus B-virus
) O O
. O O

The O O
aim O O
study O O
use O O
house O O
molecular O O
assays O O
detect O O
genotype O O
HPV B-virus B-virus
biopsies O O
patients O O
histologically O O
confirmed O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
. O O

In O O
addition O O
, O O
results O O
compared O O
p16 O O
immunohistochemistry O O
staining O O
, O O
described O O
potential O O
marker O O
HPV B-virus B-virus
infection O O
. O O

Association O O
verrucous O O
carcinoma O O
( O O
VC O O
) O O
head O O
neck O O
human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
highly O O
controversial O O
. O O

Previous O O
prevalence O O
studies O O
focused O O
mostly O O
Î±-PV B-virus B-virus
, O O
little O O
known O O
PV B-virus B-virus
genera O O
. O O

Our O O
aim O O
investigate O O
prevalence O O
broad O O
spectrum O O
HPV B-virus B-virus
VC O O
head O O
neck O O
using O O
sensitive O O
specific O O
molecular O O
assays O O
. O O

Formalin-fixed O O
, O O
paraffin-embedded O O
samples O O
30 O O
VC O O
30 O O
location-matched O O
normal O O
tissue O O
samples O O
analysed O O
, O O
using O O
six O O
different O O
polymerase O O
chain O O
reaction-based O O
methods O O
targeting O O
DNA O O
least O O
87 O O
HPV B-virus B-virus
types O O
Î±-PV B-virus B-virus
, O O
Î²-PV B-virus B-virus
, O O
Î³-PV B-virus B-virus
Î¼-PV B-virus B-virus
genera O O
, O O
immunohistochemistry O O
p16 O O
protein O O
. O O

Î±-PV B-virus B-virus
, O O
Î³-PV B-virus B-virus
Î¼-PV B-virus B-virus
detected O O
. O O

Î²-PV B-virus B-virus
DNA O O
detected O O
5æœˆ30æ—¥ O O
VC O O
( O O
16.7 O O
% O O
) O O
18/30 O O
normal O O
tissue O O
samples O O
( O O
60 O O
% O O
) O O
: O O
HPV-19 B-virus B-virus
, O O
-24 E-virus E-virus
-36 E-virus E-virus
identified O O
VC O O
, O O
HPV-5 B-virus B-virus
, O O
-9 E-virus E-virus
, O O
-12 E-virus E-virus
, O O
-23 E-virus E-virus
, O O
-24 E-virus E-virus
, O O
-38 E-virus E-virus
, O O
-47 E-virus E-virus
, O O
-49 E-virus E-virus
-96 E-virus E-virus
normal O O
tissue O O
, O O
whereas O O
HPV B-virus B-virus
type O O
determined O O
2æœˆ5æ—¥ O O
cases O O
VC O O
6æœˆ18æ—¥ O O
normal O O
tissue O O
samples O O
. O O

p16 O O
expression O O
detected O O
subset O O
samples O O
higher O O
VC O O
normal O O
tissue O O
. O O

However O O
, O O
reaction O O
predominantly O O
cytoplasmic O O
occasionally O O
nuclear O O
, O O
extent O O
staining O O
exceed O O
75 O O
% O O
. O O

Our O O
results O O
indicate O O
Î±-PV B-virus B-virus
, O O
Î³-PV B-virus B-virus
Î¼-PV O O
associated O O
aetiopathogenesis O O
VC O O
head O O
neck O O
. O O

Î²-PV B-virus B-virus
DNA O O
subset O O
VC O O
normal O O
tissue O O
might O O
reflect O O
incidental O O
colonization O O
, O O
potential O O
biological O O
significance O O
needs O O
investigation O O
. O O

Cases O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
cancers O O
rapidly O O
increasing O O
United O O
States O O
. O O

Little O O
known O O
economic O O
burden O O
cancers O O
. O O

A O O
literature O O
review O O
identified O O
7 O O
studies O O
characterized O O
aspects O O
overall O O
economic O O
burden O O
HPV-associated B-virus B-virus
head O O
neck O O
cancers O O
United O O
States O O
. O O

Other O O
cost O O
studies O O
detailed O O
highlight O O
clinical O O
reality O O
treating O O
patients O O
. O O

As O O
clinical O O
awareness O O
role O O
HPV B-virus B-virus
head O O
neck O O
cancers O O
continues O O
, O O
economic O O
impact O O
cancers O O
caused O O
virus B-virus B-virus
implications O O
role O O
various O O
preventive O O
measures O O
. O O

